The Lord is my shepherd; I shall not want.
He makes me lie down in green pastures.
He leads me beside still waters.
He restores my soul.
He leads me in paths of righteousness
for his name's sake. Psalm 23:1-3
Werewolf Therapeutics (NASDAQ: HOWL) shares closed up 103% at $0.87 after merging with Ambros Therapeutics in an all-stock deal to form Nasdaq-listed Ambros Therapeutics. The shift focuses on neridronate for CRPS-1, with Phase 3 data due in 2028, supported by a $150M private placement funding operations into 1H 2029, while legacy HOWL shareholders will retain ~6.8% ownership.
Arcturus Therapeutics (NASDAQ: ARCT) reported a widened Q2 net loss of $23.8 million as collaboration revenue declined following reduced recognition from CSL Seqirus; however, a $191.5 million cash position extends the runway through 2028, with anticipated Sep 1, 2026 ARCT-810 clinical data and a Dec 1, 2026 Phase 3 decision for cystic fibrosis candidate ARCT-032 serving as near-term catalysts. Shares closed up 22% at $13.45.
Jupiter Neurosciences (NASDAQ: JUNS) priced a $2.0 million registered direct offering of 307,692 shares, adding modest near-term capital but creating dilution shortly after securing exclusive U.S. rights to PharmAla's non-racemic MDMA formulation ALA-002 for neuropsychiatric development. Shares closed up 21% at $6.28.
Iovance Biotherapeutics (NASDAQ: IOVA) saw its price target adjusted to $7 from $4 by UBS, which reaffirmed a Neutral rating; while the revision indicates enhanced valuation backing, the analyst maintained a cautious stance pending more significant fundamental developments or a formal rating upgrade. Shares closed down 8% at $8.29.
Arbutus Biopharma (NASDAQ: ABUS) announced a modified Dutch auction tender offer to buy back as much as $230 million in common stock at a price range of $5.00 to $5.75 per share, leveraging its cash reserves to execute a significant capital return and decrease outstanding shares; J.P. Morgan will serve as the dealer-manager for the initiative, which is anticipated to commence on or about Aug 24, 2026. Shares closed up 9% at $5.21.
SELLAS Life Sciences Group (NASDAQ: SLS) saw Maxim reiterate its Buy rating and $30 price target, notably above the $27.50 market consensus; however, the update came without fresh clinical milestones, regulatory shifts, or new corporate financing activity. Shares closed up 15% at $15.46.
Senti Biosciences (NASDAQ: SNTI) subsidiary Senti Holdings finalized a $4 million senior secured convertible note issuance to Celadon Partners SPV 24, securing immediate funding while introducing potential share dilution and establishing formal debt obligations as previously indicated in its May 1, 2026 regulatory filings. Shares closed down 11% at $0.39.
Telix Pharmaceuticals (NASDAQ: TLX) reported 1H revenue of $477 million as adjusted EBITDA surged 146% to $52 million, driven by robust product sales and a $40 million collaboration milestone from Regeneron; further, $124 million in R&D investment and a $600 million convertible bond refinancing bolster a $252 million cash position to fund advancing radiopharmaceutical and precision medicine pipelines. Shares closed down 9% at $11.33.
Indaptus Therapeutics (NASDAQ: INDP) submitted a resale prospectus for approximately 58.9 million common shares on behalf of certain selling stockholders; although the filing represents a secondary distribution of existing securities rather than a primary issuance of new equity, the substantial volume introduces significant potential for market overhang and share price dilution. Shares closed up 47% at $1.38.
Werewolf Therapeutics (NASDAQ: HOWL) finalized the divestiture of its preclinical INDUCER assets and specific INDUKINE intellectual property to EMD Serono for a total consideration of $33 million, featuring a $28 million upfront payment and $5 million contingent on technology transfer; the deal permits the company to retain exclusive clinical rights for WTX-124 and WTX-330 while establishing a 24-month non-compete period regarding the transferred assets.
Tenon Medical (NASDAQ: TNON) reported a 128% surge in Q2 revenue to $1.28 million, driven by increased surgical procedure volumes and contributions from SImmetry+; however, net losses expanded to $4.05 million due to elevated commercial, sales, and R&D outlays, while a $1.68 million cash position and Nasdaq compliance measures underscore persistent funding and execution risks. Shares closed down 38% at $7.07.
Edesa Biotech (NASDAQ: EDSA) shares closed down 17% at $4.76 following the announcement of a $25 million underwritten public offering consisting of approximately 3.9 million common shares and pre-funded warrants; the transaction, priced at $5.50 per unit, is intended to support research and development, manufacturing, and general corporate purposes, but introduces significant equity dilution for existing shareholders.
Matinas BioPharma (NYSE: MTNB) secured a USPTO notice of allowance for a patent relating to encochleated antifungal formulations designed for CNS delivery and the treatment of cryptococcal infections; the allowance fortifies the intellectual property portfolio of its cochleate drug-delivery technology, though the company offered no new guidance regarding clinical milestones, financing, or strategic partnerships. Shares closed down 24% at $0.18.
eXoZymes (NASDAQ: EXOZ) reported Q2 advancements in its NCT process optimization, achieving a tenfold increase in manufacturing productivity alongside 67% higher volumetric output and an 80% reduction in reaction timelines; while a $6 million public offering and a $2 million NIH grant bolstered its capital position, the current $5.65 million cash balance provides a limited operational runway through late 2026. Shares closed up 10% at $7.04.
Radiopharm Theranostics (NASDAQ: RADX) received a positive recommendation from its Data Safety Monitoring Committee to escalate dosing to the 180 mCi cohort in the Phase 1 HEAT study evaluating RAD202 for HER2-positive advanced solid tumors; the decision reflects an encouraging safety profile in clinical assessments thus far and leverages foundational diagnostic evidence previously established in HER2-positive breast cancer patients. Shares closed down 8% at $2.29.
Moderna (NASDAQ: MRNA) and Merck reported that Phase 3 INTerpath-001 met RFS/DMFS endpoints in stage IIB-IV melanoma. Intismeran plus Keytruda is the first individualized mRNA therapy showing Phase 3 superiority over Keytruda alone; filings follow full data presentation. Moderna shares closed up 177% at $174.38.
Tenon Medical (NASDAQ: TNON) received a USPTO notice of allowance for a sacroiliac joint stabilization system patent, strengthening its IP without impacting commercial or financial guidance. Shares closed up 109% at $11.41.
Amylyx Pharmaceuticals (NASDAQ: AMLX) launched a $350M stock offering, with a $52.5M overallotment option, for avexitide launch prep and R&D after Phase 3 LUCIDITY success. Funds support commercial scaling for a late 2026 filing. Shares rose 10% to $38.60.
Matinas BioPharma (NYSE: MTNB) secured a USPTO notice of allowance for a patent relating to encochleated antifungal formulations designed for CNS delivery and the treatment of cryptococcal infections; the allowance fortifies the intellectual property portfolio of its cochleate drug-delivery technology, though the company offered no new guidance regarding clinical milestones, financing, or strategic partnerships.
Humacyte (NASDAQ: HUMA) announced that one-year V007 Phase 3 data for its ATEV dialysis-access was published in The Lancet Digital Health, demonstrating superior clinical outcomes compared to autogenous AV fistulas; the findings highlight improved efficacy in high-risk patient populations, including women and individuals with diabetes or obesity, further validating the potential for broad AV access utilization following earlier V012 successes. Shares closed up 26% at $0.73.
Ainos (NASDAQ: AIMD) debuted its second-gen AI Nose platform, featuring comprehensive software, firmware, and edge computing enhancements aimed at stabilizing its AI-driven chemical sensing for persistent real-world use; while the upgrade supports a distributed Chemical Intelligence framework, the company did not reveal specific commercial contracts or financial impacts. Shares closed up 6% at $1.48.
PMGC Holdings (NASDAQ: ELAB) announced a 1-for-10 reverse stock split to take effect on August 21, 2026, maintaining its current ticker symbol; the corporate action includes proportional adjustments across all outstanding warrants, incentive plans, and equity awards, with fractional holdings rounded up to the nearest whole share.
Amylyx Pharmaceuticals (NASDAQ: AMLX) reported that avexitide reached its primary FDA-agreed endpoint in the Phase 3 LUCIDITY study for post-bariatric hypoglycemia (PBH). In the trial, the GLP-1 receptor antagonist demonstrated a 55% decrease in Level 2/3 hypoglycemic events relative to placebo and successfully fulfilled all secondary endpoints. These results support a planned year-end 2026 NDA submission, positioning the therapy to potentially become the first approved treatment for PBH. Shares closed up 64% at $35.11.
AVITA Medical (NASDAQ: RCEL) shares closed up 25% at $9.89 following clinical data showing PermeaDerm achieved comparable outcomes to cadaveric allograft while slashing product costs by 70%; the study highlighted a reduction in mean treatment costs to $148.70 per 1% TBSA and a 95.7% faster preparation time, with no adverse events linked to the device.
bioAffinity Technologies (NASDAQ: BIAF) partnered with SDVOSB AvMEDICAL to distribute CyPath Lung across federal healthcare networks like VA medical centers, expanding commercial access via government procurement without disclosing financial terms. Shares closed up 21% at $0.47.
Psyence Biomedical (NASDAQ: PBM) shares closed up 24% at $4.42 following President Trump's commitment to broaden ibogaine research and Right to Try access; the momentum was sparked by the University of Miami donating its 1994 ibogaine IND to the federal government, fueling market interest in psychedelic clinical programs targeting PTSD, alcohol use disorder, and substance use disorder.
Coherus BioSciences (NASDAQ: CHRS) secured a $55M term loan due August 2031 to refinance debt due May 2029, gaining immediate liquidity, $45M in potential funding, and new covenants. Coherus set a September 30, 2026 record date for a special CVR dividend on biosimilar proceeds through 2028 as it pivots to immuno-oncology. Shares closed up 16% at $1.33.
Skye Bioscience (NASDAQ: SKYE) announced its merger with Redx Pharma to create Fibrx Therapeutics, a Nasdaq-listed fibrosis company led by Redx. The firm will focus on RXC008, a Fast Track GI-restricted pan-ROCK inhibitor for fibrostenotic Crohn's disease, backed by $125 million in funding to support operations into 2029 and through Phase 2 data expected in 2H 2028. Shares closed down 14% at $0.36.
Acurx Pharmaceuticals (NASDAQ: ACXP) received conditional FDA acceptance for CIFBEZY as the brand name for ibezapolstat, alongside a USPTO trademark allowance; the regulatory milestones bolster commercial-readiness efforts as the company advances its lead CDI antibiotic toward an international Phase 3 registration trial and subsequent NDA filing. Shares closed down 12% at $1.46.
Adial Pharmaceuticals (NASDAQ: ADIL) finalized its acquisition of Azora Therapeutics, pivoting its strategic priority toward AT177, a colon-targeted oral AhR agonist for ulcerative colitis, alongside securing the initial $32 million of a potential $64 million financing round; while the company reported a widened Q2 net loss of $52.0 million—primarily due to a $46.2 million non-cash IPR&D charge—its bolstered $28.7 million cash reserves provide an operational runway through the second half of 2027. Shares finished the session up 25% at $4.99.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced that its Phase 3 LUGANO trial evaluating DURAVYU in wet AMD failed to meet its primary BCVA endpoint; however, an ad hoc analysis excluding nine patients with unrelated vision loss demonstrated non-inferiority to aflibercept, alongside a 42% reduction in treatment burden and favorable safety. Shares plunged 67% to $4.87 as the market awaits LUCIA data in Q4 2026 and a potential NDA submission in the first half of 2027.
Acurx Pharmaceuticals (NASDAQ: ACXP) confirmed that the FDA granted conditional acceptance of CIFBEZY as the proprietary name for ibezapolstat, complemented by a trademark allowance from the USPTO; such milestones enhance commercial preparation as the company advances its lead CDI antibiotic into a global Phase 3 registration program targeting infection resolution and recurrence prevention. Shares finished the session up 18% at $1.65.
OmniAb (NASDAQ: OABI) raised its 2026 year-end cash outlook to $49–$53 million from $37–$41 million after recent technology licensing and business development activity, including a global collaboration and license deal with Eli Lilly for an ion channel program. Shares closed up 13% at $3.82.
Argenx (NASDAQ: ARGX) reported that its Phase 3 ALKIVIA trial of Vyvgart Hytrulo for autoimmune myositis reached its primary endpoint, highlighting a statistically significant 15.4-point TIS improvement in the pooled IMNM/DM group versus placebo over 52 weeks; although the DM-only subgroup yielded clinically relevant data without statistical significance, the IMNM subset exhibited notable efficacy, with the overall safety profile remaining consistent with prior efgartigimod clinical studies. Shares rallied 16% to end at $987.84.
Citius Pharmaceuticals (NASDAQ: CTXR) reported third-quarter financial results that missed the mark, posting a GAAP net loss of $0.34 per share which was $0.09 wider than anticipated; additionally, its $1.5 million in revenue fell $8.27 million short of consensus. With a cash balance of $17.0 million, the company faces continued funding needs while navigating the initial commercial launch phase for LYMPHIR. Shares tumbled 26% to end the day at $0.56.
Amylyx Pharmaceuticals (NASDAQ: AMLX) is scheduled to disclose primary data from its Phase 3 LUCIDITY study evaluating avexitide for post-bariatric hypoglycemia on August 18, 2026; following the announcement, leadership will conduct a conference call and webcast at 8:00 a.m. ET to review the clinical findings. Shares are currently up 16% at $24.80 during extended hours.
Cue Biopharma (NASDAQ: CUE) disclosed a widened Q2 net loss of $153.1 million, a figure heavily impacted by CUE-221 licensing fees and non-cash acquisition costs, even as a Boehringer Ingelheim milestone boosted quarterly revenue to $7.9 million; the market now anticipates Phase 2 data for CUE-221 in CSU by the close of Q3 2026, alongside a projected IND submission and Phase 1 start for CUE-401 later this year. Shares ended the day down 19% at $27.64.
Week 33
Daré Bioscience (NASDAQ: DARE) announced the pricing of a $6.0 million registered direct offering at $1.37 per share, including concurrent Series A and B warrants, with the capital infusion intended to bolster its women's health development pipeline while introducing notable equity dilution for shareholders. Shares closed down 32% at $0.93.
NeOnc Technologies (NASDAQ: NTHI) hosted an investor call highlighting favorable Phase 2a NEO100-01 results for recurrent IDH1-mutant high-grade glioma, reporting a PFS6 of 48.9% and median OS of 26.1 months that notably outperformed historical benchmarks; the company now intends to engage with the FDA regarding a randomized Phase 3 trial aimed at accelerated approval, with OS serving as the primary endpoint against lomustine. Shares closed up 31% at $4.22.
Capricor Therapeutics (NASDAQ: CAPR) shares closed up 58% at $6.65 following news that the FDA will evaluate supplemental deramiocel efficacy results for Duchenne muscular dystrophy, a move that may push back the August 22 PDUFA deadline while significantly reducing immediate regulatory hurdles and clarifying the path forward for its lead candidate.
BeyondSpring (NASDAQ: BYSI) subsidiary SEED Therapeutics secured FDA Orphan Drug Designation for ST-01156 to treat neuroblastoma, providing regulatory incentives and marketing exclusivity for the targeted protein degrader while highlighting the oncology program's progress through early-stage development. Shares closed down 16% at $0.84.
Valneva (NASDAQ: VALN) shares closed up 26% at $7.13 after the EMA validated the marketing application for PF-07307405, a Lyme disease vaccine candidate partnered with Pfizer, which showed efficacy exceeding 70% in the Phase 3 VALOR study and a favorable safety profile as it enters European regulatory review.
Eton Pharmaceuticals (NASDAQ: ETON) saw its price target adjusted upward to $70.00 from $65.00 by analysts at H.C. Wainwright, reflecting continued confidence in the company's growth trajectory and commercial portfolio development. Shares closed up 44% at $58.86.
Innate Pharma (NASDAQ: IPHA) shares closed down 14% at $2.17 following the pricing of a €30 million private placement consisting of 17.65 million shares at €1.70 per share, with the €27.6 million in expected net proceeds earmarked for the clinical advancement of IPH4502 and other preclinical ADC assets, resulting in an estimated 18.8% dilution for existing shareholders.
BeyondSpring (NASDAQ: BYSI) subsidiary SEED Therapeutics secured FDA Orphan Drug Designation for ST-01156 to treat neuroblastoma, providing regulatory incentives and marketing exclusivity for the targeted protein degrader while highlighting the oncology program's progress through early-stage development. Shares closed up 34% at $1.
Lexaria Bioscience (NASDAQ: LEXX) entered into a material transfer agreement with PegBio to evaluate DehydraTECH-enabled oral delivery of a proprietary GLP-1 molecule in animal PK trials, establishing a strategic pathway toward licensing or full commercialization should the platform enhance GLP-1 efficacy for diabetes, obesity, or MASH. Shares closed up 32% at $8.1.
Outlook Therapeutics (NASDAQ: OTLK) priced a $55 million public offering of 55.6 million shares plus matching warrants at $0.99 per share-and-warrant unit, with $1.10 five-year warrants and an 8.3 million-share underwriter option, adding capital for LYTENAVA commercialization while creating significant dilution. Shares closed down 19% at $0.89.
Omeros (NASDAQ: OMER) maintained a Buy rating from H.C. Wainwright with a $33 price target, following a robust $28.5 million Q2 U.S. launch of YARTEMLEA that exceeded projections, alongside increasing clinical uptake, favorable reimbursement tailwinds, and diminished competition following a peer's setback in an adult C5 study. Shares closed up 27% at $17.35.
INOVIO (NASDAQ: INO) shares closed up 17% at $0.9 following a Q2 GAAP loss of $0.07 per share that outperformed analyst estimates by $0.15, as the company advances its lead candidate INO-3107 through the regulatory review process with $36.7 million in liquidity, excluding an additional $18.3 million in recent funding.
Abeona Therapeutics (NASDAQ: ABEO) posted a $20.2 million Q2 net loss, reflecting persistent cash burn as the firm progresses its pipeline of cell and gene therapies for rare diseases. Shares closed down 15% at $6.35.
Bone Biologics (NASDAQ: BBLG) announced the extension of the validated shelf life for its rhNELL-1 protein to 32 months. This enhancement optimizes manufacturing and logistics as NB1 continues an Australian pilot trial for lumbar fusion in patients with degenerative disc disease. Shares closed down 28% at $0.66.
Dermata Therapeutics (NASDAQ: DRMA) plans to launch Tome Foundational Treatment on August 25, marking its transition to commercial-stage consumer skincare. Q2 net loss widened to $3.0 million, while $4.4 million in cash provides runway only into Q4 2026. Shares closed up 28% at $1.38.
Sionna Therapeutics (NASDAQ: SION) shares closed up 23% at $6.25 following a sharp decline after SION-719 failed its Phase 2a cystic fibrosis study by missing sweat chloride targets. The disappointing data sparked several analyst downgrades and solidified Vertex's dominance in the sector, while Sionna placed its SION-451 development program under strategic evaluation.
NeOnc Technologies (NASDAQ: NTHI) reported that its Phase 2a NEO100-01 trial for recurrent/progressive IDH1-mutant Grade III/IV glioma achieved its primary goal, reaching a 48.9% six-month PFS against a 20% benchmark. With median OS at 26.1 months and favorable safety data, the company intends to meet with the FDA to discuss a registrational pathway. Shares closed down 21% at $3.44.
Curis (NASDAQ: CRIS) submitted a filing to offer 3.73 million shares of common stock alongside warrants via placement agents A.G.P. and Laidlaw; the proposed dilutive financing is intended to support the ongoing clinical development of emavusertib. Shares closed down 28% at $1.67.
Silo Pharma, Inc. (NASDAQ: SILO) announced that the European Patent Office granted a patent for SPC-15, its intranasal lead candidate for PTSD and stress-induced disorders. The patent covers the use of serotonin 4 (5-HT4) receptor agonists to prevent stress-induced fear and depressive behaviors. Silo maintains an exclusive global license from Columbia University for the development and commercialization of the therapy. Shares closed down 13% at $3.1.
FocalTherics (NASDAQ: FOCL) expects Q2 revenue of $12.7–$13.2 million, up 34%–39%, with gross margin improving to 54%–56%. The company priced an $40 million public offering at $4.75 per ADS. Shares closed down 21% at $4.75.
Check-Cap Ltd. (NASDAQ: MBAI) announced a 1-for-7 reverse stock split effective August 13, consolidating its share count to approximately 1.35 million. The move is intended to satisfy the $4.00 minimum bid price for its Nasdaq listing and facilitate the pending MBody AI merger. The transaction remains on track for a third-quarter close in 2026, contingent upon regulatory and shareholder clearance.
PDS Biotechnology (NASDAQ: PDSB) announced it will halt proprietary investment into its Phase 3 VERSATILE-003 study for PDS0101 to pursue strategic partnerships, shifting focus to PDS0301 following NCI-led Phase 2 mCRC data which demonstrated a 71% ORR at six months and an 80% 24-month survival rate in MSS/pMMR colorectal cancer patients with liver metastases. Shares closed down 65% at $0.26.
Neuronetics (NASDAQ: STIM) projected its FY2026 revenue to land between $160 million and $164 million, with anticipated gross margins of 48% to 50%. The company reported a 9% increase in Q2 revenue to $41.6 million alongside a positive adjusted EBITDA. However, it forecasts cash burn of $10.5 million to $14.5 million as it advances its NeuroStar TMS and Greenbrook network initiatives. Following these developments, BTIG analyst reiterated a Buy rating on Neuronetics and bumped the price target up from $5 to $6. Shares closed up 47% at $3.19.
Septerna (NASDAQ: SEPN) reported a Q2 net loss of $0.29 per share, outperforming the anticipated consensus by $0.19 and narrowing significantly from the prior year's $0.56 loss; meanwhile, revenue surged 30% beyond estimates to $26.75 million, prompting Guggenheim to maintain its Buy rating and raise the price target from $45 to $51. Shares closed up 23% at $47.76.
Mereo BioPharma (NASDAQ: MREO) announced that Sentynl obtained an option for U.S. commercial rights and worldwide manufacturing of alvelestat for AATD-associated lung disease; Mereo stands to receive an option fee plus as much as $40 million in upfront and R&D milestones through the NDA submission, along with double-digit U.S. royalties, while maintaining its ex-U.S. rights and oversight of Phase 3 clinical development. Shares closed up 12% at $0.31.
NeOnc Technologies (NASDAQ: NTHI) reported a quarterly loss of $0.58 per share, missing consensus by $0.43 and widening from a $0.30 loss a year ago, signaling heavier-than-expected expenses or operating burn versus expectations. Shares closed up 24% at $4.35.
Belite Bio (NASDAQ: BLTE) announced the FDA accepted its NDA for tinlarebant to treat Stargardt Disease Type 1 (STGD1), granting it Priority Review with a PDUFA action date of Feb 12, 2027; the clinical-stage biotech continues to advance its lead candidate for degenerative retinal conditions with high unmet need. Shares closed up 5% at $175.95.
Tactile Systems Technology (NASDAQ: TCMD) reported Q2 adjusted EPS of $0.34, outpacing the consensus by $0.20 and surging from $0.14 in the prior year; meanwhile, revenue increased 8.6% to $85.7 million, marginally beating expectations and demonstrating steady operational performance even as the stock has lagged the wider market throughout the year. Shares closed down 17% at $24.15.
Tenax Therapeutics (NASDAQ: TENX) reported that its Phase 3 LEVEL trial of TNX-103 in PH-HFpEF missed the primary 6-minute walk distance endpoint and key KCCQ symptom endpoint, though prespecified analyses showed biomarker and hemodynamic signals including 49% NT-proBNP reduction and benefit in lower-baseline-walk patients, leaving the program dependent on FDA feedback and an enriched registrational path.
Sionna Therapeutics (NASDAQ: SION) announced its Phase 2a PreciSION CF trial of SION-719 as an add-on to Trikafta failed to meet the primary sweat chloride endpoint, showing only a -1.0 mmol/L placebo-adjusted difference, resulting in the termination of the SION-719 add-on program; the company remains well-capitalized with $268.3 million and is currently evaluating future development for its SION-451 dual-combination therapy.
Varex Imaging (NASDAQ: VREX) reported that Teledyne will acquire Varex for $18.90/share in cash, valuing the transaction at approximately $1.1 billion including net debt, adding complementary X-ray tubes, detectors, photon-counting technology and imaging software across medical, industrial and security markets, with closing expected in early 2027 subject to approvals.
AbCellera (NASDAQ: ABCL) announced that its Phase 2 ABCL635 data in menopausal vasomotor symptoms showed statistically significant week-4 reductions in hot flash frequency and severity after a single 600 mg subcutaneous dose, with 83% frequency reduction versus 33% placebo, improved sleep and PGI-C, and no serious or severe adverse events, supporting Phase 3 advancement of its long-acting non-hormonal NK3R antibody.
MoonLake Immunotherapeutics (NASDAQ: MLTX) announced that its Phase 3 IZAR-1 trial of sonelokimab in biologic-naïve psoriatic arthritis patients achieved all Week 16 clinical endpoints, with 42.1% reaching ACR50 and 61% achieving PASI90, while maintaining a safety profile consistent with prior data; the company's $537 million cash position provides a runway into mid-2028 as it awaits the primary H1 2027 readout.
Aligos Therapeutics (NASDAQ: ALGS) shares climbed following Q2 updates including a China Breakthrough Therapy Designation for pevifoscorvir in HBV, the completion of Phase 2 B-SUPREME enrollment with a late Q3 2027 readout anticipated, and non-dilutive funding from Amoytop featuring a $25 million upfront payment and an impending $3 million milestone.
Innate Pharma (NASDAQ: IPHA) entered a deal with Sobi to finance and execute the Phase 3 TELLOMAK-3 study of lacutamab for CTCL, securing a $75 million upfront payment alongside potential milestones totaling $505 million and double-digit royalties; the agreement extends Innate's cash runway into late Q3 2027 while advancing a planned accelerated approval submission in Sézary syndrome.
Week 32
CVRx (NASDAQ: CVRX) announced that second-quarter 2026 revenue rose 16% to $15.7 million with U.S. Barostim sales up 21% and gross margin expanding to 87%, but weak Q3 guidance of $13.5–$14.5 million versus $14.7 million last year and continued cash burn weighed on shares despite reimbursement progress from Humana, CPT codes, and CMS IDE coverage. Shares closed down 60% at $2.39.
AVITA Medical (NASDAQ: RCEL) reported second-quarter 2026 financial results and raised its full-year revenue guidance, with executives targeting cash flow breakeven by the fourth quarter behind accelerating commercial momentum and structural efficiency gains; following the update, BTIG analyst Ryan Zimmerman upgraded the stock to Buy from Neutral with a $7 price target. Shares closed up 64% at $7.77.
Scholar Rock (NASDAQ: SRRK) confirmed that the regulatory review for its apitegromab BLA in SMA is proceeding toward its Sep 30, 2026 PDUFA date; however, the biotech will transition away from Catalent Indiana following an OAI inspection status, instead utilizing an alternative compliant fill-finish site that has already cleared FDA scrutiny and secured commercial inventory for a potential launch.
OmniAb (NASDAQ: OABI) delivered a second-quarter revenue beat characterized by significantly improved sales and a reduced net loss, leading leadership to upwardly revise its full-year 2026 revenue target to $32–$36 million and boost its year-end cash projection to $37–$41 million, even as it forecasted a slight uptick in operational spending. Shares closed up 38% at $3.08.
VivoSim Labs (NASDAQ: VIVS) successfully regained compliance with Nasdaq's $2.5 million minimum stockholders' equity mandate, effectively eliminating immediate delisting concerns after the company fortified its balance sheet through recent capital initiatives and financial restructuring. Shares closed up 42% at $0.47.
NRx Pharmaceuticals (NASDAQ: NRXP) disclosed that the FDA finalized its preliminary ANDA assessment for preservative-free ketamine, finding no major issues with the drug itself but citing a minor concern regarding vial-cap packaging; the resulting review reset is expected to be addressed by management before the 2026 market debut. Additionally, the clinical-stage biotech announced a scheduled conference call and Q&A session for Aug 10, 2026 to provide further details on the regulatory update. Shares closed up 16% at $3.58.
QuidelOrtho (NASDAQ: QDEL) shares plummeted as management slashed full-year 2026 revenue guidance to $2.52–$2.60 billion and adjusted EPS to $0.65–$0.90, down significantly from previous ranges; the downward revision stems from IVD pricing headwinds in China and waning international respiratory demand, overshadowing a second-quarter revenue beat.
Ardelyx (NASDAQ: ARDX) shares faced downward pressure after management downwardly revised its full-year 2026 IBsrela revenue projections to $350–$370 million, falling short of the previous $410–$430 million range; the adjustment follows disappointing second-quarter performance attributed to heightened payer utilization hurdles, which has fueled investor skepticism regarding the timeline for achieving its $1 billion peak sales objective. Shares closed down 18% at $4.
BioVie (NASDAQ: BIVI) announced Phase 2 SUNRISE-PD trial results showing bezisterim enhanced motor and inflammatory markers over a 12-week period; however, the limited 57-patient cohort and reliance on exploratory biomarker signals suggest significant Phase 3 validation hurdles and durability risks remain before its disease-modifying potential is fully established. Shares closed down 26% at $1.
BioVie Inc. (NASDAQ: BIVI) reported Phase 2 SUNRISE-PD data for bezisterim in early Parkinson's met primary endpoints with statistically significant MDS-UPDRS improvements and biomarker reductions, including NfL, but the readout may have been viewed cautiously given the small proof-of-concept design, reliance on inflammatory-enriched responders, and need for larger longer-duration Phase 3 validation before disease-modifying or commercial value is de-risked. Shares closed down 34% at $1.35.
Replimune Group, Inc. (NASDAQ: REPL) disclosed that the FDA has granted accelerated approval for TUDRIQEV in combination with nivolumab for the treatment of patients with unresectable advanced cutaneous melanoma following anti-PD-1 progression. The regulatory milestone was supported by IGNYTE trial data, which demonstrated a 24.2% objective response rate (ORR) and a 14.1-month median duration of response; notably, sustained approval for this indication remains contingent upon verification of clinical benefit in confirmatory studies. Shares closed up 9% at $12.86.
Insmed Incorporated (NASDAQ: INSM) disclosed second-quarter revenue that surpassed analyst projections, propelled by the sustained commercial expansion of ARIKAYCE and Brinsupri; notably, the firm reported a narrower-than-anticipated quarterly net loss. Management emphasized robust momentum across its respiratory portfolio and underscored consistent pipeline advancement, noting that revenue trajectory continues to drive corporate valuation. Shares closed up 34% at $132.55.
Ensysce Biosciences, Inc. (NASDAQ: ENSC) finalized the acquisition of Cy Biopharma, Inc., integrating the neuroplastogenic candidate CY200 into its development pipeline; notably, the therapy holds FDA Orphan Drug Designation for Complex Regional Pain Syndrome (CRPS). The strategic transaction is supported by approximately $77 million in aggregate capital commitments, including private placements led by Ally Bridge Group and milestone-dependent funding. This capital infusion is projected to provide a financial runway through Phase 2 proof-of-concept for CY200, targeting a billion-dollar market opportunity with no currently approved treatments, while the firm simultaneously progresses its opioid abuse-resistant platform with NIDA support. Shares closed up 45% at $0.52.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) announced record second-quarter revenue of $99.3 million, representing a 66% year-over-year surge primarily fueled by $91 million in domestic Amtagvi sales; notably, the firm achieved a 56% gross margin. Management highlighted that exceptionally strong commercial demand has prompted a reevaluation of full-year 2026 revenue guidance, while simultaneously reporting pipeline advancement with FDA Fast Track designation for lifileucel in soft tissue sarcomas alongside multiple registrational TIL programs. Shares closed up 43% at $6.21.
Akebia Therapeutics, Inc. (NASDAQ: AKBA) disclosed second-quarter revenue of $49.1 million, a 21% year-over-year decrease, as a 60% surge in Vafseo sales was overshadowed by a 46% slump in Auryxia revenue due to generic entrants. Despite a net loss of $8.9 million, the firm emphasized Vafseo's momentum with over 10,500 patients and encouraging Phase 4 VOICE trial data; importantly, its $155.5 million cash reserve is projected to support at least two years of operations. Shares closed down 26% at $0.95.
Sight Sciences, Inc. (NASDAQ: SGHT) reported second-quarter revenue of $23.4 million, representing a robust 19.4% year-over-year increase and exceeding analyst projections; notably, the firm achieved a narrower-than-anticipated quarterly net loss of $0.08 per share. Management highlighted that exceptionally strong commercial momentum has driven top-line growth, while simultaneously reporting narrowing losses that outperformed market expectations. Shares closed up 28% at $7.09.
Context Therapeutics Inc. (NASDAQ: CNTX) disclosed a second-quarter net loss of $14.6 million, compared to $8.8 million in the prior year, driven by intensified R&D investment to progress its bispecific antibody portfolio. The company has strategically discontinued the development of CT-95 to focus resources on CTIM-76 and CT-202, with patient dosing in the Phase 1 trial of CT-202 projected for the third quarter of 2026. Furthermore, initial clinical readouts are anticipated to begin in the second quarter of 2027; notably, its $43.0 million cash position is expected to provide a financial runway extending into the fourth quarter of 2027. Shares closed down 27% at $0.5.
BillionToOne, Inc. (NASDAQ: BLLN) disclosed second-quarter revenue of $109.45 million, representing a robust 64% year-over-year increase fueled by a 35% rise in test volume and a 21% improvement in average selling price to $551. The company achieved a net income of $0.15 per share, meeting analyst consensus, while oncology testing revenue surged 176% to $13.7 million. With gross margins reaching 70% and positive operating income of $5.5 million, management reaffirmed its full-year 2026 revenue outlook of $450 million to $465 million. Shares closed down 39% at $91.65.
Citius Pharmaceuticals (NASDAQ: CTXR) Majority-owned Citius Oncology reported accelerating LYMPHIR uptake in CTCL, with new institutional accounts up 78% quarter over quarter, vial orders up 31%, and 42 institutions reached, supported by broad payer coverage and early wholesaler reorders. Shares closed up 25% at $0.78.
Geron (NASDAQ: GERN) reported Q2 FY2026 revenue exceeding forecasts, bolstered by Rytelo net product sales of $57.5 million, marking an 11% sequential increase. The firm expanded its reach to approximately 1,875 ordering accounts and reaffirmed its full-year 2026 Rytelo revenue guidance of $220 million to $240 million, even as it navigated increased operating expenses. Shares closed up 22% at $1.63.
LeMaitre Vascular (NASDAQ: LMAT) shares closed down 25% at $79 after it reported Q2 FY2026 net sales growth of 10% to $70.4 million, with EPS climbing 23% to $0.74 and gross margin reaching 72.1% behind a 34% increase in Artegraft sales. The company provided full-year 2026 guidance, projecting revenue between $274.3 million and $278.3 million alongside EPS of $2.84 to $2.94.
Jupiter Neurosciences (NASDAQ: JUNS) finalized a 1-for-75 reverse stock split scheduled for August 6, 2026, with adjusted trading commencing the following day under its existing ticker. Shares closed down 26% at $0.08.
Travere Therapeutics (NASDAQ: TVTX) Citi raised its price target to $85 from $70 while maintaining a Buy rating, citing better-than-expected Q2 results and an FSGS launch tracking ahead of expectations. Shares closed up 12% at $62.76.
Jin Medical International Ltd. (NASDAQ: ZJYL) reported unaudited results for the six months ended March 31, 2026, with revenue declining 9.7% year over year to $8.9 million due to weaker demand from its largest customer and suspended electric scooter sales, while gross margin improved to 26.9% from 24.3%. The company posted a net loss of $0.2 million versus slight net income a year earlier, ended the period with $9.1 million in cash and $21.0 million in short-term investments, and shares surged more than 63% after hours as investors reacted to the margin improvement despite lower revenue. Shares closed up 14% at $2.21.
Autonomix Medical, Inc. (NASDAQ: AMIX) announced that the USPTO has issued a new patent for its catheter-based systems capable of sensing, mapping, and selectively targeting tumor-related nerves and those associated with cancer pain and organ function. This allowance further strengthens the intellectual property estate for the company's minimally invasive technology platforms aimed at guiding nerve-targeted treatments and modulating the autonomic nervous system. Shares closed up 434% at $19.5.
Corvex, Inc. (NASDAQ: MOVE) disclosed a multi-year partnership to supply a prominent AI firm with NVIDIA Blackwell GPU clusters utilizing Quantum-2 InfiniBand networking, representing an expansion of an earlier agreement. This deployment reached maximum capacity between the first and third quarters of 2026, with full run-rate revenue expected to commence in the middle of this quarter. Funding for the expansion was secured through a mix of debt financing, customer prepayments, and current cash reserves. Shares closed up 28% at $13.73.
Ensysce Biosciences, Inc. (NASDAQ: ENSC) announced that the USPTO has issued a Notice of Allowance for a new patent application titled “Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof.” This allowance reinforces the intellectual property estate surrounding the company's proprietary technology platforms designed to provide abuse-resistant pain management solutions, specifically focused on its next-generation prodrug delivery systems. Shares closed up 37% at $0.38.
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) announced second-quarter 2026 financial results, notably the launch of the global Phase 3 Himalayas-1 study for rinzimetostat in metastatic castration-resistant prostate cancer and a clinical supply agreement with Bayer for darolutamide. Management anticipates updates for the rinzimetostat and enozertinib programs in the latter half of 2026, featuring data at ESMO in October. ORIC concluded the quarter with $387.6 million in liquidity, extending its operational runway into late 2028 and past the expected Phase 3 primary readout for rinzimetostat. Shares closed up 27% at $13.47.
Vistagen Therapeutics, Inc. (NASDAQ: VTGN) disclosed that SRX Global (NYSE American: SRXH) has secured an equity position in the firm. This strategic investment underscores the potential value of Vistagen's late-stage neuroscience development programs. While the news confirms a new institutional holder, the release provided no fresh clinical data, regulatory progress, or additional financing details regarding Vistagen's ongoing operations. Shares closed up 22% at $0.3.
Lunai Bioworks, Inc. (NASDAQ: LNAI) revealed a master collaboration with BrainStorm Therapeutics focused on integrating AI-led patient stratification with human brain organoid Parkinson's models, aiming for a primary data readout by the first half of 2027. Additionally, the BioSymetrics unit released a white paper regarding biomarker and therapeutic target identification. In a separate development, the firm filed an updated federal RICO complaint increasing the scope of its naked short-selling litigation to 10 defendants, claiming treble damages related to nearly 30 million failed-to-deliver shares and trading volume allegedly 15 times above its total outstanding shares. Shares are currently down 14% at $2.20 during extended hours.
AdaptHealth Corp. (NASDAQ: AHCO) shared its second-quarter 2026 financial results, emphasizing the ongoing divestiture of its Diabetes Health segment to Cardinal Health for $235 million as part of a broader portfolio optimization strategy. The report adjusted financial outlooks based on current performance but offered no fresh clinical data, regulatory milestones, or financing news beyond these standard earnings and operational developments. Shares closed down 38% at $6.7.
Bruker Corporation (NASDAQ: BRKR) delivered second-quarter 2026 financial results highlighting increased revenue and expanded operating margins. However, these operational gains were overshadowed by a substantial non-cash goodwill impairment charge, resulting in a reported GAAP net loss for the period. While management pointed to fundamental business improvements, the impairment remained the central focus of the quarterly valuation assessment. Shares closed down 22% at $50.3.
ClearPoint Neuro (NASDAQ: CLPT) released financial results for the second quarter of 2026, noting that revenue reached $10.9 million, an 18% increase compared to the previous year that nevertheless fell short of analyst estimates. The company also recorded a net loss of $0.38 per share, which was broader than anticipated, and revised its 2026 revenue forecast downward to a range of $48 million to $52 million. This adjustment follows a strategic reallocation of resources toward commercialization efforts, regulatory processes, and clinical support for partner-driven cell and gene therapy initiatives. Shares closed down 16% at $12.88.
Ensysce Biosciences, Inc. (NASDAQ: ENSC) announced that the USPTO has issued a Notice of Allowance for a new patent application titled “Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof.” This allowance reinforces the intellectual property estate surrounding the company's proprietary technology platforms designed to provide abuse-resistant pain management solutions, specifically focused on its next-generation prodrug delivery systems. Shares are currently up 82% at $0.51 during extended hours.
Autolus Therapeutics plc (NASDAQ: AUTL) disclosed preliminary second quarter 2026 financial results for AUCATZYL (obe-cel), featuring net product sales of approximately $45 million, a 70% sequential increase that drove a gross margin improvement to ~35% and led the company to elevate its full-year revenue outlook to $140–$150 million. To bolster its strategic initiatives, Autolus finalized a $250 million senior credit facility with Perceptive Advisors, consisting of an initial $75 million draw and $175 million in subsequent tranches; this financing, coupled with current reserves, extends the company's capital runway into the second quarter of 2028 to support its clinical pipeline in oncology and autoimmune indications. Shares closed up 22% at $1.82.
Inspire Medical Systems, Inc. (NYSE: INSP) revised its full-year 2026 GAAP EPS guidance downward to a range of $(0.42) to $0.17, a sharp reduction from its prior outlook of $0.07 to $0.62. This updated profitability forecast falls significantly below the consensus analyst projection of $0.90 per share. Shares are currently up 13% at $59.27 during extended hours.
Genprex, Inc. (NASDAQ: GNPX) disclosed a tactical partnership with Roche Diagnostics aimed at validating TROP2 biomarker assay parameters to refine patient enrollment for clinical studies of REQORSA (quaratusugene ozeplasmid) in non-small cell lung cancer (NSCLC). This initiative utilizes Roche's AI-powered, Breakthrough-designated TROP2 antibody assay to substantiate findings that elevated TROP2 (H-scores>100) paired with diminished PTEN expression (H-scores <100) serve as predictors for enhanced progression-free survival (PFS). Roche is slated to execute the validation phase, which is projected for completion by late 2026, allowing Genprex to formalize the biomarker-driven protocol within its ongoing NSCLC clinical development strategy. Shares closed down 21% at $4.75.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announced a clinical safety update for the initial three patients treated under a modified protocol in its pivotal Phase 2 trial evaluating RP-A501, an investigational gene therapy for Danon disease. Patients received a recalibrated dose of 3.8 times 10^13 GC/kg alongside a refined immunomodulatory regimen, which was well tolerated, with no instances of thrombotic microangiopathy (TMA) or capillary leak syndrome observed. Following these encouraging early safety signals, Rocket is actively engaging with the FDA to establish a pathway to treat the remaining patients in the 12-subject cohort and anticipates providing a comprehensive regulatory and program update in the second half of 2026. Shares closed up 10% at $3.41.
Cocrystal Pharma, Inc. (NASDAQ: COCP) secured a $5.0 million strategic private placement from its primary institutional supporter, OPKO Health, Inc. (NASDAQ: OPK), led by Dr. Phillip Frost, to fund the clinical progression of its oral norovirus protease inhibitor, CDI-988. The transaction involved the issuance of approximately 5.47 million common shares at a market-neutral price of $0.9134 per share, providing capital runway as Cocrystal anticipates Phase 1b topline results in Q4 2026. This non-dilutive equity financing bolsters the company's broader antiviral pipeline, which remains focused on developing treatments for seasonal influenza, COVID-19, and chronic hepatitis C. Cocrystal shares closed up 15% at $0.94.
None of Buffett's three children graduated from college. His daughter, Susie, came the closest — she was just three credits shy of finishing her degree before deciding not to continue. Her brothers, Howard and Peter, also left college without graduating. Susie went on to focus much of her career on philanthropy, education and helping children and families. Howard became a farmer, conservationist and philanthropist, with work focused on agriculture, food security and humanitarian efforts. Peter built a career in music, becoming an Emmy Award-winning composer and musician while also focusing on philanthropy and social issues.
Week 31
Replimune Group, Inc. (NASDAQ: REPL) shares closed up 107% at $11.20 following a 10-to-3 vote by the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee endorsing the efficacy results from the single-arm IGNYTE trial evaluating RP1 (vusolimogene oderparepvec) combined with Opdivo for anti-PD-1 refractory advanced melanoma. The positive panel vote successfully counteracted earlier agency skepticism regarding trial design deficiencies, prompting analyst upgrades from firms including Wedbush (to Outperform with a $12 price target) as the company approaches its August 2, 2026 PDUFA action date.
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) shares closed down 73% at $1.92 after H.C. Wainwright analyst Robert Burns downgraded the stock to Neutral from Buy and significantly reduced the price target to $3 from $13. This bearish shift was triggered by the failure of the Phase 3 XPORT-EC-042 trial, where selinexor as a maintenance treatment for TP53 wild-type endometrial cancer missed its primary progression-free survival (PFS) endpoint, eliminating a critical upcoming clinical catalyst for the firm.
Moleculin Biotech, Inc. (NASDAQ: MBRX) shares closed down 61% at $0.4 in the spotlight after releasing preliminary blinded data from 62 patients in Part A of its MIRACLE Phase 2/3 trial, testing Annamycin with cytarabine (AnnAraC) for R/R AML. The study reported a 24% complete remission (CR) and a 37% composite CR (CRc) rate, with a consistent 23% CR and 37% CRc observed in the venetoclax-failed subgroup—tripling historical benchmarks. With no cardiotoxicity signals identified, management expects to finish the 90-patient Part A enrollment by September 2026, targeting an unblinded data readout between December 2026 and February 2027 to set the Part B dose. Additionally, the company announced the pricing of a $9.3 million public offering involving 12.38 million shares (or pre-funded warrants) and 37.13 million common warrants at $0.75 per unit. The warrants are exercisable immediately at $0.75 and carry a five-year term, with proceeds intended to bolster the firm's clinical development efforts.
Nuwellis, Inc. (NASDAQ: NUWE) shares are in focus after the company finalized a securities purchase agreement for a registered direct offering. The deal involves the sale of 1.31 million shares at $2.59 each, priced at-the-market per Nasdaq regulations. Additionally, the medical device firm secured roughly $3.1 million in gross proceeds through the exercise of warrants originating from its June 2026 public offering, providing further capital for its operational and clinical initiatives. Shares closed down 61% at $1.74.
Novo Nordisk (NYSE: NVO) shares faced pressure following headline data from the Phase 3 ZEUS cardiovascular outcomes trial, where once-monthly ziltivekimab failed to achieve its primary endpoint of reducing major adverse cardiovascular events (MACE) vs. placebo (HR = 0.99) in patients with ASCVD, CKD, and high inflammation. While the therapy demonstrated IL-6 pathway target engagement via expected reductions in hsCRP and free IL-6, this did not result in clinical cardiovascular benefit and was accompanied by increased serious infections. Shares closed down 9% at $47.08.
SCYNEXIS, Inc. (NASDAQ: SCYX) shares were in focus as Brookline reiterated a Buy rating and $44.64 price target, pointing to updated FDA safety labeling for Brexafemme (ibrexafungerp) as a key indicator of progress toward a commercial relaunch by partner GSK. Analysts noted that milestone and royalty structures contribute roughly $13 per share to the firm's valuation, backed by a projected peak annual revenue of $672 million for the oral antifungal treatment. Shares closed up 30% at $4.84.
Glucotrack, Inc. (NASDAQ: GCTK) shares closed down 39% at $0.48 after its wholly owned subsidiary, Lōkahi Therapeutics, announced positive nonclinical minipig study results and a favorable May 2026 Type C FDA meeting supporting a simplified single subcutaneous injection regimen for its lead candidate, LT-100 (a purified honeybee venom biologic for osteoarthritis knee pain). The strategy aims to replace a burdensome historical administration approach requiring up to 15 intradermal injections per visit with a single dose, with clinical evaluation anticipated to start as early as Q4 2026 and an initial readout targeted for H1 2027.
CareDx, Inc. (NASDAQ: CDNA) posted Q2 2026 revenue of $132 million, a 52% year-over-year increase that outpaced the $113.8 million analyst consensus. Performance was bolstered by $100 million in Testing Services revenue and a 17% rise in volume, leading to a non-GAAP EPS of $0.37, which cleared the $0.23 estimate. Citing strong AlloSure and AlloMap utilization, favorable Medicare policy updates, and the Naveris integration, leadership hiked full-year 2026 revenue expectations to $490M–$500M and adjusted EBITDA to $66M–$78M. Additionally, GAAP net income reached $111 million, aided by a $113 million gain from divesting its Lab Products segment. Shares closed up 15% at $43.71.
Nuwellis, Inc. (NASDAQ: NUWE) reported preliminary unaudited Q2 2026 revenue featuring a 14% year-over-year increase for the period ended June 30. Total revenue for the first half of the year climbed 20%, fueled by broader commercial utilization of its Aquadex Ultrafiltration therapy for cardiorenal fluid overload. Additionally, Frontiers in Pediatrics accepted a 46-patient retrospective study from UPMC Children's Hospital of Pittsburgh. The data demonstrated that epoprostenol serves as a safe and effective sole anticoagulant for pediatric patients on Aquadex therapy, maintaining filter patency for a median of roughly two days without bleeding complications or the need for added vasopressor support. This study establishes a viable alternative for critically ill children who cannot receive standard anticoagulation. Shares closed up 135% at $4.45.
Glucotrack, Inc. (NASDAQ: GCTK) was granted U.S. Patent No. 12,129,085, which covers proprietary methodologies and systems designed for the continuous monitoring of patient glucose levels. This intellectual property milestone reinforces the firm's technological foundation as it advances its implantable CGM solution. Shares closed up 174% at $0.78.
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) released topline data from the Phase 3 XPORT-EC-042 study, revealing that selinexor did not achieve the primary endpoint of progression-free survival (PFS) when used as maintenance therapy for adults with TP53 wild-type advanced or recurrent endometrial cancer. While results did not reach statistical significance, maintenance treatment with selinexor showed a trend toward improved PFS compared to placebo, with a median of 12.75 months versus 7.43 months (HR = 0.76, p = 0.0791) in the modified intent-to-treat group. Management noted that the safety profile was aligned with previous findings and that these results do not affect other clinical programs currently evaluating selinexor.
Capricor Therapeutics, Inc. (NASDAQ: CAPR) encountered significant regulatory obstacles after a meeting with the FDA's CTGTAC advisory panel. In a 9 to 3 vote, the committee concluded that clinical data from the Phase 3 HOPE-3 trial did not provide sufficient proof of efficacy for Deramiocel (CAP-1002) as a treatment for Duchenne muscular dystrophy (DMD). Shares closed down 36% at $4.19.
INOVIO Pharmaceuticals, Inc. (NASDAQ: INO) priced a public offering of 21,052,632 common shares (or pre-funded warrants) and warrants for up to 42,105,264 more shares. The combined price is $0.95 per share, with warrants exercisable at $1.10. Managed by Piper Sandler, it includes a 30-day option for an additional 3,157,894 shares. The firm expects $20.0 million in gross proceeds. Shares closed down 37% at $0.66.
Corcept Therapeutics Incorporated (NASDAQ: CORT) posted Q2 2026 results featuring total revenue of $256.1 million, a 32% year-over-year increase that exceeded consensus expectations by $36.1 million. Gains were propelled by $208.6 million in Korlym sales and a $47.6 million contribution from the newly launched Lifyorli. After recording a GAAP diluted EPS of $0.36, beating estimates by $0.31, leadership raised its full-year 2026 revenue outlook to a new range of $1.1–$1.2 billion. The robust performance across its oncology and Cushing's syndrome franchises prompted price target increases from analysts at Piper Sandler ($165), H.C. Wainwright ($165), and Canaccord ($150). Shares closed up 27% at $118.32.
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported Q2 2026 financial results that fell short of Wall Street expectations across both top and bottom lines. Despite a 51.2% year-over-year surge in total revenue to $1.17 billion, the figure missed consensus estimates by $150 million. Shares closed down 28% at $205.48.
Pulmonx Corporation (NASDAQ: LUNG) posted Q2 2026 revenue of $22.8 million, a 5% year-over-year decrease that nevertheless surpassed consensus expectations by $0.39 million. While U.S. sales accounted for $14.2 million, international revenue climbed 12% excluding China to reach $8.6 million. Shares closed up 29% at $1.61.
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) revised its full-year 2026 revenue guidance downward to a new range of $310-$325 million, compared to its previous outlook of $320-$345 million. The updated forecast fell short of the $332.2 million consensus estimate. Shares closed down 22% at $9.03.
Pharming Group N.V. (NASDAQ: PHAR) posted Q2 2026 total revenue of $90.2 million, representing a 3.2% year-over-year decrease and falling $9.32 million short of consensus expectations. A 40% climb in Joenja® sales to $17.9 million was insufficient to offset a 10% volume-led contraction in RUCONEST® revenue, which totaled $72.3 million. After recording a GAAP EPS of $0.00, missing estimates by $0.06, leadership lowered its full-year 2026 revenue outlook by $30 million to a new range of $375–$395 million, though operating expense guidance was improved to $315–$320 million. Shares closed down 10% at $10.75.
Capricor Therapeutics, Inc. (NASDAQ: CAPR) encountered significant regulatory obstacles after a meeting with the FDA's CTGTAC advisory panel. In a 9 to 3 vote, the committee concluded that clinical data from the Phase 3 HOPE-3 trial did not provide sufficient proof of efficacy for Deramiocel (CAP-1002) as a treatment for Duchenne muscular dystrophy (DMD). Shares currently halted on the news.
Autonomix Medical, Inc. (NASDAQ: AMIX) reported an SEC resale registration filing for 857,462 shares tied to Series D warrants priced at $5.75. If exercised, the warrants could generate $4.9 million in gross proceeds, augmenting the firm's $5.1 million cash reserve. This liquidity boost is intended to support the development of its neural sensing catheter technology, coming on the heels of favorable preclinical results in renal nerve ablation and the receipt of new U.S. patents. Shares closed up 66% at $4.57.
Synlogic, Inc. (OTC: SYBX) announced a definitive agreement for a reverse merger with private firm Caldera Therapeutics, Inc. set for completion by early 2027. The merged organization, trading on the Nasdaq under the symbol CALD, will be directed by CEO Praveen Tipirneni. Simultaneously, Caldera closed an oversubscribed ~$278 million private placement supported by Bain Capital and Atlas Venture, which provides a capital runway through late 2029. This funding is dedicated to Phase 2 trials for CLD-423, a bispecific antibody designed to inhibit TL1A and IL-23p19 for the treatment of inflammatory bowel diseases like ulcerative colitis. Synlogic shares closed up 56% at $1.12.
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced it acquired Vidya Therapeutics in tandem with a $200 million oversubscribed private placement backed by premier institutional investors such as RA Capital and Bain Capital Life Sciences. This move integrates VT-7208—an oral, CNS-penetrating covalent BTK inhibitor engineered to reduce hepatotoxicity—into its clinical pipeline. The secured capital is projected to extend the company's cash runway through late 2029, financing Phase 2 proof-of-concept trials in food allergy, chronic spontaneous urticaria, and relapsing multiple sclerosis, with data readouts anticipated between 2027 and 2028. Shares closed down 33% at $2.03.
GE HealthCare Technologies Inc. (NASDAQ: GEHC) announced Q2 2026 results featuring total revenue of $5.30 billion, a 5.7% year-over-year increase, alongside a record 11.1% organic order growth that pushed its backlog to $23.9 billion. Gains in Pharmaceutical Diagnostics and Advanced Imaging Solutions, up 15.6% and 7.9% respectively, helped mitigate a 13.3% contraction in Patient Care Solutions. Supported by $129 million in tariff refunds, net income hit $561 million with an adjusted EPS of $1.13, leading the company to reiterate its 2026 outlook of 3.0%–4.0% organic revenue growth and an adjusted EPS range of $4.80–$5.00. Shares closed up 12% at $71.9.
NeoGenomics, Inc. (NASDAQ: NEO) had its Buy rating reiterated by Needham analyst Mike Matson, who simultaneously adjusted the price target upward to $19 from $15. The firm's optimistic outlook reflects continued confidence in the oncology diagnostics company's growth trajectory and market position. Shares closed up 14% at $15.27.
Replimune Group Inc. (NASDAQ: REPL) shares closed down 38% at $5.35 after FDA briefing documents for the July 30, 2026 Advisory Committee meeting raised key efficacy concerns on the BLA resubmission for RP1 plus nivolumab in advanced melanoma. Reviewers noted the Phase 2 IGNYTE trial lacked substantial evidence of effectiveness, citing an inability to isolate RP1's clinical contribution and issues with RECIST v1.1 interpretations, increasing uncertainty ahead of the Aug 2, 2026 PDUFA goal date.
Kiniksa Pharmaceuticals (NASDAQ: KNSA) released its second-quarter 2026 financial report, reporting ARCALYST (rilonacept) net sales of $243.6 million, a roughly 55% increase over the prior year. This performance, alongside a net income of $25.4 million, led management to raise its full-year 2026 ARCALYST revenue outlook to $980–$995 million. Kiniksa, currently holding $525.9 million in capital with no debt, also shared positive Phase 2 results for KPL-387, its subcutaneous IL-1 receptor antagonist for recurrent pericarditis. The 300 mg monthly dose achieved a median treatment response in just 4.0 days and normalized CRP within 8.0 days, supporting the launch of the pivotal Phase 3 PASTORALE trial. The company targets a market debut for this liquid formulation by 2028 or 2029. Shares closed up 25% at $79.44.
ProMIS Neurosciences Inc. (NASDAQ: PMN) announced encouraging blinded six-month interim data from the Phase 1b PRECISE-AD trial of PMN310 in 136 subjects with early-stage Alzheimer's disease. The candidate, which selectively targets amyloid-beta oligomers, showed a favorable safety profile, with no reported brain edema (ARIA-E) and a low rate of asymptomatic microhemorrhages (ARIA-H) of 4.4%. Blinded biomarker assessments indicated positive trends in target engagement, with reductions in plasma pTau217 and CSF MTBR-tau243 observed in 68.5% and 62.5% of patients, respectively. Unblinded 12-month topline results are expected in the first quarter of 2027. Shares closed up 24% at $14.52.
MapLight Therapeutics (NASDAQ: MPLT) saw its price target revised by a Canaccord Genuity analyst, who lowered it from $43 to $24. Despite the reduction in valuation, the analyst reaffirmed a Buy rating for the clinical-stage neuroscience company. Shares closed up 24% at $12.31.
Enlivex Ltd. (NASDAQ: ENLV) announced a $400 million private placement of ordinary shares with a single institutional investor. The transaction is priced at $5.00 per share for cash-equivalent funding (a 17.4% premium) and $6.00 per share for RAIN token funding (a 40.8% premium), based on the July 27, 2026, closing price. Enlivex plans to utilize the net proceeds to strengthen its treasury strategy centered on the Rain protocol while continuing clinical development of Allocetra, its immunotherapy candidate for inflammatory aging conditions, specifically age-related osteoarthritis. Shares closed down 47% at $2.24.
NeuroPace, Inc. (NASDAQ: NPCE) announced that the FDA delivered a non-approvable letter concerning its PMA Supplement for the RNS System in patients with drug-resistant idiopathic generalized epilepsy (IGE). After a recent Agency meeting, the company intends to file a Submission Issue Request (SIR) to provide further evidence from the Phase 3 NAUTILUS trial. This pivotal study showed median GTC seizure reductions of 77% at month 18 and 100% by month 24, and NeuroPace aims to use this data to address remaining clinical questions. Management noted that existing financial projections do not account for the IGE label expansion as they work with regulators to establish a trajectory for potential market authorization. Shares closed down 15% at $15 during extended hours.
OPKO Health, Inc. (NASDAQ: OPK) shares closed up 33% at $1.65 after the company shared its second-quarter 2026 financial performance. Consolidated revenue grew to $163.5 million compared to $156.8 million in the prior-year period, while the net loss significantly improved to $8.4 million, or $0.01 per share. This expansion was driven by robust international pharmaceutical sales and licensing income, which mitigated a decline in diagnostic services revenue following the divestment of oncology assets. Supported by a capital position of $314.4 million, management set a third-quarter revenue target of $131–$142 million and raised its full-year 2026 revenue outlook to $560–$585 million.
Autonomix Medical, Inc. (NASDAQ: AMIX) shares are trading up 71% at $4.70 during the after-hours session following an update on its corporate capital and liquidity status. As of Jul 28, 2026, the firm reported a cash position of roughly $5.1 million with 971,043 common shares outstanding. This updated equity base accounts for shares issued through a July 13 warrant inducement that raised $2.6 million in gross capital, coming shortly after a 1-for-21 reverse split in June. The disclosure offers a clear view of the company's financial runway as it continues to develop its medical technology assets.
Firefly Neuroscience (NASDAQ: AIFF) partnered with Next Health to debut a Precision Cognitive Health Initiative following a positive FDA Advisory Committee vote. Late last week, the committee recommended relaxing compounding limitations for half a dozen peptides, notably Epitalon and Semax, which are increasingly recognized for their potential in neuroprotection and cognitive enhancement. The initiative aims to leverage these peptides as research into their supportive properties gains momentum. Shares closed down 6% at $1.11.
Entera Bio Ltd. (NASDAQ: ENTX) priced an oversubscribed $275 million private placement with leading healthcare investors including BVF Partners, RA Capital, and Perceptive Advisors. The financing involved issuing approximately 122.96 million shares and 11.84 million pre-funded warrants at $2.04 each. This capital is intended to fully finance the Phase 3 program and subsequent NDA filing for EB613 in osteoporosis. Additionally, funds will support the Phase 1 trial of EB612 for hypoparathyroidism, being developed with OPKO Health. The deal extends Entera's cash runway through 2030 and allows BVF to appoint two members to the Board of Directors. Shares closed up 91% at $3.92.
MapLight Therapeutics, Inc. (NASDAQ: MPLT) announced positive topline results from its Phase 2 ZEPHYR trial evaluating ML-007C-MA in patients with schizophrenia experiencing acute exacerbations. The study met its primary endpoint, with the twice-daily 210/3 mg dose of the M1/M4 muscarinic agonist and peripheral anticholinergic co-formulation demonstrating a statistically significant reduction in PANSS total score versus placebo at week 5 (LS mean change of -4.5; p=0.015). Additionally, the therapy showed a 0.51 effect size (p=0.041) in cognitive improvements among patients with baseline impairment. ML-007C-MA was well-tolerated, reporting no serious drug-related adverse events and a low 2% discontinuation rate due to GI issues. While the once-daily arm did not reach statistical significance on the primary endpoint, the overall data supports an upcoming End-of-Phase 2 meeting with the FDA to align on a Phase 3 registrational program. MapLight also intends to continue developing the candidate for Alzheimer's disease psychosis. Shares closed down 73% at $9.9.
Forte Biosciences, Inc. (NASDAQ: FBRX) and Argenx (NASDAQ: ARGX) revealed a definitive merger agreement where Argenx will purchase Forte for $77 per share. This all-cash transaction values the company at an equity total of nearly $2.2 billion, reinforcing argenx's position as a leader in immunology innovation. The deal integrates FB102, a pioneering anti-CD122 antibody, into the argenx pipeline. This candidate has demonstrated clinical proof-of-concept in both celiac disease and vitiligo, offering a differentiated approach to treating various autoimmune conditions. This acquisition aligns with the company's strategy of targeting breakthrough science to establish new standards of care for underserved patient populations. Forte shares closed up 40% at $76.5.
Matinas BioPharma Holdings, Inc. (NYSE: MTNB) reported that BTIG has ended their $50 million At-The-Market (ATM) equity facility, effective Jul 23, 2026. This termination removes the company's primary avenue for share issuance through this specific platform, though Matinas confirmed no penalties or additional costs were incurred. The move occurs amidst a significant corporate pivot, following the divestment of its LNC asset MAT2203 to Azurity Pharmaceuticals and a proposed merger with GH Power. Matinas continues to manage ongoing operational deficits and listing compliance challenges as it shifts its strategic focus. Shares closed up 36% at $0.33.
Gossamer Bio, Inc. (NASDAQ: GOSS) announced it is on track to file an NDA for seralutinib in pulmonary arterial hypertension (PAH) by September 2026. This progress follows a successful Pre-NDA Type B consultation with the FDA. Concurrently, the company and Chiesi have agreed to terminate their collaboration, allowing Gossamer to regain full global rights to the candidate. In return, Chiesi will receive a $5 million settlement and a capped royalty on future sales. Financially, shareholders approved a convertible note exchange that reduces total debt by approximately $115.9 million and authorized a reverse stock split. The company concluded the second quarter of 2026 with a cash position of $57 million, including marketable securities. Shares closed up 47% at $0.2.
Capricor Therapeutics, Inc. (NASDAQ: CAPR) issued a rebuttal to recent FDA briefing materials that caused a significant stock decline. The company argued that the agency's post hoc analysis used an outdated internal draft Statistical Analysis Plan (SAP v1.1) rather than the finalized version 3.0. CEO Linda Marbán maintained that the Phase 3 HOPE-3 trial successfully reached its primary endpoint in PUL 2.0 with statistical significance, alongside positive cardiac data. The update comes just before the Jul 29, 2026 Advisory Committee meeting and the August 22, 2026 PDUFA goal date. Shares closed down 64% at $7.
Decoy Therapeutics Inc. (NASDAQ: DCOY) announced that its primary Designable Multi-Antiviral (D-MAV™) candidate, created using the IMP3ACT™ platform for coronaviruses, showed broad in vitro fusion inhibition against Lassa fever and wild-type Ebola Zaire viruses in Texas Biomedical Research Institute trials. These results support the development of single drugs targeting shared Class I fusion mechanisms across various viral families. Consequently, Decoy initiated a pandemic preparedness program for filoviruses, including Marburg and Ebola, which may qualify for the FDA's Tropical Disease Priority Review Voucher (PRV) program. The company remains focused on advancing its respiratory candidate pipeline through clinical stages. Shares closed down 24% at $3.74.
Global Pump Market Research Report 2026-2031
The global pump market size was valued at USD 65 billion in 2025 and is expected to reach USD 88.36 billion by 2031, growing at a CAGR of 5.25% during the forecast period. The market is witnessing steady growth because of the increasing investment in water and wastewater infrastructure, industrial manufacturing, and rapid adoption of smart pumps across oil and gas, chemical, power generation, and other sectors.
The pump market is witnessing a strong shift as governments across the regions encourage industrial decarbonization and sustainable water management through varied policies, stringent regulations, and infrastructure investment programs. For instance, initiatives by the European Commission's 2025–2027 Water Resilience Strategy and continuous implementation of Ecodesign regulations are likely to support the demand for high-efficiency water pumping systems.
The expansion of infrastructure and real estate projects, specifically in economies such as China, India, South Korea, Brazil, Germany, France, the UK, and Spain, among others, is gradually increasing the demand for pump systems. For instance, projects such as Hyatt House Bengaluru, India, expected to open in 2027, and the Upper House Xi'an (Shaanxi), located in the Small Wild Goose Pagoda zone, expected to open in 2028. And construction of Indonesia's new legislative and judicial complexes, which began in 2025 with completion targeted for 2027, emphasizes consistent growth, thereby supporting sustained demand for pump systems for water supply, wastewater management, HVAC circulation, and fire protection.
The Pump Market Size, Share & Trends Analysis Report By
Operation Type: Electrical and Mechanical
Product Type: Centrifugal Pump, Reciprocating Pump, and Rotary Pump
Centrifugal Pump Stage Type: Single-Stage and Multi-Stage
Reciprocating Pump Type: Piston And Diaphragm
Rotary: Gear, Screw, Lobe, Vane, and Other Rotary Pumps
End-User: Industrial, Agricultural, Commercial, and Residential
Industrial: Water & Wastewater, Chemical, Food & Beverage, Power, Oil & Gas, Pharmaceutical, Mining, and Other Industrial Segment
Geography: North America, Europe, APAC, Latin America, and Middle East & Africa
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2026–2031.\
KEY PLAYERS: Grundfos Holding A/S, Xylem Inc., EBARA Corporation, WILO SE, Flowserve Corporation, Alfa Laval, Baker Hughes Company, Bosch Rexroth, Circor International, Desmi, Dover, Franklin Electric, General Electric Company, IDEX, Kirloskar Brothers Limited, KSB Limited, Nikkiso, Pentair, SLB, SPX FLOW, Inc., Sulzer Ltd, The Weir Group PLC, Torishima Pump Mfg. Co., Ltd., and Weatherford
Outlook Therapeutics, Inc. (NASDAQ: OTLK) announced that the FDA approved LYTENAVA (bevacizumab-vikg) for treating neovascular age-related macular degeneration (wet AMD). This milestone marks LYTENAVA as the first ophthalmic bevacizumab formulation authorized for intravitreal use, providing retina specialists with a regulated alternative to off-label, repackaged intravenous products. The company plans a U.S. commercial launch by year-end 2026, targeting the $8.5 billion domestic anti-VEGF market with 12 years of regulatory exclusivity granted under the BPCIA. Shares closed up 6% at $1.41.
Codexis, Inc. (NASDAQ: CDXS) announced the pricing of an underwritten public offering of 16,666,667 shares of common stock at $1.50 per share, aiming to generate approximately $23.1 million in net proceeds. Jointly managed by Piper Sandler and Cantor Fitzgerald, the offering includes a 30-day option for underwriters to acquire up to an additional 2.5 million shares. Shares closed down 26% at $1.48.
Radiopharm Theranostics (NASDAQ: RADX) entered into a securities purchase agreement (SPA) with U.S. institutional investors for a registered direct offering of 1,282,000 American depositary shares (ADSs) at $3.16 each, targeting $4.1 million in gross proceeds. Simultaneously, the company will issue unregistered warrants for an additional 1.282 million ADSs, exercisable at $3.79, with an expiration date of July 31, 2029. Shares closed down 17% at $3.55.
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) reported that the EMA's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion regarding its Marketing Authorization Application for arimoclomol, intended for Niemann-Pick Disease Type C (NPC) treatment. Despite this setback, the company intends to seek a formal re-examination of the opinion. Neil F. McFarlane, President and CEO, emphasized Zevra's dedication to the European NPC community and the evidence supporting arimoclomol's clinical utility. The company will continue to provide the therapy via its Expanded Access Program (EAP) to gather real-world evidence and support eligible patients. Arimoclomol remains recognized as a significant treatment option within the updated international Consensus Clinical Management Guidelines for NPC, with clinical observations from experts like Prof. Thorsten Marquardt indicating stabilized disease progression in this ultra-rare condition.
China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) announced a $9 million registered direct offering. Shares closed down 81% at $0.06.
MannKind Corporation (NASDAQ: MNKD) announced that the FDA approved Furoscix ReadyFlow™ (furosemide injection) to treat edema in adult patients with chronic kidney disease or heart failure. As the first subcutaneous furosemide autoinjector to achieve IV-equivalent exposure, the device delivers an 80 mg/mL dose in less than 10 seconds. This enables rapid symptom management and at-home intervention designed to reduce hospital readmissions and emergency visits. Additionally, the company initiated a private placement financing expected to yield roughly $50 million in gross proceeds. Shares closed up 6% at $4.13.
Autonomix Medical, Inc. (NASDAQ: AMIX) reported results from a preclinical study validating its catheter-based neural sensing platform's ability to identify, localize, and verify real-time renal nerve activity in an animal model. By detecting distinct neural signal signatures along the renal artery before treatment and confirming signal attenuation following targeted radiofrequency (RF) ablation, the technology supports a novel “sense, treat, and verify” approach. Shares closed down 17% at $2.92.
Novocure (NASDAQ: NVCR) reported Q2 2026 earnings with net revenue of $183.58 million, up 16% year-over-year, beating the $172.44 million consensus estimate. Growth was driven by an 18% active patient increase to 5,128 and the launch of Optune Pax and Optune Lua. Despite a GAAP net loss of $15.66 million, Adjusted EBITDA reached $10.8 million, prompting management to upgrade its full-year 2026 guidance to $710M–$725M in revenue and $0M–$15M in Adjusted EBITDA. Shares closed up 28% at $19.99.
China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) announced a $9 million registered direct offering. Shares closed down 84% at $0.33.
Neuphoria Therapeutics Inc. (NASDAQ: NEUP) and Scancell Holdings plc (AIM: SCLP) finalized an agreement for an all-stock merger. Scancell will take over Neuphoria to form a unified company trading on the Nasdaq under the symbol SCLT while maintaining its AIM presence. Shares closed up 18% at $3.92.
KALA BIO, Inc. (NASDAQ: KALA) submitted a prospectus supplement for an “at-the-market” (ATM) equity offering to potentially sell as much as $250 million in common stock. Conducted via H.C. Wainwright & Co. acting as the sales representative, the offering is part of an active $350 million shelf registration. This move secures adaptable financing for KALA BIO to fund ongoing corporate activities and various strategic goals. Shares closed down 17% at $0.61.
MindWalk Holdings (NASDAQ: HYFT) reported a quarterly loss of $0.06 per share, missing the $0.05 consensus by 20%. This figure indicates a 50% drop from the $0.04 loss seen in the previous year's period. Quarterly revenue came in at $2.973 million, falling 8.80% below the $3.260 million forecast and representing a 41.13% decrease from the $5.050 million recorded in the same quarter last year. Shares closed down 18% at $1.18.
Jaguar Health (NASDAQ: JAGX) disclosed that its subsidiary, Napo Pharmaceuticals, has supplied a proprietary oral solution formulation of crofelemer for compassionate use. The medication is being administered to an infant within the EU to manage intestinal failure associated with microvillus inclusion disease (MVID). Shares closed down 23% at $1.03.
HCW Biologics Inc. (NASDAQ: HCWB) requested a Type B pre-IND consultation with the FDA to coordinate on the clinical framework and regulatory roadmap for HCW11-018b. Developed using the proprietary TRBC platform, HCW11-018b is a subcutaneous, second-generation tetravalent T-cell engager, or “Big BiTE,” engineered to address solid tumors expressing human tissue factor, including gynecologic and pancreatic malignancies. The candidate works by stimulating CD3+ effector T cells while neutralizing immunosuppressive factors in the tumor environment. Bolstered by preclinical data indicating strong tolerability, no cytokine release syndrome at effective doses, and efficient cGMP production, the firm is currently on schedule to begin clinical studies in the first half of 2027. Shares closed down 14% at $2.88.
Niki BioSolutions, Inc. (NASDAQ: NIKI) revealed that DiamiR Biosciences, its subsidiary, has contracted with Progressive Medical Research (PMR) to deliver Apolipoprotein E (APOE) genotyping services. This collaboration enables PMR to utilize DiamiR's CAP- and CLEP-certified testing infrastructure within its clinical study frameworks. The resulting genetic insights will bolster translational research initiatives specifically centered on Alzheimer's disease, lipid metabolic processes, and cardiovascular wellness. Shares closed down 5% at $8.58.
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) Chief Executive Officer Talat Imran purchased 35,000 shares of Class A common stock on July 17, 2026, in an open-market transaction at an average price of $0.72 per share (totaling ~$25,193). Following the transaction, his direct holding increased to 469,736 shares, reflecting insider confidence shortly after the company reported positive Phase 1a clinical data for its oral obesity drug candidate, RT-114. Shares closed up 30% at $0.9.
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) shared preclinical results for Nu-3, a Phase 2-ready topical antimicrobial gel. The Bisphosphocin-class therapy showed no resistance development during serial passage studies, acting by physically destabilizing membranes. It was effective in vitro against E. coli, K. pneumoniae, and P. aeruginosa, overcoming resistance factors like efflux pumps and enzymatic degradation. These findings support the company's plan to begin a Phase 2a study for infected diabetic foot ulcers, aligned with the National Action Plan on Combating Antibiotic-Resistant Bacteria. Shares rose 83% to $3.41.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported topline data from the Phase 3 SHASTA-3 and SHASTA-4 trials of plozasiran in adults with severe hypertriglyceridemia (sHTG). The studies reached their primary and secondary goals, with 25 mg subcutaneous doses every three months yielding median triglyceride drops of 79% and 81% at Month 12. Notably, the treatment led to a 78% overall decrease in acute pancreatitis, including a total 100% reduction in patients at high risk. Shares closed up 19% at $88.7.
Trinity Biotech plc (NASDAQ: TRIB) entered a strategic partnership and equity investment plan with Latch Medical Limited. The collaboration seeks to merge Trinity's AI-native CGM+ biosensor platform with Latch's Pharma Latch microneedle delivery technology. Supported by Perceptive Advisors, the initiative aims to link continuous metabolic data with precise intradermal administration to create biosensor-informed treatments for obesity, diabetes, and metabolic disorders. Shares closed down 15% at $0.3.
Mentari Therapeutics announced a $200 million private placement of common stock and pre-funded warrants, supported by healthcare investors including Fairmount and Blackstone. This capital will sustain operations through 2029 as it advances Phase 2a clinical data for MT-002 and other migraine programs. The financing will finalize with a $290 million initial placement before its stock-for-stock merger with InMed Pharmaceuticals (NASDAQ: INM). The post-merger company will keep the Mentari name, debut a new Nasdaq ticker, and have about 601 million shares outstanding on a fully diluted basis. Shares closed up 8% at $1.66.
Kairos Pharma (NYSE: KAPA) announced a strategic collaboration with Bayer to evaluate ENV-105, a CD105/BMP signaling inhibitor, combined with Bayer's XOFIGO (radium-223 dichloride) in metastatic castration-resistant prostate cancer (mCRPC) with bone metastases. The partnership aims to use preclinical evidence showing ENV-105's ability to block CD105-driven pro-survival signaling and re-sensitize resistant tumors to radiation, targeting a global market estimated at $570M–$1.3B. It builds on positive Phase 2 data at ESMO where ENV-105 showed an 86% clinical benefit rate and median progression-free survival exceeding 13 months. Shares closed down 13% at $0.31.
OKYO Pharma Limited (NASDAQ: OKYO) reported that its Chief Medical Officer, Flavio Mantelli, MD, PhD, executed a purchase of 20,000 ordinary shares of the Company on the NASDAQ. The transaction was completed at a price of $1.40 per share. OKYO is a clinical-stage firm focused on developing treatments for neuropathic corneal pain (NCP) and other diseases of the eye's anterior segment. Shares closed up 6% at $1.52.
PolyPid Ltd. (NASDAQ: PYPD) established a sole commercial partnership with Azurity Pharmaceuticals to market and distribute D-PLEX100 in the U.S. and Canada, targeting the prevention of abdominal surgical site infections (SSIs). The deal provides PolyPid with a $15M initial payment, followed by $15M once the FDA accepts its NDA, which is expected by Aug 1, 2026. Total potential compensation through milestones reaches ~$300M, alongside tiered royalties from the mid-teens to mid-twenties. Azurity will oversee North American sales and finance studies for label expansion, while PolyPid retains manufacturing control and rights outside North America. After achieving a 60% reduction in risk during the Phase 3 SHIELD II trial, the company anticipates a domestic market launch in the first quarter of 2027. Shares closed down 27% at $3.74.
Lisata Therapeutics (NASDAQ: LSTA) shares closed down 36% at $2.24 reaching their lowest point in almost half a year, following a breach of contract by Kuva Labs. Although approximately 6.1 million shares—representing 66.8% of the company—were tendered by the July 20 deadline, Kuva failed to finalize the acquisition due to financing difficulties. Lisata confirmed that the minimum acceptance threshold was met, yet payment was never delivered; the company is now exploring potential legal recourse against Kuva for failing to honor the purchase agreement.
Celldex Therapeutics (NASDAQ: CLDX) shared primary findings from a Phase 2 trial investigating subcutaneous barzolvolimab for prurigo nodularis (PN). The study failed to meet its primary objective, as it did not achieve a statistically significant proportion of patients reaching a four-point reduction on the Worst Itch Numeric Rating Scale (WI-NRS) by Week 12. Key secondary skin-lesion endpoints were also not satisfied compared to placebo. While the drug successfully demonstrated systemic mast cell depletion by reducing serum tryptase levels, the lack of clinical improvement suggests that mast cells may not be the primary drivers of PN pathogenesis. Celldex noted that barzolvolimab remained well tolerated across the 150 mg and 300 mg regimens. The company is now halting the PN program to prioritize late-stage assets, including a Phase 3 readout in chronic spontaneous urticaria (CSU) anticipated in October 2026. Shares are currently down 7% at $33.05 during extended hours.
Niki BioSolutions, Inc. (NASDAQ: NIKI), formerly Aptorum Group Limited, finalized its all-stock business combination with DiamiR Biosciences Corp. The transaction included a 1-for-10 share consolidation and redomestication from the Cayman Islands to Delaware, establishing the new brand. Shares closed up 8% at $9.54.
Palvella Therapeutics (NASDAQ: PVLA) saw LifeSci Capital reaffirm its Buy rating and $225 price target, despite the FDA's recent denial of Breakthrough Therapy Designation (BTD) for QTORIN in cutaneous vascular malformations (CVMs). Analyst Sam Slutsky characterized the setback as a procedural delay rather than a clinical failure, noting that Phase 3 CVM trials remain scheduled to start in late 2026. The company intends to reapply for BTD using more comprehensive patient data, while a rolling NDA submission for microcystic lymphatic malformations (MLMs) targets a potential 2027 green light. The positive sentiment is reinforced by TD Cowen's $267 price target, existing Fast Track statuses, and intellectual property extending U.S. exclusivity through the 2040s. Shares closed up 16% at $143.94.
Calidi Biotherapeutics (NYSE: CLDI) disclosed a 1-for-16 reverse stock split scheduled to take effect on Jul 31, 2026. The company will continue trading under its current ticker while consolidating equity to bolster investor interest. All outstanding warrants, options, and convertible instruments will undergo proportional adjustments following the share consolidation. Shares closed down 14% at $0.1.
Agios Pharmaceuticals (NASDAQ: AGIO) revealed Phase 2 data for tebapivat in sickle cell disease (SCD), reporting hemoglobin responses ranging from 29.4% to 47.1% versus 33.3% in the placebo group. Due to a lack of significant differentiation, the company has decided to halt the SCD program. Shares closed down 7% at $37.36.
Vyne Therapeutics (NASDAQ: VYNE) convened a special meeting of shareholders to deliberate on a proposal to merge with Yarrow. Investors granted approval for issuing shares to Yarrow equity holders, fulfilling a vital prerequisite for finalizing the business combination. A share consolidation was ratified, with the Board of Directors authorized to determine a final ratio between 1-for-10 and 1-for-70 at a later date. Shareholders also voted to expand the total authorized common stock to 300 million shares. Shares closed up 11% at $0.89.
Advanced Biomed (NASDAQ: ADVB) announced via an SEC filing that it has terminated its June 2025 stock purchase agreement with Helena Global Investment Opportunities I. The agreement previously granted Advanced Biomed the right to issue and sell up to $25 million worth of common stock to Helena. The company confirmed that all outstanding amounts owed to Helena were fully settled at the time of the termination notice. Shares closed up 77% at $8.9.
CDT Equity (NASDAQ: CDT) disclosed in a recent filing that it finalized the acquisition of 1,020 shares of Sarborg on Feb 20, 2026. This equity position represented approximately 20% of the total issued share capital at the time of the transaction. Shares closed up 14% at $3.56.
BioVie Inc. (NASDAQ: BIVI) submitted a registration statement to the SEC on July 17, 2026, for a proposed sale of Class A common stock and warrants, with specific pricing and volume details yet to be determined. ThinkEquity will act as the transaction's exclusive placement agent. This financing follows the biopharmaceutical firm's recent finalization of a $300 million shelf registration for mixed securities. BioVie recently concluded the SUNRISE-PD trial for early-stage Parkinson's and achieved full enrollment in its ADDRESS-LC study, which tests bezisterim as a treatment for ascites. Shares closed down 21% at $1.42.
Valion Bio (NASDAQ: VBIO) and Sheba Medical Center have finalized an agreement to fund and execute a clinical trial of Entolimod. This study, which will involve up to 10 irradiated oncology patients, is designed to evaluate the treatment for radiation-induced neutropenia. The partnership establishes a capital-efficient expansion of Valion's oncology-supportive pipeline, complementing its primary medical countermeasure program for Acute Radiation Syndrome. Shares closed down 29% at $0.37.
Armata Pharmaceuticals (NYSE American: ARMP) confirmed the submission of its Phase 3 superiority study protocol for AP-SA02, targeting Staphylococcus aureus bacteremia, after resolving all FDA clinical and regulatory inquiries from the End-of-Phase 2 meeting. The company also finalized four manufacturing engineering runs at its California site and received a $2.5 million funding increase from the Department of Defense, bringing its total support to $28.7 million. Armata is currently positioned to launch the pivotal Phase 3 trial during the second half of 2026. Shares closed up 12% at $5.06.
Faeth Therapeutics (NASDAQ: FTH) received a new Market Outperform rating from a Citizens analyst. Along with initiating coverage, the firm set a price target of $51 for the oncology-focused biotechnology company. Shares closed up 9% at $28.19.
Daré Bioscience, Inc. (NASDAQ: DARE) received formal notification from the Nasdaq Listing Qualifications Staff on July 13, 2026, regarding a deficiency in stockholders' equity. The company failed to maintain the $2.5 million minimum required by Nasdaq Listing Rule 5550(b), as reported in its most recent Form 10-Q. Additionally, Daré does not currently meet alternative listing criteria, which include a $35 million market value of securities or $500,000 in net income from continuing operations. Shares closed down 32% at $1.34.
Glucotrack, Inc. (NASDAQ: GCTK) completed a $4.45 million senior secured convertible bridge loan. This short-term financing, which matures in 9 months and is backed by a first-lien security interest in company assets, was executed concurrently with a stock-for-stock merger with Lōkahi Therapeutics. While the capital infusion, brokered by E.F. Hutton & Co., delivers essential operational liquidity to the Lōkahi-led public entity, the secured debt structure and potential equity dilution triggered a distinct decline in the share price during pre-market trading. Shares closed down 21% at $0.41.
Week 29
(NASDAQ: BRK.A) Greg Abel's recent purchases have been significant investments in Japanese trading houses, Mitsubishi, Sumitomo, and Marubeni. These positions are part of Berkshire Hathaway's strategy to diversify its portfolio and capitalize on the strong dividend income generated by these companies. The investments are funded with yen borrowings, which have an average interest cost of just 1.2%, making them a cost-effective option for Berkshire Hathaway. As of the end of 2025, Berkshire Hathaway's stakes in these Japanese trading houses are valued at $35.4 billion, with a total cost of $15.4 billion. This strategy has already paid off handsomely and is expected to continue to pay off as a long-term investment for Berkshire Hathaway.
REGENXBIO (NASDAQ: RGNX) finalized the pricing of a $100 million public offering, consisting of common stock at $9.00 per share and pre-funded warrants at $8.9999. The financing includes a 30-day underwriters' option to purchase an additional 1.67 million shares. While the transaction provides necessary capital for the company's pipeline development, it results in immediate equity dilution for current investors. Shares closed down 12% at $9.89.
Jasper Therapeutics (NASDAQ: JSPR) finalized an all-stock acquisition of Kira Pharmaceuticals in conjunction with a $132 million private placement. The deal establishes a robust immunology-focused biologics pipeline featuring KP-104, briquilimab, and KP-701. This strategic move extends the company's projected cash runway into the second half of 2028 and sets the stage for several upcoming clinical milestones across transplant, autoimmune, and complement-mediated indications. Shares closed up 14% at $0.89.
Cosmos Health (NASDAQ: COSM) acquired an additional 274,000 shares at a mean price of $0.2554, which increases its total repurchase volume to 5.11 million shares. Under the current $5 million program, the company has deployed approximately $1.11 million to date. This ongoing buyback activity reflects management's continued strategy of returning value to shareholders based on their assessment that the equity remains undervalued. Shares closed down 16% at $0.23.
Xencor (NASDAQ: XNCR) announced that Phase 1 expansion-cohort data for XmAb819 in advanced ccRCC has been selected for a proffered oral presentation at ESMO 2026. The findings will facilitate IV dose selection for a pivotal monotherapy trial scheduled for 2027. Meanwhile, the company continues to enroll patients in subcutaneous administration and broader ENPP3-positive tumor cohorts to further evaluate the candidate's clinical profile. Shares closed up 17% at $17.47.
Intuitive Surgical (NASDAQ: ISRG) reported a 19% increase in Q2 revenue to $2.89 billion, bolstered by a 16% rise in procedure volume and the installation of 468 da Vinci systems. The continued rollout of the da Vinci 5 platform contributed to a non-GAAP EPS of $2.80. Furthermore, the company utilized $380 million for share buybacks, which underscores its robust operational performance within the robotic-assisted surgery market. Shares closed down 14% at $345.42.
Trevi Therapeutics (NASDAQ: TRVI) announced that its leadership team will engage in several upcoming industry events, including the BIO International Convention, Leerink Therapeutics Forum, and ERS Cough Conference. Discussions will focus on the company's lead candidate, Haduvio (oral nalbuphine ER), which is currently being developed for chronic cough associated with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (ILD), and refractory chronic cough (RCC). Notably, management confirmed that these presentations will not include any updated clinical, regulatory, or financial disclosures. Shares closed up 10% at $19.07.
STAAR Surgical (NASDAQ: STAA) announced preliminary Q2 2026 revenue projections surpassing $90 million, a substantial increase from the $44.3 million recorded during the same period last year. This operational momentum is primarily attributed to a recovery in China and sustained strength across the broader Asia-Pacific and Americas regions. Despite these gains, the company continues to navigate macroeconomic and geopolitical headwinds within the Middle East and other specific regional markets. Shares closed down 9% at $26.44.
Eli Lilly and Company (NYSE: LLY) announced a definitive agreement on July 16, 2026, to acquire AtaiBeckley Inc. (NASDAQ: ATAI) in a deal valued up to approximately $3.8 billion, significantly expanding Lilly's neuropsychiatric pipeline into rapid-acting neuroplastogens.Under the terms of the agreement, Lilly will pay $6.75 per share in upfront cash (an aggregate equity value of ~$2.8 billion), representing a 40% premium to ATAI's 30-day volume-weighted average price. Shareholders will also receive a Contingent Value Right (CVR) worth up to $2.50 per share (up to ~$1.0 billion aggregate) tied to regulatory and clinical milestones for AtaiBeckley's lead psychiatric candidates. Shares closed up 33% at $7.15.
Medicus Pharma (NASDAQ: MDCX) secured FDA feedback and central IRB approval for its modified Phase 2 trial of Teverelix in patients with acute urinary retention (AUR). The multicenter study, titled ANT-2111-02, will investigate the pharmacodynamic impact of its long-acting GnRH antagonist on prostate volume and urinary metrics. By optimizing the protocol, Medicus reduced the projected enrollment from 390 to approximately 126 participants across the U.S. and Europe. This strategic redesign aims to accelerate dose selection and provide an early efficacy signal for the program's continued clinical advancement. Shares closed up 17% at $0.41.
VivoSim Labs (NASDAQ: VIVS) announced the pricing of a $4.0 million private placement at $0.85 per share, involving common stock and warrants for a sole healthcare-dedicated investor. The transaction bolsters available working capital but introduces equity dilution and necessitates shareholder approval to reprice May 2024 warrants from $9.60 down to $0.85. This fiscal restructuring aims to strengthen the company's balance sheet while adjusting previous warrant obligations to current market valuations. Shares closed down 28% at $0.61.
Immuron (NASDAQ:IMRN) FY26 unaudited global Travelan sales rose 6% to AUD$7.7 million, led by 10% growth in Australia and 13% growth in the U.S. in USD, marking four consecutive quarters of year-over-year growth, while Canada remains small but is rebounding sharply from prior-period pipeline-fill effects. Shares closed down 6% at $1.13.
Aptorum Group (NASDAQ: APM) anticipates the completion of its merger with DiamiR on approximately July 20, 2026. Following the transaction, the Delaware-incorporated entity will be rebranded as Niki BioSolutions and commence trading under the ticker NIKI. To maintain Nasdaq bid-price compliance, the company will implement a 1-for-10 reverse stock split as part of the consolidation process. Shares closed down 16% at $0.69. Shares closed down 15% at $0.69.
Jaguar Health (NASDAQ: JAGX) submitted an SEC registration statement for the potential disposition of approximately 5.52 million shares by specific selling securityholders. While Jaguar will not realize proceeds from this secondary offering, the filing follows a series of corporate developments, notably a new supply contract for crofelemer and the final conversion of all Series O preferred stock into common equity. Shares closed down 31% at $1.34. Shares closed down 31% at $1.34.
Kairos Pharma (NASDAQ: KAPA) disclosed preliminary safety results from its Phase 1 study of ENV-105 paired with osimertinib for advanced EGFR-mutated non-small cell lung cancer (NSCLC). This update marks a key development for the company's primary initiative to restore sensitivity in patients resistant to osimertinib, the current therapeutic benchmark. No treatment-related serious adverse events were reported among the 13 participants, establishing a safety foundation as the trial advances toward initial efficacy assessments. Shares closed up 7% at $0.34.
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) established a strategic partnership with Barcode Nanotech to engineer a novel lipid nanoparticle (LNP) delivery system for Aramchol, its proprietary SCD1 inhibitor. The initiative focuses on leveraging Barcode's specialized platform to enhance the candidate's therapeutic reach in cardiovascular medicine. Shares closed up 7% at $0.55.
Virax Biolabs (NASDAQ: VRAX) issued a corporate update detailing a strengthened financial position, including $6.4 million in cash for FY2026 and an additional $3.3 million secured through post-period financing. The company reported a narrower net loss and confirmed its return to Nasdaq bid-price compliance, reinforcing fiscal stability. On the commercial front, Virax finalized a supply agreement with Fosun Diagnostics to distribute its ImmuneSelect platform across six Southeast Asian territories, marking a significant milestone in its early-stage regional expansion. Shares closed up 13% at $3.9.
Abbott (NYSE: ABT) reported a 13.0% increase in second-quarter sales, with comparable growth reaching 4.8% and adjusted EPS at $1.31. The company returned $2.1 billion to its shareholders and updated its FY2026 adjusted EPS forecast to a range of $5.45–$5.60. Additionally, management confirmed its full-year outlook for comparable sales growth between 6.5% and 7.5%. Shares closed up 11% at $98.83.
Senti Biosciences, Inc. (NASDAQ: SNTI) finalized a strategic agreement to divest its SENTI-202 program and Gene-Circuit technology to a Celadon-backed entity. In consideration of the transfer, Senti will receive contingent value rights (CVRs) that could total $60 million. This tactical realignment allows the company to focus exclusively on its Regulator Dial controllable genetic medicine platform. Realization of the CVR value remains contingent upon future SENTI-202 milestones, including BLA acceptance, regulatory approval, and specific commercial sales targets. Shares closed down 40% at $0.58.
Gossamer Bio, Inc. (NASDAQ: GOSS) announced that its shareholders have formally approved a significant charter amendment that increases the company's authorized common shares to 4 billion. Shares closed up 15% at $0.16.
Ernexa Therapeutics (NASDAQ: ERNA) revealed robust preclinical data that independently verify the anti-tumor potency of its primary cell therapy candidate, ERNA-101. When utilized alongside PD-1 checkpoint inhibitors, the therapy demonstrated significant efficacy in addressing advanced oncological and autoimmune conditions. This new data confirms the candidate's clinical potential as the company continues to innovate within the cell therapy landscape. Shares closed up 11% at $6.73.
Cardiff Oncology, Inc. (NASDAQ: CRDF) priced a $10 million registered direct offering, involving the sale of 8,571,429 common shares and equivalent warrants at a unit price of $1.05. Internal participation from directors and officers contributed an additional 731,707 shares and warrants at a premium rate of $1.435 per unit. The warrants, with a $1.31 exercise price, will be exercisable over a 5.5-year term following a six-month deferral period, contingent on shareholder authorization. Shares closed down 32% at $0.89.
Evogene Ltd. (NASDAQ: EVGN) subsidiary AgPlenus introduced a novel AI-driven antifungal potency prediction tool as part of its ChemPass AI for Ag platform. This technological advancement facilitates the expedited screening and prioritization of fungicide leads based solely on chemical architecture. The system is designed to bolster the development of crop-protection candidates targeting resilient pathogens, including Septoria, Botrytis, and Fusarium, by optimizing the discovery process for next-generation agricultural solutions. Shares closed up 20% at $0.58.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) announced that it has secured multiple favorable patent actions, comprising three notices of allowance and one grant decision, to expand global intellectual property protection for its proprietary INTASYL self-delivering siRNA gene-silencing platform. Issued across key international markets including the United States, Canada, and Japan, these additions strengthen the clinical-stage biotech's total issued patent portfolio to 54 patents. The robust IP package comprehensively covers INTASYL's unique chemistry, specific gene targets, immuno-oncology compounds, and therapeutic indications. According to CEO Robert Bitterman, these patent advancements will serve as critical strategic assets to facilitate future biopharma partnerships, accelerate internal R&D, and protect the company's eventual commercial pathways for localized gene-silencing therapies. Shares closed down 14% at $0.89.
Annexon, Inc. (NASDAQ: ANNX) announced it will present post hoc analyses from its Phase 2 ARCHER trial at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting. The presentation will highlight baseline characteristics correlated with a confirmed loss of 15 letters in Best Corrected Visual Acuity (BCVA) among patients with geographic atrophy (GA). These findings are intended to refine patient selection strategies for the ongoing Phase 3 ARCHER II clinical trial. Annexon remains on track to report pivotal topline data for vonaprument in GA during the fourth quarter of 2026. Shares closed up 17% at $6.5.
Veradermics, Incorporated (NYSE: MANE) revealed successful topline data on Jul 15, 2026 from its Phase 2 Study 207, an open-label trial testing VDPHL01 for female pattern hair loss. This specialized gel-matrix oral minoxidil is engineered for extended release to sustain therapeutic growth levels while mitigating cardiovascular risks linked to traditional immediate-release formulations. The trial successfully achieved its primary endpoints over six months, with 4.5mg QD and BID cohorts showing significant mean target area hair count (TAHC) gains of 22.7 and 23.3 hairs/cm², respectively. Clinical activity was noted as early as the second month, and by the study's conclusion, approximately 90% of subjects reported improved coverage via the AAIRS scale. With a favorable safety profile showing no drug-related serious adverse events or cardiac complications, Veradermics is progressing with its Phase 2/3 Study 306, with a topline readout anticipated during the first half of 2027. Shares closed up 12% at $123.7.
NextCure, Inc. (NASDAQ: NXTC) finalized a definitive all-stock reverse merger with Avere Therapeutics, forming a clinical-stage entity that will trade under the name Avere Therapeutics (NASDAQ: AVRX). Guided by CEO Dr. Andrew Cheng, the reorganized firm will focus on AVR-001, a long-acting cyclic peptide IL-23 receptor antagonist licensed from Hansoh Pharma. Engineered with a 100-hour half-life for once-weekly oral dosing, AVR-001 demonstrated Phase 1b PASI 75 psoriasis responses at Week 8, comparable to those of established daily inhibitors. Supported by a $320 million private placement led by Fairmount and Hansoh, the agreement provides Avere stockholders with ~98.79% ownership, while NextCure holders retain 1.21% and a two-year CVR for 90% of proceeds from legacy assets. This financing extends the operational runway through a Phase 2b psoriasis readout in early 2028 and the launch of a Phase 2b ulcerative colitis study. Nextcure shares closed up 202% at $6.58.
AEON Biopharma, Inc. (NYSE American: AEON) disclosed the pricing for its expanded underwritten public offering, which is projected to generate roughly $13.75 million in initial gross capital. Shares closed up 11% at $0.36.
Spero Therapeutics, Inc. (NASDAQ: SPRO) concluded a transformative financial and strategic realignment, anchoring $105 million through a non-dilutive royalty monetization with Healthcare Royalty and a $1.1 billion worldwide licensing pact with Innovent Biologics. The transaction involves Spero trading future milestones and net sales royalties from Utebzi™, its GSK-partnered oral antibiotic, for upfront capital; the company is slated to recapture 35% of these revenues post-repayment. These funds will facilitate a strategic pivot into immunology via the in-licensing of SP001, a Phase 2-ready anti-CD40L monoclonal antibody designed to bypass platelet activation and B-cell depletion hurdles. Spero, which holds rights for all territories excluding Greater China, plans to initiate a Phase 2 trial in IgG4-related disease (IgG4-RD) during the second quarter of 2027, extending its financial runway into the latter half of 2029.
Matinas BioPharma (NYSE: MTNB) executed a definitive merger with GH Power, thereby pivotally shifting its operations toward the clean energy and green hydrogen sector as a public company. The transaction leaves Matinas stockholders with roughly 9% ownership in the reorganized company. Simultaneously, Matinas sold its LNC platform and MAT2203 asset to Azurity Pharmaceuticals, receiving $4.0 million upfront. The divestiture includes potential milestone incentives of up to $17.5 million and mid-single-digit royalties on subsequent commercial sales. Shares closed down 27% at $0.35.
Hemab Therapeutics (NASDAQ: COAG) reported favorable clinical outcomes from its Phase 2 long-term extension study of sutacimig (HMB-001) for the subcutaneous prevention of bleeds in Glanzmann thrombasthenia (GT). Results from 34 patients with up to 15.9 months of drug exposure showed a 92% reduction in treated bleeding events and an 84% reduction in the mean annualized treated bleeding rate (ATBR) in the low-dose cohort. The trial also confirmed successful hemostatic control across three surgical procedures and a tolerable safety profile, with Grade 2 thromboembolic events limited to high-exposure or multi-risk-factor groups. Following positive preclinical data in Factor VII deficiency and alignment with the FDA on a 0.2mg/kg weekly dose, Hemab plans to initiate its registration-directed Phase 3 trial during the second half of 2026. Shares closed up 10% at $43.31.
Evotec SE (NASDAQ: EVO) announced preliminary first-half 2026 financial results, reporting revenue of €300.1 million and an adjusted EBITDA loss of €42.7 million alongside €465.6 million in liquidity. Citing a significant deceleration in growth and profitability, the company issued a downward revision to its full-year 2026 outlook. Evotec now anticipates annual revenue between €570 million and €610 million, with adjusted EBITDA projected to range from a loss of €70 million to €105 million, reflecting performance well below previous market expectations. Shares closed down 12% at $2.14.
Q32 Bio (NASDAQ: QTTB) reported Phase 2a SIGNAL-AA Part B results for bempikibart in patients with severe alopecia areata. Data revealed a 35.3% mean Salt reduction within the mITT population alongside a 40% SALT-20 response rate. With encouraging PK/PD profiles and no emerging safety concerns, the company expects to initiate a registration-directed clinical program during the first half of 2027. Shares closed up 91% at $21.38.
Agenus (NASDAQ: AGEN) closed an oversubscribed private placement, securing $85 million in initial capital with potential proceeds reaching $255 million via warrant exercises. These funds will advance the registration-directed Phase 3 ROBBIN1 trial evaluating neoadjuvant BOT/BAL in MSS colon cancer. To focus on this curative-intent pathway, the firm is halting financial backing for the BATTMAN study in late-line metastatic MSS CRC. Shares closed up 83% at $6.12.
Matinas BioPharma (NYSE: MTNB) entered into a definitive merger agreement with GH Power, transitioning to a publicly traded clean energy and green hydrogen enterprise. Under the terms, Matinas shareholders will retain approximately 9% equity in the combined entity. Concurrently, the company divested its MAT2203 candidate and LNC platform to Azurity Pharmaceuticals for $4.0 million in upfront cash, with potential milestone payments of up to $17.5 million, plus mid-single-digit royalties on future net sales. Shares closed down 37% at $0.48.
Cadrenal Therapeutics (NASDAQ: CVKD) disclosed the resignation of Chief Medical Officer James J. Ferguson III, effective July 31, 2026. The cardiovascular and renal-specialized firm has commenced an executive search to fill the vacancy and is finalizing a separation agreement to ensure uninterrupted oversight of its Phase 3 clinical objectives and regulatory milestones. Shares closed down 16% at $2.42.
BNB Plus Corp. (NASDAQ: BNBX) received a formal delisting notice from the Nasdaq Listing Qualifications Department for failing to maintain the $1.00 minimum bid price. While the firm intends to appeal the ruling to the Nasdaq Listing and Hearing Review Council, citing its recent capital infusion and strategic pivot, the request will not pause the suspension. Consequently, shares will be delisted from the Nasdaq Capital Market at the open on Jul 14, 2026. To provide continued liquidity, the company has transitioned its equity to the OTCQB Venture Market, with quoting expected to commence under the same ticker symbol. Shares closed down 57% at $0.16.
Apollomics (NASDAQ: APLM) confirmed it has satisfied all Nasdaq listing requirements following a ten-day period where its market value of listed securities remained consistently above the $35 million threshold. This regulatory milestone resolves immediate delisting concerns as the oncology firm advances the clinical development of vebreltinib for patients with c-Met-driven malignancies. Shares closed down 25% at $14.21.
Cue Biopharma (NASDAQ: CUE) appointed immunology veteran Dominic Borie as Chief Medical Officer and Head of R&D. The leadership transition precedes critical clinical milestones, including Phase 2 data for CUE-221 in CSU expected by late Q3 2026 and the Q4 2026 launch of a Phase 1 study for CUE-401. These initiatives are bolstered by a recent $50 million private placement to fund advancing oncology and autoimmune pipelines. Shares closed down 16% at $30.92.
Erasca (NASDAQ: ERAS) unveiled plans for an underwritten public offering to sell $500.0 million of common stock, contingent upon market conditions. The oncology-focused firm also expects to provide underwriters with a 30-day option for an additional $75.0 million in shares. While the company aims to secure this capital to advance its pipeline, final execution remains subject to market volatility and closing terms. Shares are currently down 13% at $15.15 during extended hours.
Week 28
Forte Biosciences, Inc. (NASDAQ: FBRX) shares closed up 20% at $43.92 following the release of positive 24-week interim results from a Phase 1b trial evaluating FB102, an anti-CD122 monoclonal antibody for vitiligo. The double-blind, placebo-controlled study achieved its primary endpoint, showing a statistically significant 29.6% mean improvement in the Facial Vitiligo Area Scoring Index (FVASI) at Week 24 (p=0.020). Among patients with high-severity disease, FB102 achieved a mean improvement of 43.2% (p=0.006), with 58.8% achieving an FVASI50 response. The candidate maintained a favorable safety profile, and, based on the data, Guggenheim reiterated its Buy rating with a $75.00 price target. The firm is now awaiting the upcoming Phase 2 top-line readout for FB102 in celiac disease.
Virax Biolabs Group Limited (NASDAQ: VRAX) finalized a deal to immediately exercise certain preferred investment options, resulting in approximately $3.3 million in gross proceeds. The exercise price was lowered to $6.00 per share to facilitate the transaction, which is intended to bolster working capital. The move also involved the issuance of new Series A and Series B warrants, introducing the possibility of further dilution of shares. Shares closed down 36% at $4.08.
Q32 Bio Inc. (NASDAQ: QTTB) announced it will report 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA on Monday, July 13, 2026. Following the announcement, Q32 Bio will host a conference call and webcast on July 13, 2026, to discuss the results. Shares are currently trading up 30% at $14.66 during extended hours.
Silo Pharma, Inc. (NASDAQ: SILO) executed an at-the-market private placement for approximately 619,965 common shares or pre-funded warrants, yielding initial gross proceeds of roughly $4 million. The transaction included the issuance of Series A-3 and A-4 warrants, each exercisable at $6.21 per share. Total liquidity from the arrangement could reach $11.7 million upon full exercise of these instruments, which are subject to a resale registration filing with the SEC. Shares closed down 26% at $5.7.
Tvardi Therapeutics Inc saw its rating upgraded by Piper Sandler to Overweight from Neutral. The firm also significantly increased its price target for the company to $13, up from the previous $3 target. Shares closed down 14% at $3.28.
Glucotrack, Inc. (NASDAQ: GCTK) announced that the USPTO has issued a notice of allowance for a new patent application, broadening the intellectual property portfolio of its continuous blood glucose monitoring (CBGM) platform. This latest allowance strengthens the company's patent portfolio as it develops its fully implantable, multi-year CBGM system for future commercial use. The newly allowed claims, which build upon three patents secured in late 2025, specifically address sensor architecture and intravascular sensing leads designed for long-term monitoring. The protection covers the device's unique electronics assembly, electrode configurations, and specialized implantation methods required for continuous glucose detection within the vasculature. Shares closed up 7% at $0.42.
Ionis Pharmaceuticals (NASDAQ: IONS) announced that its Phase 3 CARDIO-TTRansform trial evaluating eplontersen for ATTR-CM failed to reach its primary composite endpoint regarding cardiovascular mortality and recurring events. While the addition of eplontersen to stabilizers showed no incremental benefit, treatment in the monotherapy subgroup and secondary metrics trended favorably, supported by a consistent safety profile. Shares closed down 24% at $64.27.
Virax Biolabs Group Limited (NASDAQ: VRAX) disclosed that its UK-based subsidiary has finalized an exclusive commercial supply deal with Fosun Diagnostics. Effective Jul 9, 2026, the agreement grants Fosun exclusive rights to distribute the ImmuneSelect portfolio across Singapore, Thailand, Vietnam, Indonesia, the Philippines, and Malaysia. The partnership enables the immediate, order-based distribution of Virax's peptide pools and ELISpot assay plates, with an initial focus on tuberculosis research in Thailand. While providing immediate revenue through these research-use-only tools, the arrangement remains separate from the company's ongoing clinical development of its flagship T-cell platform, ViraxImmune. Shares closed up 101% at $6.38.
Aptevo Therapeutics Inc (NASDAQ: APVO) announced it has been granted a U.S. notice of allowance for a patent covering binding proteins and antibodies targeting 4-1BB and OX40, along with associated compositions and therapeutic methods intended for oncology treatments. Shares closed down 12% at $3.94.
Tvardi Therapeutics Inc saw its rating upgraded by Piper Sandler to Overweight from Neutral. The firm also significantly increased its price target for the company to $13, up from the previous $3 target. Shares closed down 24% at $3.8.
Forte Biosciences, Inc. (NASDAQ: FBRX) shared results from a Phase 1b trial of FB102 in vitiligo. The study met its goals, with patients showing a mean improvement of 29.6% in the Facial Vitiligo Area Scoring Index (FVASI) by week 24. Notably, efficacy was observed as early as day 64. In a subgroup with more severe disease, the mean improvement was 43.2%, and 58.8% achieved an FVASI50. The candidate maintained a favorable safety profile, with 84% of treated subjects showing improvement, compared with a 27% decline in the placebo arm. Shares closed up 78% at $36.7.
Alector, Inc. (NASDAQ: ALEC) disclosed that GSK plc (NASDAQ: GSK) has provided formal notice to end their 2021 immuno-neurology alliance, effective January 2, 2027. This termination follows clinical setbacks for the joint progranulin-elevating antibody programs, including the Phase 3 INFRONT-3 trial for latozinemab and the Phase 2 PROGRESS-AD trial for nivisnebart. While Alector previously secured $700 million upfront under the agreement, the partnership's end removes potential milestones totaling $1.5 billion. To preserve capital, the company has cleared its $10.4 million debt with Hercules Capital and terminated the associated credit facility. Shares closed down 11% at $1.65.
Bone Biologics Corporation (NASDAQ: BBLG) announced it has entered into a definitive agreement for a private placement of common stock at $1.42 per share, generating $3.0 million in initial gross proceeds. The financing includes warrants that could provide an additional $6.0 million upon exercise. Capital from this offering is earmarked to fund ongoing clinical trials, strengthen its patent portfolio, and support general working capital requirements, though the issuance introduces potential equity dilution for current shareholders. Shares closed down 12% at $1.3.
Satellos Bioscience Inc. (NASDAQ: MSLE) reported encouraging six-month interim Phase 2 TRAILHEAD results for SAT-3247, an oral muscle-regenerating small molecule for Duchenne muscular dystrophy (DMD). In adults, the therapy achieved a 3.7% average muscle fat fraction reduction on MRI, a 34% mean upper-limb effort increase, and a 38% creatine kinase reduction, while maintaining stable strength. With a clean safety profile and no serious adverse events, the data reinforces Satellos's pediatric BASECAMP study and plans to launch additional U.S. clinical sites this quarter. Shares closed up 9% at $8.87.
BioLineRx Ltd. (NASDAQ: BLRX) and Hemispherian AS disclosed promising preclinical findings on Jul 8, 2026 exhibiting potent therapeutic synergy between GLIX1, a novel oral TET2 activator, and the PARP inhibitor olaparib. Utilizing a patient-derived xenograft model of HR-proficient ovarian cancer, the combination successfully triggered synthetic lethality, bypassing traditional resistance to PARPi therapies. Notably, the low-dosage regimen achieved tumor shrinkage comparable to standard cisplatin treatment and outperformed monotherapy benchmarks. Consequently, the partners intend to integrate an ovarian cancer cohort into their Phase 1/2a expansion study, targeting platinum-resistant gynecologic cancers. Shares closed down 5% at $2.96.
Chemomab Therapeutics Ltd. (NASDAQ: CMMB) revealed it has entered into a definitive merger agreement with Scipher Medicine. Following the all-stock transaction, the combined entity will operate under the Scipher Medicine name and trade under the ticker SCIP. The strategic pairing integrates Chemomab's lead candidate, nebokitug, with Scipher's AI-driven precision medicine platform to advance a Phase 2 clinical trial in rheumatoid arthritis. Backed by $30 million in committed financing, the company anticipates a clinical data readout in the first half of 2028 and projects a cash runway extending into the second half of that year. Shares closed down 29% at $1.97.
Seres Therapeutics, Inc. (NASDAQ: MCRB) revealed encouraging primary data on Jul 8, 2026 from a Phase 1b investigator-led study of SER-155, its live biotherapeutic asset for immune-mediated enterocolitis (irEC). Conducted by Memorial Sloan Kettering, the trial showed that 80% of participants achieved an immunosuppression-free clinical response by the 15th day, meeting the primary goal of symptom relief without the need for systemic steroids that often compromise oncology treatments. Notably, 33% of patients saw full clinical remission, supported by significant biomarker evidence of decreased gut inflammation and improved mucosal integrity. With a clean safety report featuring no therapy-related severe adverse events, Seres is now pursuing strategic collaborations with oncology-focused pharmaceutical firms to advance the development of this candidate. Shares closed down 12% at $7.14.
Immunome, Inc. (NASDAQ: IMNM) disclosed on Jul 8, 2026 that the FDA has accepted its New Drug Application (NDA) for varegacestat, setting a PDUFA action date of April 28, 2027. Shares closed down 2% at $24.01.
Prime Medicine, Inc. (NASDAQ: PRME) announced a decisive legal victory following a binding arbitration ruling regarding its collaboration agreement with Beam Therapeutics. The tribunal confirmed that PM647, a prime editing candidate for Alpha-1 Antitrypsin Deficiency (AATD), remains within Prime's exclusive therapeutic field, dismissing all breach-of-contract claims without damages or penalties. PM647 leverages a proprietary liver-targeted LNP system to repair the SERPINA1 gene mutation, a process that has successfully restored physiologic levels of functional M-AAT protein in preclinical humanized models. With this regulatory and legal cloud removed, the company is proceeding with its plan to submit an IND and/or CTA in the third quarter of 2026, targeting a clinical data readout in 2027. Shares closed up 16% at $4.62.
Aptevo Therapeutics Inc. (NASDAQ: APVO) announced it has received a Notice of Allowance from the USPTO for a patent covering its 4-1BB and OX40 binding proteins. The intellectual property includes bispecific antibodies and related compositions specifically engineered for oncology applications. This allowance further validates the company's proprietary platform and strengthens its competitive position in developing next-generation cancer immunotherapies. Shares are currently up 10% at $4.96 during extended hours.
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) finalized a definitive agreement on July 6, 2026, to acquire Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) for $85.00 per share in cash, valuing the deal at an equity total of ~$10.0 billion. The strategic move integrates a high-growth endocrinology franchise with a projected peak sales potential surpassing $5 billion annually. Key assets include PALSONIFY (paltusotine), a recently approved oral treatment for acromegaly seeing strong market traction, and atumelnant, a Phase 3 ACTH receptor antagonist poised to redefine the standard of care for congenital adrenal hyperplasia. Vertex plans to fund the acquisition through existing cash reserves and a $4.5 billion bridge loan facility. Unanimously approved by both boards, the merger is expected to conclude in the third quarter of 2026 and become accretive to non-GAAP operating income by 2029. Crinectics shares are trading up 101% at $85.50 during extended hours
IceCure Medical Ltd. (NASDAQ: ICCM) showcased the growing international adoption of its ProSense cryoablation system at the SOBRICE Onco 2026 congress in Brazil, highlighting commercial expansion in Latin America's largest healthcare market. Leveraging momentum from its recent U.S. FDA marketing authorization for early-stage breast cancer, the company is actively increasing procedural volume via exclusive importer KTR Medical for the treatment of breast, lung, kidney, and musculoskeletal tumors. The platform's clinical utility was further validated through presentations by Dr. Vanessa Sanvido on Brazil's independent 750-patient SIX trial and by Dr. Toulsie Ramtohul, who conducted master classes at Albert Einstein Hospital ahead of the launch of France's 900-patient CRYODESC comparative study. Shares closed down 14% at $4.61.
Seer (NASDAQ: SEER) filed an investor presentation ahead of its July 28, 2026, annual meeting, emphasizing momentum in its proteomics platform, cost reductions, a ~$220 million debt-free cash position, share repurchases, and board governance, while urging shareholders to support Seer's nominees on the BLUE proxy card. Shares closed up 35% at $2.19.
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) reported that CEO and Chairman Quang X. Pham sold 7,400 shares in an open-market transaction on June 29, 2026, at an average price of $3.03 per share, for a total of $22,422. While his direct ownership decreased to 98,589 shares, Pham preserves a significant stake in the cardiorenal-focused company through 200,000 shares held indirectly via The PVBQ Living Trust. Shares closed down 7% at $3.35.
Mangoceuticals, Inc. (NASDAQ: MGRX) entered into a Subscription Agreement for a private placement of 850,000 restricted common shares with an accredited investor on June 29, 2026. Priced at $0.32 per share, the transaction generated $272,000 in gross proceeds intended to bolster operating capital. Executed under Section 4(a)(2) and Rule 506 of Regulation D, the placement avoids standard underwriting commissions while granting the investor one-year piggyback registration rights, though the newly issued shares remain subject to strict legal resale restrictions. Shares closed down 7% at $0.44.
PMGC Holdings Inc. (NASDAQ: ELAB) finalized the legal merger of AGA Precision Systems LLC into its subsidiary, A&B Aerospace, Inc., a move designed to centralize its high-precision manufacturing operations. As part of this structural reorganization, the AGA entity will be dissolved, while A&B Aerospace will utilize a DBA registration to preserve the AGA brand and ensure uninterrupted service for its Tier 1 customers and vendors. Shares closed up 14% at $1.34.
OS Therapies (NYSE: OSTX) detailed multiple third-quarter 2026 milestones for OST-HER2 in treating metastatic osteosarcoma, featuring an upcoming FDA Type B meeting focused on statistical methodology. The firm is preparing to launch a Phase 3 study in Australia and expects an EMA CMAA filing window to open by September 30, 2026. Management is exploring early market-entry strategies using three-year overall survival data alongside biomarker results, while confirming that existing capital remains sufficient to fund operations through 2027. Shares closed down 14% at $1.61.
Curis, Inc. (NASDAQ: CRIS) successfully consented the initial six participants for its TakeAim CLL clinical trial, which evaluates emavusertib in combination with zanubrutinib. This enrollment milestone surpassed the firm's internal projections and reinforces its timeline to have five patients dosed by late July 2026. Management reaffirmed that preliminary data from the CLL cohort remains on track for release in December 2026. Shares closed down 14% at $5.94.
Cosmos Health (NASDAQ: COSM) acquired 220,000 additional common shares at a mean price of $0.2229 per share, increasing its total repurchase volume to 3.64 million shares. With approximately $700,000 deployed to date under its existing $5 million buyback initiative, the move reinforces management's confidence in the company's valuation while maintaining substantial capital for future open-market transactions. Shares closed up 14% at $0.27.
NanoViricides (NYSE: NNVC) accelerated efforts for its Phase 2 clinical trial in the DRC, evaluating NV-387 oral gummies for the treatment of Bundibugyo Ebola. While the company has secured Pillar Committee endorsement, a principal investigator, and vital regional logistics, initiation of patient dosing remains contingent upon final regulatory clearances from the ethics committee and ACOREP. Shares closed up 13% at $1.5.
07/06/2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) finalized a definitive agreement on July 6, 2026, to acquire Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) for $85.00 per share in cash, valuing the deal at an equity total of ~$10.0 billion. The strategic move integrates a high-growth endocrinology franchise with a projected peak sales potential surpassing $5 billion annually. Key assets include PALSONIFY (paltusotine), a recently approved oral treatment for acromegaly seeing strong market traction, and atumelnant, a Phase 3 ACTH receptor antagonist poised to redefine the standard of care for congenital adrenal hyperplasia. Vertex plans to fund the acquisition through existing cash reserves and a $4.5 billion bridge loan facility. Unanimously approved by both boards, the merger is expected to conclude in the third quarter of 2026 and become accretive to non-GAAP operating income by 2029. Crinectics shares are trading up 101% at $85.50 during extended hours
IceCure Medical Ltd. (NASDAQ: ICCM) showcased the growing international adoption of its ProSense cryoablation system at the SOBRICE Onco 2026 congress in Brazil, highlighting commercial expansion in Latin America's largest healthcare market. Leveraging momentum from its recent U.S. FDA marketing authorization for early-stage breast cancer, the company is actively increasing procedural volume via exclusive importer KTR Medical for the treatment of breast, lung, kidney, and musculoskeletal tumors. The platform's clinical utility was further validated through presentations by Dr. Vanessa Sanvido on Brazil's independent 750-patient SIX trial and by Dr. Toulsie Ramtohul, who conducted master classes at Albert Einstein Hospital ahead of the launch of France's 900-patient CRYODESC comparative study. Shares closed down 14% at $4.61.
Seer (NASDAQ: SEER) filed an investor presentation ahead of its July 28, 2026, annual meeting, emphasizing momentum in its proteomics platform, cost reductions, a ~$220 million debt-free cash position, share repurchases, and board governance, while urging shareholders to support Seer's nominees on the BLUE proxy card. Shares closed up 35% at $2.19.
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) reported that CEO and Chairman Quang X. Pham sold 7,400 shares in an open-market transaction on June 29, 2026, at an average price of $3.03 per share, for a total of $22,422. While his direct ownership decreased to 98,589 shares, Pham preserves a significant stake in the cardiorenal-focused company through 200,000 shares held indirectly via The PVBQ Living Trust. Shares closed down 7% at $3.35.
Mangoceuticals, Inc. (NASDAQ: MGRX) entered into a Subscription Agreement for a private placement of 850,000 restricted common shares with an accredited investor on June 29, 2026. Priced at $0.32 per share, the transaction generated $272,000 in gross proceeds intended to bolster operating capital. Executed under Section 4(a)(2) and Rule 506 of Regulation D, the placement avoids standard underwriting commissions while granting the investor one-year piggyback registration rights, though the newly issued shares remain subject to strict legal resale restrictions. Shares closed down 7% at $0.44.
PMGC Holdings Inc. (NASDAQ: ELAB) finalized the legal merger of AGA Precision Systems LLC into its subsidiary, A&B Aerospace, Inc., a move designed to centralize its high-precision manufacturing operations. As part of this structural reorganization, the AGA entity will be dissolved, while A&B Aerospace will utilize a DBA registration to preserve the AGA brand and ensure uninterrupted service for its Tier 1 customers and vendors. Shares closed up 14% at $1.34.
OS Therapies (NYSE: OSTX) detailed multiple third-quarter 2026 milestones for OST-HER2 in treating metastatic osteosarcoma, featuring an upcoming FDA Type B meeting focused on statistical methodology. The firm is preparing to launch a Phase 3 study in Australia and expects an EMA CMAA filing window to open by September 30, 2026. Management is exploring early market-entry strategies using three-year overall survival data alongside biomarker results, while confirming that existing capital remains sufficient to fund operations through 2027. Shares closed down 14% at $1.61.
Curis, Inc. (NASDAQ: CRIS) successfully consented the initial six participants for its TakeAim CLL clinical trial, which evaluates emavusertib in combination with zanubrutinib. This enrollment milestone surpassed the firm's internal projections and reinforces its timeline to have five patients dosed by late July 2026. Management reaffirmed that preliminary data from the CLL cohort remains on track for release in December 2026. Shares closed down 14% at $5.94.
Cosmos Health (NASDAQ: COSM) acquired 220,000 additional common shares at a mean price of $0.2229 per share, increasing its total repurchase volume to 3.64 million shares. With approximately $700,000 deployed to date under its existing $5 million buyback initiative, the move reinforces management's confidence in the company's valuation while maintaining substantial capital for future open-market transactions. Shares closed up 14% at $0.27.
NanoViricides (NYSE: NNVC) accelerated efforts for its Phase 2 clinical trial in the DRC, evaluating NV-387 oral gummies for the treatment of Bundibugyo Ebola. While the company has secured Pillar Committee endorsement, a principal investigator, and vital regional logistics, initiation of patient dosing remains contingent upon final regulatory clearances from the ethics committee and ACOREP. Shares closed up 13% at $1.5.
07/02/2026
Elicio Therapeutics (NASDAQ: ELTX) shares fell 37% to $3.22 following a $15 million registered direct offering of 4.38 million shares. Net proceeds will fund the Phase 1 trial of ELI-002 7P for metastatic pancreatic cancer, along with pipeline development and working capital.
Tenax Therapeutics, Inc. (NASDAQ: TENX) announced that Phase 3 LEVEL trial data for TNX-103 (oral levosimendan) will be featured in a Late-Breaking Clinical Science session at the ESC Congress 2026 in Munich, held August 28-31. Topline results for the LEVEL study are anticipated in August 2026, with the company currently finalizing database lock and statistical analyses. Shares closed up 16% at $15.46.
Cosmos Health Inc. (NASDAQ: COSM) announced that it has acquired an additional 770,000 shares of its common stock through open market purchases at an average cost of roughly $0.1956 per share. This transaction continues the buyback momentum the vertically integrated healthcare group initiated earlier this week. Shares closed up 18% at $0.24.
NewGenIvf Group (NASDAQ: NIVF) announced a 1-for-3 reverse stock split of its Class A ordinary shares, which will become effective at 12:01 a.m. ET on July 6, 2026. Shares closed down 16% at $0.46.
PMGC Holdings (NASDAQ: ELAB) issued a formal release detailing Phase 3 results for NorthStrive's AI-driven collaboration with Yuva Biosciences, which focuses on enhancing muscle metabolism. Data revealed that four small molecules identified by AI improved ANT1 expression levels in primary skeletal muscle cells, with peak responses hitting 50%. The development program is advancing toward confirmatory testing within more mature skeletal muscle models to facilitate additional clinical progress. Shares closed down 8% at $1.18.
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) was granted a Notice of Allowance from the USPTO for a patent application covering its methods for the treatment and inhibition of fibrosis. The newly allowed claims strengthen the company's intellectual property portfolio surrounding its clinical-stage assets targeting fibrotic diseases. Shares closed down 12% at $0.57.
Polyrizon Ltd. (NASDAQ: PLRZ) announced NASARIX Allergy Blocker biocompatibility results. All safety tests met ISO 10993 and FDA standards for the mucoadhesive nasal spray. The program confirmed safety across endpoints such as cytotoxicity and systemic toxicity, with risk assessments indicating wide safety margins for long-term use. The final product evaluation confirmed that the materials were chosen to minimize biological risk. Shares closed up 9% at $13.8.
Tenon Medical, Inc. (NASDAQ: TNON) received 510(k) clearance from the FDA for its Catamaran SI Joint Fusion System, a platform for sacro-pelvic disorders. Additionally, the company finalized a $4.2 million public offering of securities, with proceeds calculated before deducting placement agent fees and other related offering expenses. Shares closed down 10% at $0.29.
Mdxhealth SA (NASDAQ: MDXH) reported that it was issued a deficiency notice by the Nasdaq Listing Qualifications Department on June 30, 2026. The communication indicated that the diagnostics firm failed to satisfy the minimum bid price criteria necessary for its shares to remain listed on the Nasdaq Capital Market. In accordance with exchange regulations, the company released this disclosure following the formal notification of non-compliance. Shares closed down 6% at $0.48.
07/01/2026
(NYSE: CANF) announced that its Phase 2a study evaluating Namodenoson in patients with advanced pancreatic ductal adenocarcinoma met its primary safety endpoint and demonstrated durable overall survival. Shares closed up 58% at $4.63.
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) entered into a definitive agreement with a single healthcare-focused institutional investor for a private placement of up to $8.8 million, priced at-the-market under Nasdaq rules. The financing includes $3 million upfront through the sale of 960,000 shares of common stock (or pre-funded warrants) and accompanying series C-1 and C-2 warrants, at a combined purchase price of $3.125 per share and accompanying warrant. If fully exercised for cash, the warrants could generate an additional $5.8 million in gross proceeds. H.C. Wainwright & Co. acted as exclusive placement agent for the offering. Shares closed down 5% at $3.17.
Guardant Health (NASDAQ: GH) announced that UnitedHealth Group has initiated coverage for its Shield blood-based screening test. The policy extends to eligible individuals aged 45 and older for colorectal cancer (CRC) screening. This expansion increases the total number of covered lives for the FDA-approved diagnostic to 100 million, representing a pivotal commercial reimbursement milestone for the company. Shares closed up 14% at $170.77.
Curis, Inc. (NASDAQ: CRIS) approved a charter amendment authorizing a reverse stock split of its issued and outstanding common stock in a range of 1-for-5 to 1-for-25. Following the authorization, Curis's board of directors immediately exercised its discretion to implement a definitive 1-for-20 reverse stock split. The structural capital consolidation is engineered to dramatically compress the oncology-focused biotech's outstanding share base, artificially elevate its per-share trading price, and directly cure its ongoing Nasdaq minimum bid price noncompliance to preserve its public listing. Shares closed down 19% at $0.42.
X4 Pharmaceuticals (NASDAQ: XFOR) has named Kelly Gold, the current CFO of CAMP4, to its board of directors and audit committee. Gold brings extensive expertise in biotech strategy, capital markets, and finance within public companies to the leadership team. This strategic appointment comes as the firm prepares for the prospective regulatory approval and subsequent commercial launch of mavorixafor. Shares closed down 13% at $4.09.
Neurogene Inc. (NASDAQ: NGNE) priced its public offering of 3,500,000 shares of its common stock at a public offering price per share of $30.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 666,666 shares of its common stock at a public offering price of $29.999999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.000001 per share and are exercisable immediately. The aggregate gross proceeds to Neurogene from the offering are expected to be approximately $125 million before deducting underwriting discounts and commissions and other offering expenses payable by Neurogene, excluding any exercise of the underwriters' option to purchase additional shares. Shares closed up 8% at $33.88.
Matinas BioPharma Holdings, Inc. (NYSE: MTNB) disclosed that on Jun 24, 2026, it was notified by NYSE American LLC of a deficiency regarding continued listing requirements. The clinical-stage company fell short of the minimum $4 million stockholders' equity threshold, a mandate triggered by reporting net losses across three of its previous four fiscal years. Shares closed up 3% at $0.63.
NewcelX AG (NASDAQ: NCEL) convened its annual general meeting of shareholders to review corporate proposals and governance matters. During the assembly, participants voted to adopt the full suite of proposals as submitted by the board. The regulatory filing provided limited visibility into the specific nature of the individual resolutions passed. Consequently, the particulars of each agenda item and their subsequent implementation remain undisclosed. Shares closed up 5% at $3.85.
Zura Bio Limited (NASDAQ: ZURA) released an updated corporate presentation highlighting its late-stage clinical progress and robust financial profile. The company's pipeline centers on tibulizumab (ZB-168), a first-in-class dual-action bispecific antibody engineered to concurrently target and inhibit both the IL-17 and BAFF (B-cell activating factor) pathways. This dual mechanism is designed to stabilize immune dysregulation across both B-cell and T-cell driven pathobiology, mitigating chronic systemic inflammation and tissue destruction. Shares closed down 15% at $5.01.
06/30/2026
Unicycive Therapeutics (NASDAQ: UNCY) shares closed down 41% at $4.57 following an FDA CRL on its resubmitted OLC NDA, citing unresolved manufacturing issues at a third-party facility. Importantly, the agency did not identify concerns related to clinical data or safety, nor did it request new trials, indicating that a path to approval relies solely on CMC resolution and successful vendor inspections.
Vistagen (NASDAQ: VTGN) released topline data from its PALISADE-4 Phase 3 study evaluating intranasal fasedienol for social anxiety disorder. Topline results indicated that fasedienol did not meet its primary endpoint in the 238-patient population, with an LS mean SUDS change of -9.5 versus -11.4 for the placebo arm (p=0.427). Secondary endpoints also failed to demonstrate a significant treatment difference, though the safety profile remained favorable and aligned with previous clinical observations. These findings present a significant challenge to the candidate's immediate regulatory trajectory for acute social anxiety. Shares closed down 70% at $0.23.
Abivax (NASDAQ: ABVX) reported encouraging data from its ABTECT Maintenance Part 2 study of obefazimod for ulcerative colitis. Findings revealed that 37.2% of those who initially did not respond during induction reached clinical remission, while 45.5% of patients who relapsed successfully regained remission via dose escalation. Long-term Phase 3 safety results indicated malignancy rates aligned with standard UC background levels, supporting the treatment's utility in refractory cases. Shares closed up 39% at $133.69.
Nuvectis Pharma (NASDAQ: NVCT) announced the pricing of a $100 million public offering at $20.00 per share. The gross proceeds are intended to fund the development of its newly licensed NXP100 and NXP200 programs alongside NXP900, bolstering its clinical pipeline while resulting in immediate shareholder dilution. This substantial capital injection provides the necessary runway for multiple high-priority pipeline initiatives. Shares closed down 36% at $18.36.
Decoy Therapeutics Inc (NASDAQ: DCOY) shares closed down 22% to $ 7.50 following a $21 million private placement with a healthcare investor at $5.91 per share.
OS Therapies, Inc. (NYSE American: OSTX) requested an FDA Type B meeting to harmonize regulatory clinical endpoints for its osteosarcoma immunotherapy, OST-HER2, with international standards. The company aims to use 3-year overall survival and BEST program biomarkers to support an Accelerated Approval pathway, with a joint FDA-EMA regulatory review and a synthetic control arm from its OST-400 natural history database. This engagement seeks to finalize statistical strategies for a 2026 data readout while pursuing BTD and RMAT expedited designations. Shares closed down 16% at $1.89.
Moleculin Biotech (NASDAQ: MBRX) released interim results from its Phase 2/3 MIRACLE trial for relapsed/refractory AML, where the Annamycin plus HiDAC combination demonstrated superior efficacy over HiDAC monotherapy. Data revealed first-cycle complete remission rates of 43% and 36%, compared with 12% in the control arm, and composite CR rates up to 57%, providing strong validation for ongoing enrollment and final dose optimization.
AC Immune (NASDAQ: ACIU) shared interim 12-month ABATE data for ACI-24 in prodromal Alzheimer's disease, highlighting a favorable safety profile with no observed ARIA-E. Results demonstrated dose-dependent antibody responses against amyloid-beta, and the company initiated a new AD4 cohort using an adjuvant to further enhance immunogenicity. This update provides mid-study validation of the vaccine's tolerability and biological activity. Shares closed down 11% at $2.38.
06/29/2026
Decoy Therapeutics (NASDAQ: DCOY) finalized a PIPE agreement for $3.5 million upfront at $5.91 per share, with additional funding potential of up to $17.5 million contingent on clinical and regulatory achievements. This staged financing structure provides necessary capital to transition its lead D-MAV antiviral program into clinical development while anchoring further investment to key milestone completions. Shares closed up 74% at $9.59.
Larimar Therapeutics (NASDAQ: LRMR) initiated its rolling BLA submission seeking accelerated approval for nomlabofusp in Friedreich's ataxia following alignment with the FDA. Concurrently, long-term open-label data revealed consistent increases in skin frataxin levels alongside positive clinical trends over 12 months, with a confirmatory Phase 3 study slated to commence in the third quarter of 2026. Shares closed down 13% at $3.2.
Universe Pharmaceuticals (NASDAQ: UPC) entered into a definitive agreement to purchase Best Praise International for $10.8 million in equity. The acquisition adds five Chinese patents spanning neurodegeneration, cardiovascular health, antibacterial solutions, drug delivery, and geriatric care to its portfolio, with the transaction anticipated to conclude in the third quarter of 2026, pending standard closing requirements. Shares closed up 311% at $12.18.
Satellos Bioscience Inc. (NASDAQ: MSLE) announced that the FDA has granted Fast Track designation to SAT-3247 for the treatment of Duchenne. The Company is currently advancing SAT-3247 through its ongoing Phase 2 BASECAMP and TRAILHEAD studies in children and adults living with Duchenne. Shares closed up 11% at $7.89.
Evommune (NYSE: EVMN) EVO756 missed the primary endpoint in a 160-patient Phase 2b CSU trial, with no dose achieving a significant UAS7 improvement at 12 weeks, ending development in CSU while the company continues testing the oral MRGPRX2 antagonist in atopic dermatitis and migraine, with AD Phase 2b data expected in Q3 2026 and cash runway projected through 2028. Shares closed down 40% at $15.05.
NovaBridge Biosciences (NASDAQ: NBP) designated Dr. Srishti Gupta as Chief Executive Officer and a director, succeeding Sean Fu starting July 1, 2026. Under her guidance, the firm intends to prioritize the registrational path for givastomig, grow the Visara ophthalmic line, and explore additional corporate. Shares closed up 21% at $1.98.
NeuroSense Therapeutics (NASDAQ: NRSN) Phase 2b PARADIGM met its primary endpoint in ALS, showing a statistically significant reduction in neuron-derived TDP-43 versus placebo at Day 180, with deeper effects through 18 months, alongside previously reported slowing of functional decline, survival benefit, biomarker modulation, and a favorable safety profile, supporting PrimeC's advancement into the FDA-cleared Phase 3 PARAGON study. Shares closed down 6% at $0.71.
Trinity Biotech (NASDAQ: TRIB) terminated its standby equity purchase agreement with Yorkville, signaling it does not plan further use of the equity line and reflecting a shift in its current financing strategy, with the key implication being reduced reliance on this dilutive funding facility. Shares closed up 16% at $0.42.
Gain Therapeutics (NASDAQ:GANX) received FDA IND clearance for GT-02287, enabling U.S. Phase 2a development in early Parkinson's disease expected in Q3 2026, supported by Phase 1 safety, tolerability, target engagement and biomarker signals, making this a key validation milestone for its Magellan AI-derived allosteric small-molecule platform. Shares are currently trading up 19% at $2.35 during after hours trading.
Abivax (NASDAQ:ABVX) reported positive ABTECT Maintenance Part 2 Phase 3 results for obefazimod in refractory ulcerative colitis, showing clinical remission in 37.2% of induction non-responders and remission recapture in 45.5% of relapsed patients after 50 mg treatment, while expanded safety data across 1,704 patient-years showed malignancy rates consistent with expected UC background rates, supporting the planned NDA submission later this year. Shares are currently halted during after hours trading.
06/26/2026
Curis, Inc. (NASDAQ: CRIS) confirmed eleven active sites for its Phase 2 TakeAim CLL trial evaluating emavusertib with zanubrutinib. Initial dosing for the first five-patient group is slated for late July 2026, with a data readout targeted for December. Additionally, stockholders authorized a reverse stock split to regain compliance with Nasdaq's minimum bid price requirements. Shares closed up 56% at $0.32.
Hemab Therapeutics (NASDAQ: COAG) will share nine updates at ISTH 2026, highlighted by first-in-human HMB-002 data demonstrating subcutaneous VWF and FVIII elevation. Additionally, sutacimig showed sustained bleeding-rate reductions in GT prior to a H2 2026 Phase 3 start, while the HMB-003 plasmin inhibitor program is slated for clinical entry in late 2026. Shares closed up 17% at $32.37.
Omeros Corporation (NASDAQ: OMER) faced a European regulatory headwind as the EMA's CHMP delivered a negative opinion regarding narsoplimab for TA-TMA. Omeros intends to pursue a formal re-examination involving an Ad Hoc Expert Group; however, the news marks a distinct setback in the EU market, even as the therapy maintains its U.S. commercial status following the December 2025 approval of YARTEMLEA. Shares closed down 19% at $8.67.
Lantheus Holdings, Inc. (NASDAQ:LNTH) FDA issued a CRL for LNTH-2501, a Gallium-68 edotreotide PET imaging kit for SSTR-positive neuroendocrine tumors, due solely to unresolved third-party manufacturing facility issues, with no cited safety, efficacy, or data concerns, making this a likely timing setback rather than a fundamental product-risk event. Shares are currently trading down 8% at $101 during after hours trading.
CDT Equity (NASDAQ: CDT) showcased Sarborg's strategic growth of SarborgQ into the realm of quantum-assisted coformer selection. By leveraging proprietary datasets and agentic AI, the platform aims to accelerate solid-form development and IP creation. This progress positions CDT to pursue external formulation partnerships, deeper integrating its Sarborg investment within the broader AI-driven drug development infrastructure. Shares closed down 11% at $0.64.
Capricor Therapeutics (NASDAQ:CAPR) announced the FDA has set an advisory committee meeting for July 29, 2026, to evaluate the Deramiocel BLA for Duchenne muscular dystrophy. The application remains on schedule for its August 22, 2026 PDUFA goal date, representing a pivotal regulatory milestone backed by clinical findings from the HOPE-2, HOPE-2-OLE, and Phase 3 HOPE-3 trials. Shares closed down 13% at $26.44.
Can-Fite BioPharma Ltd. (NYSE: CANF) announced that the Japan Patent Office has granted a patent for Namodenoson and other A3AR agonists targeting obesity and weight reduction. This allowance strengthens the company's international intellectual property for its oral anti-obesity program and bolsters potential collaboration prospects within the metabolic disease sector. Shares closed down 6% at $2.75.
06/25/2026
ARS Pharmaceuticals (NASDAQ: SPRY) announced that its Neffy nasal spray failed to secure commercial insurance coverage. The company said no new commercial formulary additions or coverage decisions were issued for Neffy, its epinephrine nasal. The company also lowered its FY 2026 cash-based operating expense guidance, excluding cost of goods sold, to ~$248M, citing lower spending in the second half of the year and continued investment discipline. Shares closed down 24% at $8.02.
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) priced its public offering of 32,500,001 common shares at $6.00 per share. The clinical-stage biotech, which focuses on AAV-based gene therapies for CNS disorders, also offered pre-funded warrants for 833,333 shares at $5.999 each to select investors. The company expects total gross proceeds of roughly $200.0 million, excluding a 30-day underwriter option for an additional 5,000,000 shares. The transaction is scheduled to close on Jun 26, 2026, pending standard conditions. Shares closed down 11% at $6.21.
Nuvation Bio Inc. (NYSE: NUVB) announced its proposal for a $200 million offering of convertible senior notes maturing in 2032. The company intends to utilize the proceeds to finance capped call transactions, settle its outstanding senior secured loan, and provide capital for general corporate purposes. While the move enhances financial flexibility, it also introduces the potential for future shareholder dilution. Shares closed down 10% at $5.81.
Ernexa Therapeutics (NASDAQ: ERNA) introduced its “CEO Corner” communications portal, intended to keep shareholders apprised of its strategic direction, scientific progress, and off-the-shelf cell therapy vision. While enhancing investor engagement, the update provided no new clinical results, financing developments, or regulatory milestones. Shares closed up 17% at $7.4.
Kymera Therapeutics, Inc. (NASDAQ: KYMR) announced the successful completion of enrollment for its global BROADEN2 Phase 2b trial evaluating KT-621, a first-in-class oral STAT6 degrader for moderate to severe atopic dermatitis (AD). This early enrollment milestone allows the company to move its topline data readout forward by six months, now anticipated by year-end 2026. Pending regulatory consultations, Kymera aims to launch Phase 3 AD trials by mid-2027. Shares closed up 17% at $116.46.
Satellos Bioscience (NASDAQ: MSLE) is set to share clinical progress for its SAT-3247 program at the upcoming ICNMD 2026 conference. The presentation will feature six-month follow-up results from the Phase 1b cohort now participating in the Phase 2 TRAILHEAD study, offering a critical update on the company's efforts in degenerative muscle disease. Shares closed up 19% at $6.69.
INmune Bio (NASDAQ: INMB) announced that the MHRA granted approval for its Pediatric Investigation Plan (PIP) regarding Ebstrocel for recessive dystrophic epidermolysis bullosa in less than 90 days. This regulatory progress bolsters the biotech's objective for a 2026 UK MAA submission and a U.S. accelerated approval path by early 2027. Furthermore, the expedited review minimizes regulatory hurdles for its CORDStrom platform.
Helus Pharma (NASDAQ: HELP) finalized its underwritten public offering of shares at $4.85 each, generating $50 million in gross proceeds. The clinical-stage biotech intends to use the capital to fund the development of its lead candidate, HLP003, for major depressive disorder as it approaches a Phase 3 APPROACH data readout in the final quarter of 2026. Remaining funds will support HLP004, HLP005, and general corporate activities. Shares closed up 18% at $6.02.
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) issued a shareholder letter detailing its inclusion in the Russell 2000 and 3000 Indices. Management emphasized the significant repayment of its Scilex loan and a solid financial position, with ~$270 million in total cash and assets as of Mar 31, 2026. The company also recognized a $128 million gain from its Alpha Tau investment, reflecting a robust balance sheet and successful portfolio value enhancement. Shares closed up 16% at $5.
ProQR Therapeutics N.V. (NASDAQ: PRQR) priced a registered direct offering of common shares at $1.81 each, aiming for $50 million in gross proceeds. Eli Lilly and Company also committed $9.2 million via a concurrent private placement to preserve its pro rata ownership stake. While the capital supports the advancement of its Axiomer RNA-editing platform, the transaction introduces further equity dilution for current shareholders. Shares closed down 14% at $1.57.
06/24/2026
Nuvectis Pharma, Inc. (NASDAQ: NVCT) entered into a licensing agreement for the ex-China rights to Haisco Pharmaceutical's NXP100 and NXP200. NXP100 is a late-stage oral Factor B inhibitor with regulatory applications currently under review in China for paroxysmal nocturnal hemoglobinuria (PNH). Meanwhile, NXP200 represents a brain-penetrant BRAF inhibitor. These acquisitions significantly broaden the company's portfolio into complement-mediated disorders and advanced oncological therapies. Shares closed up 39% at $24.48.
IceCure Medical Ltd. (NASDAQ: ICCM) showcased a publication in a peer-reviewed surgical journal detailing the clinical superiority and procedural benefits of cryoablation compared to radiofrequency ablation (RFA) for specific early-stage breast cancer cases. This data bolsters the clinical foundation for the ProSense system as the firm gears up for the JBCS 2026 conference and a forthcoming regulatory filing in Japan through its partner, Terumo Corporation. Shares closed up 52% at $9.3.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) received conditional FDA acceptance for QYLEKI as the designated brand name for its lead candidate, QRX003. This 4% topical lotion is being developed for Netherton Syndrome, a devastating and life-threatening genetic condition driven by SPINK5 gene mutations. Shares closed up 18% at $3.83.
Nuwellis, Inc. (NASDAQ: NUWE) filed with the SEC to announce a reverse stock split. The corporate action will take effect on Jun 25, 2026, with split-adjusted trading commencing the following day. Shares closed down 30% at $0.09.
Absci Corporation (NASDAQ: ABSI) reported encouraging interim results from the Single Ascending Dose (SAD) segment of its Phase 1 HEADLINE trial for ABS-201. This generative AI-designed monoclonal antibody targets the prolactin receptor (PRLR) to trigger hair follicle renewal. Positioned as a potential first-in-class therapy for androgenetic alopecia (AGA) and a best-in-class option for endometriosis, the candidate demonstrated a favorable safety profile. In the randomized, placebo-controlled study involving 32 healthy volunteers across four IV dose levels (150 mg to 1,800 mg), blinded data through June 8, 2026, indicated ABS-201 was well tolerated with no serious adverse events (SAEs) observed. Shares closed up 36% at $10.07.
Cognition Therapeutics, Inc. (NASDAQ: CGTX) secured regulatory alignment from the FDA regarding the clinical path for zervimesine (CT1812) in DLB psychosis. The agency confirmed that successful outcomes in this indication could serve as an approvable basis for the candidate. Consequently, Cognition is advancing plans for a pivotal study slated for mid-2027, which will evaluate the safety and efficacy of a once-daily oral regimen compared to placebo over a nine-month period. The trial is expected to utilize the Neuropsychiatric Inventory (NPI) as its primary endpoint to measure therapeutic impact. Shares closed down 38% at $1.02.
Creatd, Inc. (OTCQB: CRTD) highlighted its significant balance sheet exposure and deepening operational relationship with Catheter Precision, Inc. (NYSE American: VTAK). Following the complete disposition of its Flyte aviation platform to VTAK, Creatd secured a powerful liquidity and asset-backed equity position, transforming its balance sheet into an incubation engine. Out of its $12.1 million in total assets, Creatd's balance sheet is heavily reinforced by transactional consideration from the Flyte sale, including a $5.6 million preferred stock receivable and a $4.8 million promissory note receivable owed by VTAK. Shares closed up 29% at $1.19.
Evogene Ltd. (NASDAQ: EVGN) announced it has achieved a major milestone in its second joint initiative with Google Cloud. The company, which operates at the intersection of computational biology and chemistry, utilizes artificial intelligence to identify and design novel small-molecule candidates serving both the agricultural and pharmaceutical sectors. Shares closed down 13% at $0.44.
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) delivered a broad corporate progress report detailing its commercial, developmental, and fiscal management objectives spanning the next year. While the firm engaged in sustained negotiations with payers throughout mid-June, no additional commercial formulary placements or coverage determinations were finalized for its needle-free epinephrine delivery system, neffy, for the upcoming cycle beginning Jul 1, 2026. Shares are currently doen 21% at $8.35 during extended hours.
06/23/2026
Boundless Bio, Inc. (NASDAQ: BOLD) entered into a definitive merger agreement with privately-held Serapha Bio, Inc., which is currently developing an in vivo base editing candidate for Alpha-1 Antitrypsin Deficiency (AATD). The all-stock consolidation will see Boundless issue a cash dividend to existing shareholders prior to closing, after which the combined entity will transition its operations and trade on the Nasdaq under the new ticker “AATD” as Serapha Bio, Inc.To facilitate the business combination, Serapha has obtained approximately $230 million in committed capital through private investments slated to close ahead of the merger. Shares closed up 85% at $2.6.
Heart Test Laboratories, Inc. (NASDAQ: HSCS) entered into a definitive all-stock merger agreement with Fortitude, a digital asset mining entity owned by DCG with shares closed up 58% at $2.77. This strategic shift will transform the combined company into a Zcash-centric infrastructure platform, which is slated to trade under the ticker “TUDE” following the anticipated close in late 2026. Under the terms of the consolidation, the company's existing AI-powered ECG technology portfolio is expected to be maintained as a dedicated healthcare operating unit led by Andrew Simpson, while the parent entity transitions to the leadership of Fortitude CEO Andrea Childs.
Tenon Medical Inc. (NASDAQ: TNON) initiated a public offering of common stock and warrants via an S-1 filing, aiming to sell 1.81 million shares, along with warrants exercisable for an additional 6.98 million shares, at an estimated unit price of $0.6021. The offering includes a structural adjustment tied to a proposed reverse stock split pending July 2026 shareholder approval, which would increase warrant-related shares to 8.72 million pre-split; proceeds are earmarked for the commercial expansion of its Catamaran Sacroiliac (SI) Joint Fusion System following a 90% year-over-year revenue jump to $1.4 million in Q1 2026. Shares closed down 27% at $0.45.
Catheter Precision, Inc. (NYSE American: VTAK) filed a prospectus for a public offering involving 68.07 million shares of common stock; the move follows the company's recent efforts to expand its cardiac arrhythmia mapping technologies and secure the necessary capital to drive commercial adoption of its lead medical devices. Shares closed up 8% at $0.94.
Trinity Biotech plc (NASDAQ: TRIB) introduced Trinovium, a strategic initiative to redirect its clinical-grade fluid production and analytical expertise toward the AI data center liquid cooling industry. By utilizing established manufacturing footprints in the U.S. and EU, the firm intends to develop high-purity coolant chemistry and specialized monitoring hardware to address the expanding requirements of high-performance computing infrastructure. Shares closed down 40% at $0.35.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) achieved a significant commercial milestone as the FDA granted conditional acceptance for QYLEKI, the designated brand name for its lead candidate QRX003. Currently being developed for Netherton Syndrome, the therapy holds Orphan Drug, Fast Track, and Rare Pediatric Disease designations. The company remains on track to initiate a pivotal Phase 3 trial in the second half of 2026, establishing a regulatory path toward a potential NDA submission by 2027. Shares closed down 18% at $3.63.
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) announced that the first patients have been dosed in a Phase 2 investigator-sponsored study of DM199. The trial targets early-onset fetal growth restriction, a condition currently lacking any FDA-sanctioned medical treatments. This clinical milestone marks the candidate's primary assessment within pregnancy-related pathologies, investigating if enhanced maternal uterine blood circulation can effectively bolster placental perfusion and promote healthy development of the fetus. Shares closed up 7% at $6.3.
Galectin Therapeutics Inc. (NASDAQ: GALT) secured regulatory alignment with the FDA regarding the Phase 3 clinical pathway for belapectin, targeting MASH cirrhosis complicated by portal hypertension. The agreed-upon trial design incorporates a composite liver-related outcome endpoint and utilizes centralized endoscopy for data review. The firm anticipates submitting the final study protocol during the third quarter of 2026, while concurrently exploring strategic collaborations or financial partnerships to support the program's advancement. Shares closed up 12% at $3.14.
aTyr Pharma, Inc. (NASDAQ: ATYR) is slated to participate in the Life Sciences Virtual Investor Forum on Jun 25, 2026 7:30 PM ET. The engagement facilitates direct management dialogue and interactive sessions for the investment community; however, the firm indicated that no novel clinical results or financial disclosures will be released during the event. Shares closed up 15% at $0.54.
06/22/2026
Apogee Therapeutics, Inc. (NASDAQ: APGE) and AbbVie Inc. (NYSE: ABBV) announced a definitive agreement under which AbbVie will acquire Apogee for $135.11 per share in cash, representing a total equity value of approximately $10.9 billion. The multi-billion-dollar acquisition deepens AbbVie's dominant core immunology footprint and aggressively accelerates its clinical pipeline across inflammatory, immunological, and respiratory diseases. The transaction integrates Apogee's diverse portfolio of highly differentiated, clinical-stage assets designed to address immense market needs, including advanced candidates for atopic dermatitis (AD) and asthma. Unanimously approved by the boards of directors of both corporations, the cash transaction is scheduled to close in the third quarter of 2026, subject to standard closing conditions, regulatory clearances, and the formal approval of Apogee's shareholders. Shares closed up 47% at $132.55.
Definium Therapeutics, Inc. (NASDAQ: DFTX) announced topline data from its first randomized, double-blind, placebo-controlled Phase 3 Emerge trial. The study evaluated a single 100 µg dose of DT120 (lysergide) ODT in adult patients suffering from major depressive disorder (MDD), focusing on the therapy's potential to target underlying psychiatric and neurological drivers. The Emerge trial met its primary endpoint, with DT120 ODT 100 µg achieving a statistically significant and clinically meaningful reduction in the MADRS total score at Week 6 compared with placebo. Shares closed up 50% at $36.65.
MoonLake Immunotherapeutics (NASDAQ: MLTX) shares are in up following highly positive, long-term 52-week data from its pivotal Phase 3 VELA-1 and VELA-2 trials of sonelokimab (SLK) in moderate-to-severe hidradenitis suppurativa (HS). The Nanobody candidate demonstrated a potential best-in-disease profile, with 67.2% of patients achieving HiSCR75 at one year, notably outperforming historic results from currently available therapies. Clinical clearance (HiSCR100) was reached by 33.1% of participants, while 26.0% achieved complete inflammatory remission (IHS4-100), alongside significant pain reduction and quality-of-life improvements. Following successful Phase 3 VELA-TEEN results in adolescents and pre-BLA alignment, the company plans to submit its BLA by late September 2026, including a request for Priority Review to accelerate its regulatory timeline. Shares closed up 15% at $22.15.
CDT Equity Inc. (NASDAQ: CDT) shares are currently up following news that its portfolio subsidiary, Sarborg Limited, secured an exclusive investment from a New York private fund at a premium price of $125,000 per share. The financing implies a $638.3 million valuation for Sarborg; consequently, CDT's 1,020-share holding is now valued at approximately $127.5 million, representing a significant valuation arbitrage compared to CDT's previous micro-cap market value of less than $3.4 million. Shares closed up 45% at $1.5.
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announced it has finalized a modified merger agreement with Colospan, securing a CE-marked device for colorectal surgery supported by German reimbursement codes and anticipated commercial revenue across the EU and Israel by 2026. Under the revised transaction structure, Galmed minimized immediate equity dilution by substituting initial shares with a larger cash component and a performance-contingent earnout capped at $20 million based on future sales milestones. Shares closed down 3% at $0.56.
Jaguar Health (NASDAQ: JAGX) announced it has commenced a formal evaluation of strategic alternatives, exploring potential mergers, business combinations, or licensing opportunities. The initiative follows encouraging early pediatric results for crofelemer in rare disease-related intestinal failure, where the therapy achieved up to a 37% decrease in parenteral support requirements. These findings support the company's ongoing clinical progress and preparations for a future New Drug Application (NDA) filing. Shares closed up 16% at $2.61.
Entera Bio Ltd. (NASDAQ: ENTX) received favorable regulatory guidance from the FDA regarding its registrational Phase 3 trial design for EB613, an oral PTH (1-34) peptide for postmenopausal osteoporosis. The agency agreed that a single, 750-patient study evaluating 12-month hip bone mineral density (BMD) could support a potential 505(b)(2) NDA submission. The company intends to initiate the trial by late 2026, with topline results anticipated in the second half of 2028, potentially providing a non-invasive, bone-building alternative to traditional injectable osteoporosis treatments. Shares closed up 22% at $1.48.
Catheter Precision (NYSE: VTAK) subsidiary Flyte established a partnership with GSE Worldwide and PGA TOUR golfer Emiliano Grillo, leveraging the 2026 U.S. Open to showcase its Cirrus Vision Jet platform for premium regional travel. While financial specifics remained undisclosed, the collaboration aims to position the platform as a premier mobility solution for professional athletes. Shares are currently trading up 56% after hours at $0.87.
06/18/2026
CDT Equity (NASDAQ: CDT) announced a fresh strategic funding round for Sarborg, which establishes an implied valuation of $638.3 million and debuts SarborgQ for quantum-driven biological data processing. The update suggests a $127.5 million valuation for CDT's 1,020-share equity position in Sarborg based on the current financing terms. Shares closed up 47% at $1.02.
Legend Biotech Corporation (NASDAQ: LEGN) announced the pricing of its public offering of 7.7 million American Depositary Shares (ADSs) at $29.35 per share, aiming to generate roughly $226 million in gross proceeds to bolster its financial position; the move secures significant capital for operations but introduces immediate share dilution for existing investors. Shares closed down 17% at $27.93.
Cosmos Health Inc. (NASDAQ: COSM) announced its strategic entry into the skincare sector with the U.S. commercial launch of its premium collagen line developed in Korea; by expanding its direct-to-consumer reach into the high-margin beauty market, the company aims to diversify its revenue streams and broaden its portfolio beyond traditional healthcare segments. Shares closed down 12% at $0.21.
Novocure Limited (NASDAQ: NVCR) reported that its Phase 3 TRIDENT trial in newly diagnosed glioblastoma failed to meet the primary overall survival (OS) endpoint; despite early initiation of Tumor Treating Fields (TTFields) appearing feasible and well-tolerated without new safety concerns, the median OS of 17.7 months did not significantly improve upon the 17.5 months observed in the maintenance-phase initiation group. Shares closed down 20% at $14.28.
CervoMed Inc. (NASDAQ: CRVO) entered into definitive agreements for the purchase and sale of 2,500,000 shares of common stock at a purchase price of $4.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about June 22, 2026, subject to the satisfaction of customary closing conditions. Shares closed up 11% at $4.24.
GRI Bio, Inc. (NASDAQ: GRI) announced that the FDA granted Orphan Drug Designation to its lead candidate, GRI-0621, for treating idiopathic pulmonary fibrosis (IPF); the designation follows Phase 2a results where the program achieved its primary and secondary endpoints in patients concurrently receiving standard antifibrotics, providing the company with vital regulatory incentives and potential market exclusivity. Shares closed down 19% at $1.88.
06/17/2026
IceCure Medical Ltd. (NASDAQ: ICCM) saw a 70% growth in its U.S. active install base for the ProSense breast cancer cryoablation system, reflecting faster adoption and increased physician demand after FDA approval in October 2025. ProSense uses liquid nitrogen to treat early-stage, low-risk tumors as a minimally invasive, office-based alternative to surgery for women 70 and older. Market demand is also driven by updated clinical guidelines from the American Society of Breast Surgeons (ASBrS), which now recommends cryoablation for suitable low-risk patients.
uniQure N.V. (NASDAQ: QURE) shares are currently up in premarket hours following a brief news halt after the company announced a major regulatory breakthrough for AMT-130, its investigational one-time adeno-associated virus (AAV) gene therapy for Huntington's disease. During a recent Type B meeting, the U.S. FDA confirmed that the long-term, 3-year analysis from uniQure's Phase 1/2 clinical program will be acceptable as the primary clinical basis for a Biologics License Application (BLA) under the accelerated approval pathway.
Elicio Therapeutics, Inc. (NASDAQ: ELTX) highlighted new data showing multiple complete responses (CRs) among patients with metastatic mKRAS pancreatic cancer receiving ELI-002 7P followed by checkpoint inhibitors. Notably, these responses occurred in microsatellite stable (MSS) or mismatch repair proficient (MMR-p) patients, a group that typically sees a 0% CR rate with standard immunotherapy. Management suggests the vaccine sensitized these “cold” tumors to treatment.
uniQure N.V. (NASDAQ: QURE) shares rose premarket after the FDA confirmed that its Phase 1/2 long-term, 3-year analysis of AMT-130 for Huntington's disease can serve as the primary clinical basis for an accelerated approval BLA.
Elicio Therapeutics, Inc. (NASDAQ: ELTX) shares fell after its Phase 2 AMPLIFY-7P trial missed its primary adjuvant endpoint. However, the firm reported complete responses in metastatic mKRAS pancreatic cancer patients receiving ELI-002 7P with checkpoint inhibitors. Securities litigation investigations were initiated on Jun 17, 2026 following the miss.
Lunai Bioworks Inc. (NASDAQ: LNAI) shares are up after regaining Nasdaq compliance via a 1-for-8 reverse split. The company now enters a one-year monitoring period to maintain the $1.00 minimum bid price.
Lunai Bioworks Inc. (NASDAQ: LNAI) shares are trading higher premarket after an SEC filing confirmed the company has regained Nasdaq's $1.00 minimum bid price. The Nasdaq Hearings Panel confirmed on June 11 that the AI biotech met the Bid Price Rule, satisfying previous exception extensions. To do so, Lunai executed a 1-for-8 reverse split on May 22. Although the delisting threat is lifted, the company now faces a one-year Panel monitoring period. If the stock falls below $1.00 within 12 months, Nasdaq will issue an immediate delisting notice, but Lunai can request a hearing to stay the suspension.
BioAffinity Technologies (NASDAQ: BIAF) announced a July 21, 2026, webinar hosted by NAVREF, featuring experts from Philips and 4DMedical. It will cover early lung disease detection, imaging advancements, and noninvasive screening for U.S. veterans at risk of respiratory issues and lung cancer, including those affected by toxic military exposures under the PACT Act. The presentation highlights mobile CT screenings, lung imaging, and bioAffinity's CyPath Lung test—a noninvasive, sputum-based test with 92% sensitivity and 88% accuracy for early-stage malignancies in high-risk patients. The company aims to expand in the federal healthcare and veterans' market, promoting clinical adoption and reducing unnecessary, invasive biopsies.
Ainos, Inc. (NASDAQ: AIMD) initiated a one-year collaborative research endeavor with National Taiwan University (NTU) commencing July 2026. The program is designed to assess the utility of the company's Smell AI breath-print analysis in emergency triage settings for dyspnea; the initiative scales the existing VOC-based platform into patient-centric digital breath intelligence while maintaining a focus on early-stage research applications.
Spero Therapeutics (NASDAQ: SPRO) received FDA approval for Utebzi to treat adults with complicated urinary tract infections (cUTIs), marking the first U.S. clearance of an oral carbapenem for Spero and its collaborator GSK. The decision validates Phase 3 PIVOT-PO non-inferiority results and provides a unique outpatient treatment for patients facing restricted oral options.
06/16/2026
Outlook Therapeutics, Inc. (NASDAQ: OTLK) announced the FDA has acknowledged receipt of the resubmission of the Biologics License Application (BLA) for ONS-5010/LYTENAVA for the treatment of neovascular age-related macular degeneration (nAMD), or wet AMD. The Company has been informed that the resubmission is a Class 1 review, with a PDUFA target action date of July 29, 2026. Shares closed up 34% at $1.57.
NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) NeOnc received Abu Dhabi Department of Health IND clearance for NEO212, its oral perillyl alcohol-temozolomide conjugate for aggressive brain tumors, enabling planned UAE Phase 2 development after Phase 1 established a 610 mg recommended dose and showed early disease-stabilization signals in recurrent GBM and brain metastases, while U.S. registrational-pathway discussions and additional UAE NEO100 regulatory reviews remain ongoing. Shares closed up 14% at $5.18.
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) announced topline results from the 12-week Phase 2 Part D CIRRUS-HCM trial evaluating EDG-7500, an oral, selective cardiac sarcomere modulator, in 53 patients with obstructive (oHCM) and nonobstructive (nHCM) hypertrophic cardiomyopathy. The drug successfully improved impaired cardiac relaxation and diastolic function without compromising systolic performance, demonstrating no relationship between drug exposure and reductions in left ventricular ejection fraction (LVEF) below 50%. Phase 3 development program in Q4 2026. Shares closed down 4% at $33.95.
Scilex Holding Company (NASDAQ: SCLX) announced that its distributed Dream Bowl I Meme Coin tokens are expected to debut on the Biconomy cryptocurrency exchange around June 23, 2026. This follows a corporate action providing eligible stockholders of record as of April 30, 2026, with a special dividend of five tokens per share of common stock. Initially valued at $0 as personal collectibles, the upcoming listing on Biconomy—a top-40 global exchange with approximately $2.0 billion in daily trading volume—aims to provide structural liquidity and broad distribution for holders who complete the company's digital wallet verification process. Shares closed up 19% at $5.88.
SOPHiA GENETICS (NASDAQ:SOPH) SOPHiA GENETICS launched a proposed underwritten public offering of ordinary shares, with a potential 15% underwriters' option, adding possible balance sheet capital for its AI-driven precision medicine platform, though final size, pricing and completion remain subject to market conditions. Shares are currently trading down 9% at $4.50 during afterhours trading.
Alvotech (NASDAQ: ALVO) launched an underwritten public offering and concurrent European private placement expected to raise approximately $125M in gross proceeds, with all shares issued by the company and a potential 15% underwriters' option, adding growth capital for its global biosimilar development and manufacturing platform while final size and pricing remain subject to market conditions. Shares are currently trading down 8% at $3.88 during after-hours trading. Shares closed down 9% at $3.87.
CytoSorbents Corporation (NASDAQ: CTSO) shares increased in premarket hours following significant insider buying. CFO Peter J. Mariani purchased 100,000 shares at an average of $0.44 ($44,000 total), bringing his ownership to 638,113 shares. CEO Phillip P. Chan invested $104,109.32 to acquire 261,469 shares at averages of $0.40 and $0.43, increasing his direct holding to 1,744,432 shares. Shares closed up 20% at $0.52.
Greenland Mines Ltd (NASDAQ:GRML) Greenland Mines entered a strategic share exchange agreement for an initial 9.9% stake in AnorTech, with an option to increase ownership to 19.9%, adding exposure to AnorTech's Greenland anorthosite platform targeting sustainable alumina, high-purity alumina, CO2-free cement and related industrial materials, and broadening GRML's critical materials strategy toward midstream processing and Western supply-chain optionality. Shares closed up 12% at $0.32.
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Adial closed the initial $32M tranche of its previously announced up to $64M private placement tied to the Azora Therapeutics acquisition and granted inducement equity awards to newly appointed executives Matthew Davidson and Julie Saiki, reinforcing management integration and providing near-term capital to advance Azora's AT177 ulcerative colitis program. Shares closed down 11% at $2.54.
FibroBiologics (NASDAQ: FBLG) announced the administration of the initial doses in its Phase 1/2 CYWC628 clinical study targeting diabetic foot ulcers. Alongside this milestone, the company dispatched further GMP-grade drug product to Australian sites, achieving key clinical milestones while verifying the scalability and consistency of its fibroblast-derived therapeutic manufacturing platform. Shares closed down 9% at $0.81.
06/15/2026
Traws Pharma, Inc. (NASDAQ: TRAW) deferred its planned Phase 2a human influenza challenge study of tivoxavir marboxil after negative MHRA regulatory feedback, creating a clinical-timeline setback for its lead influenza antiviral despite prior animal efficacy and supportive pharmacokinetics, while the company shifts focus to backup long-acting influenza candidates and notes cash runway into Q1 2027. Shares closed down 41% at $0.76.
Alvotech (NASDAQ:ALVO) Alvotech launched an underwritten public offering and concurrent European private placement expected to raise approximately $125M in gross proceeds, with all shares issued by the company and a potential 15% underwriters' option, adding growth capital for its global biosimilar development and manufacturing platform while final size and pricing remain subject to market conditions. Shares are currently trading down 8% at $3.88 during after hours trading.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Adaptive plans to separate its profitable MRD diagnostics business from its Immune Medicine platform, with a preferred separation path expected by year-end 2026, while also launching a proposed $250M convertible senior notes offering due 2031, potentially increasing to $287.5M, to support corporate strategy as it refocuses on clonoSEQ-led MRD growth and seeks to unlock value from Immune Medicine outside its diagnostic commercial model. Shares are currently trading down 8% at $15.97 during after hours trading.
Elicio Therapeutics, Inc. (NASDAQ: ELTX) reported that its randomized Phase 2 AMPLIFY-7P clinical trial evaluating its therapeutic cancer vaccine, ELI-002 7P, did not meet its pre-specified primary Disease-Free Survival (DFS) endpoint within the broad Intent-to-Treat (ITT) population. The trial evaluated patients with mutant KRAS (mKRAS)-driven pancreatic ductal adenocarcinoma (PDAC) in the adjuvant setting following surgical resection and standard chemotherapy. Shares closed down 73% at $4.08.
Lexeo Therapeutics, Inc. (NASDAQ: LXEO) announced the formal finalization of its SUNRISE-FA 2 pivotal trial protocol and statistical analysis plan (SAP) for its lead AAV-based gene therapy candidate, LX2006. The study design establishes a defined, FDA-aligned regulatory runway tailored to support a Biologics License Application (BLA) submission under the accelerated approval pathway in the first half of 2028. Shares closed up 6% at $4.65.
Neumora Therapeutics, Inc. (NASDAQ: NMRA) announced that its flagship kappa opioid receptor (KOR) antagonist, navacaprant (NMRA-140), failed to meet the primary endpoint across two pivotal Phase 3 trials (KOASTAL-2 and KOASTAL-3) for Major Depressive Disorder (MDD). Consequently, Neumora is entirely discontinuing the navacaprant development program and implementing an immediate corporate restructuring. Shares closed down 49% at $0.91.
Dyadic International, Inc. (NASDAQ: DYAI) highlighted increasing global interest in its proprietary C1 protein production platform as a scalable microbial solution for infectious disease preparedness. The spike in market attention directly responds to the worsening Bundibugyo Ebola virus (BDBV) outbreak in the Democratic Republic of the Congo and Uganda—which was declared a Public Health Emergency of International Concern (PHEIC) by the WHO. Shares closed up 17% at $0.8.
NanoViricides, Inc. (NYSE: NNVC) received DRC Pillar Committee approval for a proposed Phase 2 clinical trial evaluating oral NV-387 gummies for the treatment of Bundibugyo Ebola; this advances a scalable antiviral strategy within the current outbreak setting, although ethical and final regulatory clearances remain necessary prior to study commencement. Shares closed up 16% at $1.41.
Context Therapeutics Inc. (NASDAQ: CNTX) announced interim Phase 1 clinical data for CTIM-76, revealing a 29% confirmed Objective Response Rate (ORR) and a 57% disease control rate among a heavily pretreated population with platinum-resistant ovarian cancer; the therapy demonstrated a favorable safety profile with only Grade 1 Cytokine Release Syndrome (CRS) at active dose levels, while pharmacokinetic data supports moving toward a Q3W dosing schedule evaluation in the second half of 2026. Shares closed down 51% at $0.68.
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) announced plans to initiate a Phase 2a proof-of-concept clinical trial evaluating CAD-1005 for the prevention of cardiac surgery-associated acute kidney injury (CSA-AKI). This expansion of its 12-LOX inhibitor program beyond Phase 3-ready HIT is intended to generate critical safety and mechanistic renal data to bolster ongoing partnering discussions at BIO 2026. Shares closed down 10% at $3.33.
06/12/2026
Gelteq Limited (NASDAQ: GELS) announced positive outcomes from its veterinary palatability trials conducted with Kemin. The results highlighted exceptional canine acceptance and the successful masking of bitter flavors utilizing Gelteq's specialized gel delivery technology. These findings bolster the development of new animal health formulations and potential collaborations, although specific commercial agreements have yet to be disclosed. Shares closed down 35% at $0.99.
Outlook Therapeutics (NASDAQ: OTLK) saw its price target increased to $10 from $6 by Ascendiant Capital, who simultaneously reiterated a Buy rating on the stock. Shares closed up 11% at $1.22.
Adial Pharmaceuticals Inc. (NASDAQ: ADIL) announced the acquisition of Azora Therapeutics Inc. and gained its lead asset AT177, developed for the treatment of ulcerative colitis, as part of the deal. Shares closed down 1% at $2.96.
LIXTE Biotechnology (NASDAQ: LIXT) entered into a definitive agreement to acquire NOMAD Transportable Power Systems, signaling a strategic transition to be rebranded as NOMAD Power Solutions. This pivot shifts the firm's focus toward utility-grade mobile energy storage to address power-capacity limitations, with the finalization of the deal remaining contingent upon customary closing conditions. Shares closed down 14% at $6.21.
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Enliven priced an upsized public offering expected to raise approximately $400M in gross proceeds through common stock and pre-funded warrants at $37.50 per share equivalent, materially strengthening its balance sheet to support development of its small-molecule oncology pipeline, with potential additional proceeds from a 1.6M-share underwriters' option. Shares closed up 14% at $46.07.
BiomX Inc. (NYSE:PHGE) BiomX received NYSE American acceptance of its plan to regain compliance with stockholders' equity listing standards, giving the company until September 25, 2027 to cure deficiencies tied to a $1.3M stockholders' deficit and recurring losses, while its shares remain listed and traded subject to periodic review and continued compliance. Shares closed down 24% at $0.54.
06/11/2026
Purple Biotech Ltd. (NASDAQ: PPBT) announced the presentation of new preclinical data from its lead CAPTN-3 program, IM1240, at the European Association for Cancer Research (EACR) 2026 Annual Congress, being held June 8-11, 2026, in Budapest, Hungary. The preclinical study in non-human primate (NHP) toxicology study validates the CAPTN-3 masking strategy, with IM1240 showing an 8-fold longer half-life, 16-fold greater exposure, and a markedly improved cytokine-release safety profile compared to the non-capped variant. Shares closed down 48% at $1.54.
Atossa Therapeutics, Inc. (NASDAQ: ATOS) revealed a registered direct offering intended to generate gross proceeds of approximately $16.5 million. The clinical-stage biopharmaceutical company intends to use the capital to advance its oncology pipeline and support general corporate operations, though the financing event will result in immediate equity dilution for existing shareholders. Shares closed down 41% at $2.59.
Valion Bio Inc. (NASDAQ: VBIO) confirmed that the U.S. House Armed Services Committee's FY27 National Defense Authorization Act (NDAA) report directs the Assistant Secretary of Defense for Nuclear Deterrence, Chemical, and Biological Defense Policy and Programs (ASD (ND-CBD)), in coordination with the Assistant Secretary of Defense for Health Affairs (ASD (HA)), to develop a resources and fielding plan for prioritizing radiation/nuclear countermeasures that are both prophylactic (pre-exposure) and therapeutic (post-exposure). Shares closed down 25% at $0.6.
Humacyte (NASDAQ: HUMA) priced a $50 million public offering of 47.6 million shares at $1.05 per share, with proceeds intended to support Symvess commercialization, a planned hemodialysis BLA supplement, pipeline development, and general corporate needs, adding near-term funding while creating meaningful shareholder dilution. Shares closed down 19% at $1.08.
Enliven Therapeutics (NASDAQ: ELVN) provided refreshed Phase 1 results for ELVN-001 in pre-treated CML patients, highlighting a 61% cumulative MMR at the 80 mg daily dosage alongside a positive safety profile; additionally, finalized FDA feedback on dosing and the Phase 3 framework for second-line therapy enables the company to start its ENABLE-2 registrational study in late 2026. Shares closed up 9% at $40.36.
Cosmos Health Inc. (NASDAQ:COSM) Cosmos Health signed a non-binding LOI to acquire 100% of Doc Pharma, adding a GMP-licensed European-standard manufacturing facility with a $24M asset base, ~$6.7M average annual revenue and ~$3.2M average annual gross profit, in a transaction positioned to deepen vertical integration, expand in-house dosage-form capacity, broaden generics and OTC offerings, and support margin expansion, profitability and cash flow. Shares closed down 10% at $0.21.
BiomX (NYSE: PHGE) Zorronet issued an AI-security evaluation highlighting a strategic pivot from mere detection volume to deep contextual analysis and integrated responses. This development aligns BiomX's Autonomous Command Center framework with defense, critical infrastructure, and large-scale event security needs, although no specific financial details or definitive customer agreements were revealed. Shares closed up 13% at $0.71.
Anixa Biosciences (NASDAQ: ANIX) announced it will showcase two clinical immunotherapy initiatives, featuring Phase 1 survival data from its lira-cel CAR-T ovarian cancer program; additionally, final Phase 1 results for its breast cancer vaccine demonstrated that all primary objectives were achieved, with 74% of subjects exhibiting measurable immune responses. Shares closed up 6% at $2.48.
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Adial acquired Azora Therapeutics and secured up to $64M in concurrent private placement financing, including $32M upfront, to advance AT177, a colon-targeted oral AhR agonist for ulcerative colitis designed for localized activity with limited systemic exposure, with proceeds expected to fund IND-enabling work and Phase 1a/1b studies ahead of planned Phase 1 initiation in mid-2027. Shares closed up 38% at $2.98.
Theriva Biologics, Inc. (NYSE:TOVX) Theriva reported published Phase 1 data for IV VCN-01 plus durvalumab in 20 heavily pretreated, immunotherapy-refractory metastatic HNSCC patients, showing median OS of 10.3 months with concomitant low-dose VCN-01, 15.5 months with sequential low-dose dosing and 17.3 months with sequential high-dose dosing, with translational analyses supporting VCN-01's proposed stroma-degrading, immune-enhancing mechanism and potential to resensitize refractory tumors to checkpoint inhibition. Shares closed up 26% at $0.31.
06/10/2026
Aptorum Group (NASDAQ: APM) announced that shareholders from both Aptorum and DiamiR have greenlit their definitive all-stock merger agreement. The closing of this transaction will transform DiamiR into a wholly owned subsidiary, pivoting the corporate focus toward the development of blood-based diagnostic solutions for neurodegenerative conditions and brain health. Shares closed down 19% at $0.9.
CervoMed Inc. (NASDAQ: CRVO) entered into a private placement securing $10.5 million in upfront gross proceeds, extending its financial runway through the second quarter of 2027. The company is actively seeking a strategic partnership for the Phase 3 clinical evaluation of neflamapimod in dementia with Lewy bodies (DLB), while anticipating key Phase 2a biomarker data and ALS-related milestones over the next half-year. Shares closed down 22% at $2.25.
Humacyte (NASDAQ: HUMA) announced that its Acellular Tissue Engineered Vessel (ATEV) successfully achieved the primary interim endpoint in the Phase 3 V012 clinical trial for female dialysis access patients. The candidate demonstrated 91 additional catheter-free days compared to arteriovenous (AV) fistulas alongside a reduced infection rate and a clean safety profile, providing clinical evidence to support a supplemental BLA submission scheduled for the second half of 2026. Shares are currently down 8% at $1.23 during extended hours following the announcement of a public offering.
Basel Medical Group (NASDAQ: BMGL) authorized a 1-for-12 reverse stock split to take effect on June 22, 2026, aimed at satisfying Nasdaq's minimum bid requirement, which will contract the share count from roughly 18.8 million to 1.57 million. Shares closed down 8% at $0.59.
Harrow (NASDAQ: HROW) executed the commercial re-launch of VERKAZIA (cyclosporine ophthalmic emulsion) 0.1% for the treatment of vernal keratoconjunctivitis (VKC). The company is prioritizing clinician education alongside patient access initiatives to broaden adoption of the steroid-sparing pediatric therapy in an underdiagnosed market. Shares closed up 7% at $35.9.
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) shares closed down 10% at $76.42 following a major regulatory development from Sanofi (NASDAQ: SNY), which terminated its Phase 3 MOBILIZE trial evaluating its neuro-immunology candidate, riliprubart, due to a lack of clinical efficacy.
Aditxt, Inc. (NASDAQ: ADTX) entered into a senior secured note purchase agreement alongside its wholly owned subsidiary, Ignite Proteomics LLC, acting as joint and several co-borrowers. The transaction structures the issuance of a new series of senior secured convertible notes to accredited institutional investors, securing $725,000 in immediate cash proceeds while simultaneously consolidating the company's outstanding debt obligations from March and April 2026 into a single unified instrument. Shares closed down 36% at $0.02.
Scinai Immunotherapeutics (NASDAQ: SCNI) reported a 17% decline in first-quarter revenue to $0.49 million, while expenses climbed to $1.6 million following the acquisition of Recipharm Israel. The company is leveraging its expanded CDMO capacity and prioritizing its IL-17 bispecific NanoAb program while seeking non-dilutive financing options. Shares closed down 8% at $0.33.
06/09/2026
AIM ImmunoTech Inc. (NYSE American: AIM) submitted a Form S-1 registration statement to the SEC on June 8, 2026. The filing facilitates the potential resale of 31,290,000 common stock shares currently possessed by selling stockholders. Shares closed down 22% at $0.4.
RedHill Biopharma Ltd. (NASDAQ: RDHL) announced that the FDA has granted Rare Pediatric Disease Designation to its oral sphingosine kinase-2 (SK2) selective inhibitor, opaganib (ABC294640), for the treatment of neuroblastoma. This designation complements the asset's existing orphan drug status and qualifies RedHill to receive a transferable Priority Review Voucher (PRV) upon regulatory approval. Concurrently, the company initiated formal recognition and enforcement proceedings in South Korea to collect a final $10.9 million New York court judgment against Kukbo Co. Ltd., following preliminary asset attachments. The combined legal and regulatory developments provide near-term non-dilutive capital pathways and enhanced commercial exclusivity through 2032 for the $5.35 million market-cap specialty pharma company. Shares closed down 22% at $0.8.
Aditxt, Inc. (NASDAQ: ADTX) and Ignite Proteomics, LLC, a functional proteomics company and 100%-owned subsidiary of Aditxt, announced that Ignite and a strategic counterparty agreed to sign a definitive business combination agreement. The transaction values Ignite at an implied equity value of approximately $150 million, subject to the terms and conditions of the business combination agreement. Shares closed down 42% at $0.03.
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) shares closed up 17% at $6.85 following the announcement of a strategic licensing agreement with China-based WestGene Biopharma to co-develop in vivo mRNA chimeric antigen receptor T-cell (CAR-T) therapies for autoimmune diseases.
MetaVia Inc. (NASDAQ: MTVA) announced its 2026 virtual annual meeting results on June 8, 2026, with all ballot measures approved. Shareholders authorized a flexible reverse stock split of 1-for-5 to 1-for-22, giving the Board discretion to execute the consolidation as needed to manage capital structures. Shares closed down 15% at $1.89.
Actuate Therapeutics, Inc. (NASDAQ: ACTU) announced that elraglusib was chosen for the BEACON2 Phase 1/2 platform trial targeting relapsed or refractory pediatric neuroblastoma. This inclusion allows for a capital-efficient study alongside dinutuximab beta and chemotherapy, building on a previously observed complete response and the asset's recent FDA Rare Pediatric Disease Designation. Shares closed up 10% at $2.01.
Alterity Therapeutics (NASDAQ: ATHE) shares are trading up following successful alignment with the FDA on its registrational Phase 3 trial design for ATH434 in multiple system atrophy (MSA). The agreed-upon protocol utilizes a 50 mg twice-daily dosage and the UMSARS Part I primary endpoint, significantly de-risking the regulatory path. The move follows Phase 2 data demonstrating a 48% reduction in disease progression; the company anticipates initiating the pivotal study by late 2026. Shares closed up 9% at $4.29.
Canaccord Genuity analyst maintained Zevra Therapeutics (NASDAQ: ZVRA) with a Buy and raised the price target from $24 to $29. Shares closed up 13% at $13.66.
Shattuck Labs, Inc. (NASDAQ: STTK) announced that the exercise of outstanding warrants is projected to yield $54.9 million in gross proceeds. The capital infusion strengthens the firm's balance sheet relative to its $90.4 million cash position as of March 31, 2026, effectively extending its operational runway into 2029. This bolstered liquidity provides a sustained financial path for the company's ongoing clinical development programs. Shares closed up 9% at $4.27.
QTREX Quantum (NASDAQ: QTEX) was awarded a $1 million grant from the Israel Innovation Authority to pioneer a low-loss RF dielectric specifically for superconducting quantum systems. The funding will enhance its additively manufactured connectivity solution, which targets critical bottlenecks in signal attenuation, thermal management, and packaging density as qubit architectures continue to scale. Shares closed up 13% at $1.6.
06/08/2026
Tango Therapeutics (NASDAQ: TNGX) reported positive initial Phase 1/2 data for its PRMT5 inhibitor, vopimetostat, combined with Revolution Medicines' RAS(ON) inhibitors for MTAP-deleted, RAS-mutant pancreatic cancer (PDAC). The vopimetostat-daraxonrasib cohort showed a 92% ORR, 100% disease control rate, and 90% six-month PFS in pre-treated patients. The zoldonrasib combination reached a 52% ORR. Both regimens were well tolerated, with mostly Grade 1/2 side effects. Due to clinical synergy, Tango will skip intermediate cohorts to start Phase 3 registrational trials for first-line PDAC, with designs finalized by late 2026. Shares closed up 53% at $30.93.
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announced it will acquire Colospan Ltd., a medical device company with a solution for colorectal surgery complications, including anastomotic leaks and diverting stomas. Shares closed down 33% at $0.47.
Alvotech (NASDAQ: ALVO) reported that the FDA has formally accepted for review its Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio (vedolizumab), in the lyophilized vial for intravenous administration. Developed under a commercial partnership with Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), the regulatory submission for adult ulcerative colitis and Crohn's disease is backed by comprehensive analytical, pharmacokinetic, and immunogenicity data, including a pivotal trial that satisfied the clinical similarity threshold for both AVT16 and its subcutaneous counterpart, AVT80. Shares closed up 20% at $4.24.
Alliance Global Partners initiated coverage on Incannex Healthcare (NASDAQ: IXHL) with a Buy rating and announced a Price Target of $18. Shares closed up 16% at $3.4.
Zevra Therapeutics (NASDAQ: ZVRA) filed a patent for MIPLYFFA for inclusion in the FDA Orange Book, providing protection until November 2041. The filing bolsters the commercial exclusivity of its approved treatment for Niemann-Pick disease type C, with an additional patent term extension application currently under regulatory review. Shares closed up 14% at $12.09.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced that it intends to offer and sell up to $300.0 million of shares of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase its common stock in an underwritten public offering. In addition, IDEAYA intends to grant the underwriters a 30-day option to purchase up to $45.0 million of shares of its common stock. Shares closed up 11% at $31.48.
06/05/2026
Nyxoah SA (NASDAQ: NYXH) priced a $95M public offering of 55,232,558 ordinary shares at $1.72 per share, including an 8.2M-share underwriter option. The medical technology firm, specializing in OSA solutions, intends to use the capital for Genio commercialization and product development, with the financing expected to be finalized by June 9, 2026, subject to standard closing requirements. Shares closed down 50% at $1.45.Shares closed down 50% at $1.45.
Nuwellis Inc. (NASDAQ: NUWE) Nuwellis priced a highly dilutive US$6M public offering at US$0.30 per share with accompanying Series C and D warrants, including reset and zero-cash exercise features, alongside a warrant repricing to US$0.30, signaling urgent capital needs and meaningful overhang ahead of required stockholder approvals and a reverse split. Shares closed down 61% at $0.17. Shares closed down 61% at $0.17.
BioCardia Inc. (NASDAQ: BCDA) shares closed up 12% at $1.03 following FDA Q-Sub minutes confirming its ongoing CardiAMP Heart Failure II trial may support PMA approval for ischemic HFrEF, positioning the study as a potentially pivotal second trial after prior CardiAMP HF data and reinforcing the regulatory path for a high-risk device-cell therapy system.
Bio Green Med Solution, Inc. (NASDAQ: BGMS) jumped more than 186% overnight following the announcement of a definitive Business Combination Agreement to acquire Future NRG Sdn. Bhd., a Malaysia-based technology integrator specializing in sustainable medical waste management. Shares closed up 42% at $1.5.
Clearmind Medicine Inc. (NASDAQ: CMND) announced that it will host a live investigative webinar on Wednesday, June 10, 2026 to present the latest clinical dataset from its ongoing multi-center Phase I/IIa clinical trial. The FDA-approved study is evaluating CMND-100, the company's proprietary oral, non-hallucinogenic MEAI-based neuroplastogen candidate, specifically targeted for patients suffering from moderate-to-severe Alcohol Use Disorder (AUD). Shares closed up 37% at $3.98.
AIM ImmunoTech Inc. (NYSE American: AIM) released an on-demand virtual investor presentation and an updated corporate brief highlighting the biodefense and emerging antiviral potential of its lead asset, Ampligen (rintatolimod), against Ebola virus disease. Aimed at addressing the ongoing Bundibugyo strain outbreak in East Africa following a WHO Public Health Emergency declaration, the materials review previously published Biosafety Level 4 preclinical data from USAMRIID showing 100% protective survival in a lethal mouse model when administered early post-infection. While shares tumbled following the announcement, automated metrics maintain a Neutral rating due to minimal revenue, multi-year net operational losses, and a persistent cash-burn profile. .Shares closed down 23% at $5.46.
Edesa Biotech (NASDAQ: EDSA) released exploratory post hoc results for paridiprubart in 101 patients with ARDS who presented with acute kidney injury. The data revealed a 32% relative reduction in 28-day mortality, along with positive signals of kidney recovery, bolstering the clinical rationale for advancing its anti-TLR4 antibody candidate in high-risk patients with immuno-inflammatory organ damage. Shares closed down 13% at $0.52
06/04/2026
Health Catalyst (NASDAQ: HCAT) reached a definitive agreement to divest its Vitalware revenue workflow and analytics software business to Med-Metrix. The transaction involves the transfer of Vitalware's chargemaster, revenue integrity, price transparency, and coding workflow solutions to the specialized revenue-cycle platform, facilitating a strategic transition for Health Catalyst as it moves into its subsequent operational phase. Shares closed up 46% at $1.94.
Alvotech (NASDAQ: ALVO) announced the U.S. BLA resubmission for AVT05 and AVT06, proposed biosimilars to Simponi and Eylea, respectively. The filings follow the company's resolution of manufacturing-related observations at its Reykjavik site. The FDA is anticipated to complete its review within a six-month window, with Teva Pharmaceuticals slated to lead commercial efforts in the United States upon potential approval. Shares closed up 19% at $3.74.
SciSparc Ltd. (NASDAQ: SPRC) disclosed insider activity as Director Itschak Shrem executed an open-market sale of 462 ordinary shares on June 1, 2026. The transaction was processed at a flat price of $10.00 per share, resulting in a total liquidation value of $4,620 and reducing his direct beneficial holding to 10,596 ordinary shares. Shares closed up 22% at $11.54.
ADC Therapeutics SA (NYSE: ADCT) shares traded lower following the release of topline Phase 3 LOTIS-5 trial data for ZYNLONTA plus rituximab in r/r DLBCL. While the trial met its primary PFS endpoint with statistical significance (6.1 vs. 4.7 months) and showed higher overall and complete response rates, concerns emerged regarding safety. The combination arm reported more serious (49.0% vs. 34.5%) and Grade 5 adverse events, particularly in patients over 75. ADC is initiating cost reductions and plans an August FDA meeting ahead of a Q4 2026 sBLA submission. Shares closed down 57% at $1.32.
AIM ImmunoTech Inc. (NYSE American: AIM) announced the successful final patient enrollment for its Phase 2 clinical trial, dubbed DURIPANC, evaluating its lead asset Ampligen (rintatolimod) in combination with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab). The investigator-initiated, exploratory open-label study—conducted in collaboration with Erasmus Medical Center in the Netherlands—focuses on patients with metastatic pancreatic cancer whose disease has stabilized following initial FOLFIRINOX chemotherapy. The milestone was achieved significantly ahead of the company's initial July 2026 target timeline, with the final cohort scheduled to begin receiving treatment in mid-June. Shares closed down 19% at $0.59.
NewGenIVF Group Limited (NASDAQ:NIVF) NewGen invested an additional US$4M to lift its K25.ai stake to 6% and formally adopted a Digital Asset Treasury strategy targeting Bitcoin, Solana and other high-conviction digital assets, marking a strategic pivot away from its IVF roots toward AI, prediction markets and crypto-linked balance sheet exposure. Shares closed down 19% at $0.69.
Nyxoah SA (Euronext Brussels/NASDAQ:NYXH) Nyxoah launched a proposed U.S. underwritten public offering with a 15% underwriter option, seeking capital to fund U.S. Genio commercialization, OSA product development, cost-reduction initiatives and broader commercial expansion, with dilution dependent on final offering size and terms. Shares are currently trading down 12% at $2.52 during afterhours trading.
06/03/2026
Verastem Oncology (NASDAQ: VSTM) announced that the FDA has granted Fast Track Designation (FTD) to VS-7375, an oral and potential best-in-class investigational selective KRAS G12D (ON/OFF) inhibitor, for the treatment of adult patients with KRAS G12D-mutated unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received platinum-based chemotherapy and an anti-PD-(L)1 antibody either concurrently or sequentially. FDA Fast Track Designation was previously granted for VS-7375 for the treatment of KRAS G12D-mutated advanced or metastatic pancreatic cancer. Shares are currently up 12% at 4.07 during extended hours.
ADC Therapeutics SA (NYSE: ADCT) reported topline Phase 3 LOTIS-5 trial data for ZYNLONTA plus rituximab in r/r DLBCL. The trial met its primary PFS endpoint (6.1 vs. 4.7 months) with statistical significance, with no detrimental effect on OS. The combination showed higher overall and complete response rates, with a median CR duration of 16.8 months. While TEAE rates were comparable, the test arm had more serious (49.0% vs. 34.5%) and Grade 5 adverse events, primarily in patients over 75. ADC plans an August FDA meeting ahead of a Q4 2026 sBLA submission while initiating cost reductions. Shares are currently down 39% at $1.87 during extended hours.
HC Wainwright & Co. analyst reiterated Alpha Tau Medical (NASDAQ: DRTS) with a Buy and maintained a $15 price target. Shares closed up 18% at $10.58.
Lyell Immunopharma (NASDAQ: LYEL) announced its executive team will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8. The session may include updates on its next-gen CAR-T pipeline and commercial manufacturing progress. Shares fell 16% to $12.57.
Rezolute, Inc. (NASDAQ: RZLT) announced interim Phase 3 upLIFT study results for ersodetug in tumor hyperinsulinism (HI). Six of the eight currently enrolled participants (out of a planned 16) met the primary endpoint with a >50% reduction in intravenous glucose needs, and all six completely stopped glucose therapy. Ersodetug remains well-tolerated with no drug-related adverse events across the pivotal and extension phases. Shares closed up 15% at $4.58.
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) Mineralys priced an underwritten offering of 5,660,378 common shares at $26.50 each, expecting approximately $150.0 million in gross proceeds. Additionally, the company repurchased its lorundrostat royalty obligation from Tanabe for $200 million upfront, with up to $100 million in potential commercial milestones. Shares closed down 13% at $25.06.
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) priced a 5.7M-share public offering at US$3.50 per share for ~US$20M in gross proceeds, with potential proceeds of US$23M if the underwriter option is fully exercised, providing working-capital funding while creating near-term shareholder dilution. Shares closed down 12% at $4.05.
06/02/2026
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) inked a strategic partnership with Argonaut Manufacturing Services to support the advancement of Bluejay's Symphony platform. Shares closed up 100% at $4.34.
Fulcrum Therapeutics (NASDAQ: FULC) discontinued pociredir in sickle cell disease after FDA feedback left no viable regulatory path due to PRC2-class malignancy concerns, despite fetal hemoglobin activity and no new pociredir safety signals to date; the company will cut costs and pursue strategic alternatives, making the story now primarily a balance-sheet and transaction-value situation rather than a clinical development thesis. Shares closed down 51% at $3.14.
Heron Therapeutics, Inc. (NASDAQ: HRTX) announced a significant legal setback after the U.S. District Court for the District of Delaware ruled against the company in its ongoing patent litigation with Azurity Pharmaceuticals (including Azurity India and Slayback Pharma). The court held that the asserted claims of Heron's U.S. Patent Nos. 12,115,255 and 12,290,520, which protect its Cinvanti (aprepitant) injectable emulsion, are invalid. The decision has no impact on prior settlement agreements related to Cinvanti or Aponvie injectable emulsions, and Heron intends to aggressively appeal the ruling to the United States Court of Appeals for the Federal Circuit. Shares closed down 46% at $0.45.
Celcuity (NASDAQ: CELC) reported pivotal Phase 3 VIKTORIA-1 data in PIK3CA-mutant HR+/HER2- advanced breast cancer, with gedatolisib plus fulvestrant/palbociclib and gedatolisib plus fulvestrant both cutting progression or death risk by about 50% versus alpelisib plus fulvestrant and nearly doubling median PFS to roughly 11 months, supporting gedatolisib's potential competitive positioning in the post-CDK4/6 setting. Shares closed down 26% at $91.41.
Praxis Precision Medicines (NASDAQ: PRAX) shares closed down 23% at $258.08, reported that the Phase 2/3 POWER1 trial of vormatrigine in focal onset seizures did not meet expectations, though the company noted a signal in the higher-dose arm, low discontinuation, and favorable safety; Praxis will review next steps for vormatrigine and POWER2 while prioritizing planned launches of relutrigine and ulixacaltamide.
Abivax (NASDAQ: ABVX) reported Phase 3 ABTECT maintenance data for once-daily oral obefazimod in moderately to severely active ulcerative colitis, with both 25 mg and 50 mg doses meeting the Week 44 primary endpoint of clinical remission and all key secondary endpoints, showing placebo-adjusted remission rates near 40% with no new safety signals, supporting a planned U.S. NDA filing in late Q4 2026. Shares closed down 44% at $72.41.
Evogene Ltd. (NASDAQ: EVGN) shares closed down 14% at $0.59 following the completion of a first-in-human Phase 1 clinical trial evaluating BMC128, a rationally designed live bacterial product developed by its subsidiary, Biomica Ltd., in combination with Bristol Myers Squibb's blockbuster checkpoint inhibitor Nivolumab (Opdivo). The study met its primary endpoint, demonstrating favorable safety and tolerability, with no dose-limiting toxicities observed.
ODDITY Tech Ltd. (NASDAQ: ODD) reported first-quarter 2026 financial results showing net revenue of $197.9 million, down 26% year-over-year, and a swing to a net loss of $21.4 million. The digital-first beauty and wellness company attributed the compression to a technical ad-account dislocation with its largest advertising partner, which caused customer acquisition costs to spike across multiple geographies. Shares closed down 30% at $9.84.
IceCure Medical (NASDAQ: ICCM) announced that it will complete a 1-for-30 reverse stock split on June 4, 2026, while continuing to trade under the ticker ICCM. The move is aimed at lifting the share price above Nasdaq's $1 minimum bid requirement and helping the company maintain its Nasdaq listing. Shares closed down 31% at $0.14.
Cingulate Inc. (NASDAQ: CING) announced that the FDA has issued a Complete Response Letter for its New Drug Application (“NDA”) for CTx-1301 (dexmethylphenidate HCl) for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). The response identified specific Chemistry, Manufacturing, and Controls (CMC) information requests and raised no current concerns regarding the clinical safety or efficacy of CTx-1301. Cingulate expects a prompt submission to FDA of the requested information addressing issues raised. Shares closed up 12% at $4.03.
NRx Pharmaceuticals (NASDAQ: NRXP) initiated a proposed underwritten public offering of its common shares, featuring a 15% overallotment option for underwriters; with capital earmarked for corporate needs and working funds, the narrative shifts toward potential equity dilution and the eventual size and pricing of the capital raise. Shares are currently down 21% at $3.66 during extended hours.
06/01/2026
Edgewise Therapeutics Inc. (NASDAQ: EWTX) entered into a definitive agreement to be acquired by Servier for up to $2.65 billion; the deal includes a $1.55 billion upfront payment and $1.1 billion in potential milestones, transitioning Edgewise's muscular dystrophy business to the international pharmaceutical group with a target close in the third quarter of 2026. Shares closed up 18% at $40.26.
Fulcrum Therapeutics (NASDAQ:FULC) discontinued pociredir in sickle cell disease after FDA feedback left no viable regulatory path due to PRC2-class malignancy concerns, despite fetal hemoglobin activity and no new pociredir safety signals to date; the company will cut costs and pursue strategic alternatives, making the story now primarily a balance-sheet and transaction-value situation rather than a clinical development thesis. Shares are currently trading down 46% at $3.41 during after hours trading. Shares closed down 7% at $6.42.
Praxis Precision Medicines (NASDAQ:PRAX) reported that the Phase 2/3 POWER1 trial of vormatrigine in focal onset seizures did not meet expectations, though the company noted a signal in the higher-dose arm, low discontinuation, and favorable safety; Praxis will review next steps for vormatrigine and POWER2 while prioritizing planned launches of relutrigine and ulixacaltamide. Shares are currently halted during after hours trading. Shares closed down 4% at $335.16.
Abivax (NASDAQ:ABVX) reported Phase 3 ABTECT maintenance data for once-daily oral obefazimod in moderately to severely active ulcerative colitis, with both 25 mg and 50 mg doses meeting the Week 44 primary endpoint of clinical remission and all key secondary endpoints, showing placebo-adjusted remission rates near 40% with no new safety signals, supporting a planned U.S. NDA filing in late Q4 2026. Shares are currently halted in the after hours trading session. Shares closed down 2% at $129.69.
Needham analyst maintained Oculis Holding (NASDAQ: OCS) with a Buy and lowered the price target from $46 to $38. Shares closed down 36% at $14.51.
Ascendiant Capital analyst maintained AIM ImmunoTech (AMEX: AIM) with a Buy and lowered the price target from $10 to $9. Shares closed up 120% at $0.9.
Jasper Therapeutics, Inc. (NASDAQ: JSPR) announced that its Board of Directors has initiated a comprehensive review of strategic alternatives to maximize shareholder value, including potential asset sales, licensing, mergers, or an orderly wind-down, as the clinical-stage biotech evaluates its path forward for briquilimab in mast cell-driven diseases like chronic spontaneous urticaria (CSU). The company plans to implement cost-saving measures to preserve cash throughout the evaluation process while maintaining necessary regulatory and financial compliance. Shares closed down 36% at $0.53.
Rallybio Corporation (NASDAQ: RLYB) and Avenzo Therapeutics, Inc., a clinical-stage biotechnology company developing next-generation oncology therapies, announced that they have entered into a definitive agreement pursuant to which Rallybio will acquire Avenzo through a merger transaction. Upon completion of the Merger, the combined company is expected to operate under the name Avenzo Therapeutics, Inc. and is expected to trade on Nasdaq under the ticker symbol “AVZO”. In connection with the Merger, Avenzo entered into subscription agreements for a concurrent oversubscribed private placement financing of $215 million in gross proceeds. Shares closed up 17% at $16.87.
BriaCell Therapeutics (NASDAQ: BCTX) priced a best-efforts offering of 1.45 million shares at $3.25, raising approximately $4.7 million gross proceeds for working capital and corporate purposes, a modest financing that provides incremental liquidity but is dilutive and not tied to a specific clinical catalyst. Shares closed down 9% at $3.31.
LIXTE Biotechnology Holdings (NASDAQ:LIXT) announced a strategic pivot from biotech toward AI energy infrastructure equipment and services for data centers, while seeking a strategic acquisition partner for its clinical-stage oncology and med-tech assets; the move may reposition the public vehicle toward a larger market theme, but it also marks a major business-model shift away from its core drug-development pipeline. Shares closed up 15% at $7.21.
NextCure (NASDAQ: NXTC) revealed encouraging Phase 1 dose-escalation results at ASCO for SIM0505, its CDH6-targeted TOPO1 ADC; the data demonstrated a 55% ORR among therapeutic dose cohorts in gynecologic malignancies, specifically highlighting a 52.9% response in ovarian cancer and 66.7% in uterine serous carcinoma, with a safety profile that justifies further dose optimization and eventual advancement toward pivotal trials in platinum-resistant settings. Shares closed down 45% at $3.38.
